<!DOCTYPE html>
<html>
<head>

<script id="f5_cspm">
(function(){var f5_cspm={f5_p:'LCOFEFKCELLCOFBJPGFIJOMFPABGPANGMNFGFDFGJMPBPKBPIDDLKJJHAFPANDPOKFANKMFJLAOLAEDBAOLANIPBKIHEIJIFIKEMCJMKDLAKBHEJGNIHCDLHEBJBNNFJ',setCharAt:function(str,index,chr){if(index>str.length-1)return str;return str.substr(0,index)+chr+str.substr(index+1);},get_byte:function(str,i){var s=(i/16)|0;i=(i&15);s=s*32;return((str.charCodeAt(i+16+s)-65)<<4)|(str.charCodeAt(i+s)-65);},set_byte:function(str,i,b){var s=(i/16)|0;i=(i&15);s=s*32;str=f5_cspm.setCharAt(str,(i+16+s),String.fromCharCode((b>>4)+65));str=f5_cspm.setCharAt(str,(i+s),String.fromCharCode((b&15)+65));return str;},set_latency:function(str,latency){latency=latency&0xffff;str=f5_cspm.set_byte(str,32,(latency>>8));str=f5_cspm.set_byte(str,33,(latency&0xff));str=f5_cspm.set_byte(str,27,2);return str;},wait_perf_data:function(){try{var wp=window.performance.timing;if(wp.loadEventEnd>0){var res=wp.loadEventEnd-wp.navigationStart;if(res<60001){var cookie_val=f5_cspm.set_latency(f5_cspm.f5_p,res);window.document.cookie='aaaaaaaaaaaaaaa='+encodeURIComponent(cookie_val)+';path=/';}
return;}}
catch(err){return;}
setTimeout(f5_cspm.wait_perf_data,100);return;},go:function(){var chunk=window.document.cookie.split(/\s*;\s*/);for(var i=0;i<chunk.length;++i){var pair=chunk[i].split(/\s*=\s*/);if(pair[0]=='f5_cspm'){if(pair[1]=='1234'){var d=new Date();d.setTime(d.getTime()-1);window.document.cookie='f5_cspm=;expires='+d.toUTCString()+';path=/;';setTimeout(f5_cspm.wait_perf_data,100);}}}}}
f5_cspm.go();}());
</script>
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta charset="utf-8">
<title>DailyMed - CYMBALTA- duloxetine hydrochloride capsule,
delayed release</title>
<!--[if lt IE 9]>
        <script src="/dailymed/scripts/html5shiv.min.js"></script>
    <![endif]-->

<script src="/dailymed/scripts/modernizr-2.0.6.min.js">
</script>
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/skeleton.min.css">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/jquery.jqzoom.min.css">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/style.min.css?v=2">
<link rel="stylesheet" type="text/css" media="screen" href=
"/dailymed/css/header-search.min.css">
<link rel="stylesheet" type="text/css" media="all" href=
"/dailymed/css/responsive.min.css">
<link rel="stylesheet" type="text/css" media="print" href=
"/dailymed/css/print.min.css"><!--[if !IE]><!-->
<link rel="stylesheet" type="text/css" media="all" href=
"/dailymed/css/responsive-tables.min.css"><!--<![endif]-->
<link rel="icon" href="/dailymed/images/favicons/favicon.ico" type=
"image/x-icon">
<link rel="shortcut icon" href=
"/dailymed/images/favicons/favicon.ico" type="image/x-icon">
<link rel="apple-touch-icon" sizes="57x57" href=
"/dailymed/images/favicons/apple-touch-icon-57x57.png">
<link rel="apple-touch-icon" sizes="114x114" href=
"/dailymed/images/favicons/apple-touch-icon-114x114.png">
<link rel="apple-touch-icon" sizes="72x72" href=
"/dailymed/images/favicons/apple-touch-icon-72x72.png">
<link rel="apple-touch-icon" sizes="144x144" href=
"/dailymed/images/favicons/apple-touch-icon-144x144.png">
<link rel="apple-touch-icon" sizes="60x60" href=
"/dailymed/images/favicons/apple-touch-icon-60x60.png">
<link rel="apple-touch-icon" sizes="120x120" href=
"/dailymed/images/favicons/apple-touch-icon-120x120.png">
<link rel="apple-touch-icon" sizes="76x76" href=
"/dailymed/images/favicons/apple-touch-icon-76x76.png">
<link rel="apple-touch-icon" sizes="152x152" href=
"/dailymed/images/favicons/apple-touch-icon-152x152.png">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-196x196.png" sizes="196x196">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-160x160.png" sizes="160x160">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-96x96.png" sizes="96x96">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-16x16.png" sizes="16x16">
<link rel="icon" type="image/png" href=
"/dailymed/images/favicons/favicon-32x32.png" sizes="32x32">
<meta name="msapplication-config" content=
"/dailymed/images/favicons/browserconfig.xml">
<meta name="msapplication-TileColor" content="#da532c">
<meta name="msapplication-TileImage" content=
"/dailymed/images/favicons/mstile-144x144.png">
<meta name="description" content="">
<meta name="keywords" content="">
<meta name="robots" content="noimageindex, noodp, noydir">
<meta name="viewport" id="viewport" content=
"width=device-width,minimum-scale=1.0,maximum-scale=10.0,initial-scale=1.0"><!-- Magnific Popup core CSS file -->
<link rel="stylesheet" href="/dailymed/css/magnific-popup.min.css">
<meta name="format-detection" content="telephone=no">
</head>
<body class="inner drug-info">
<div class="container_1000 bg_shadow">
<div style="width: 0; height: 0;"><a href="#" id=
"top-of-page"></a></div>
<header>
<div class="topHeader">
<ul id="skip">
<li><a href="#skip-main-content">Skip to Main Content</a></li>
</ul>
<nav class="topHeaderNav">
<div class="topNIHLogo mobileview"><a href="http://www.nih.gov"
class="top-logo" title="National Institutes of Health" target=
"_blank"><img src="/dailymed/images/nih-toplogo.png" alt=
"NIH Logo"></a> <a href="//www.nlm.nih.gov" title=
"U.S. National Library of Medicine" target="_blank">U.S. National
Library of Medicine</a></div>
<div class="container">
<div class="sixteen columns">
<div class="topNIHLogo"><a href="http://www.nih.gov" title=
"National Institutes of Health" target="_blank"><img src=
"/dailymed/images/nih-toplogo.png" alt="NIH Logo"></a> <a href=
"//www.nlm.nih.gov" title="U.S. National Library of Medicine"
target="_blank">U.S. National Library of Medicine</a></div>
<ul>
<li class="safety"><a title="Report Adverse Events" href=
"//www.accessdata.fda.gov/scripts/medwatch/" target="_blank">Report
Adverse Events</a> <span>|</span><a title=
"FDA Safety Reporting and Recalls" href=
"http://www.fda.gov/Safety/Recalls" target=
"_blank">Recalls</a></li>
</ul>
</div>
</div>
</nav>
<div class="divider"></div>
</div>
<div class="dailymedlogoprint"><img src="/dailymed/images/logo.png"
alt="DailyMed"></div>
<div class="bottomHeader">
<div class="header-image">
<div class="mobile-menu-btn closed hasjs" tabindex="0"></div>
<div class="mobile-menu">
<div class="mobile-menu-container">
<div class="pro-menu active">
<div class="first half">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><a href="/dailymed/about-dailymed.cfm">About Dailymed</a></li>
<li><a href="/dailymed/contact-us.cfm">Contact Us</a></li>
<li>Safety Reporting &amp; Recalls
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/">Report
Adverse Events</a></li>
<li><a href="http://www.fda.gov/Safety/Recalls">FDA Saftey
Recalls</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
</ul>
</div>
<div class="last half">
<ul>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">- All
Drug Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">- All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">- All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-all-mapping-files.cfm">Articles &amp;
Presentations</a></li>
</ul>
</li>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">- Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">- Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
</div>
</div>
</div>
<a href="/dailymed/index.cfm" class="logo" title=
"DailyMed">DailyMed</a>
<div class="header-search-container">
<div id="header-search">
<form action="/dailymed/search.cfm">
<div class="searchNav">
<ul class="searchType">
<li class="all active"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-all" value="all"> <label for=
"labeltype-all">All Drugs</label></li>
<li class="human"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-human" value="human"> <label for=
"labeltype-human">Human Drugs</label></li>
<li class="animal"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-animal" value="animal"> <label for=
"labeltype-animal">Animal Drugs</label></li>
<li class="more-ways" id="header-search-more-ways"><a href="#" id=
"more-ways-button" class="more-ways-label">More ways to search</a>
<ul id="more-ways-dropdown" class="dropdown" style="display:none;">
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Label Archives</a></li>
<li><a class="external-link" href="http://pillbox.nlm.nih.gov"
target="_blank">Tablet/Capsule ID Tool</a></li>
</ul>
</li>
</ul>
</div>
<div class="searchForm">
<div class="searchInput"><input id="searchQuery" name="query"
tabindex="0" type="text" placeholder=
"Enter drug, NDC code, drug class, or Set ID" autocorrect="off"
autocapitalize="off"></div>
<input class="search" tabindex="0" title="Search" type="submit"
value="Search"></div>
</form>
</div>
</div>
<div class="mobile-search-btn" tabindex="0"></div>
<div class="header-bg"></div>
<div class="divider"></div>
</div>
<div class="bottomHeaderContent">
<div class="search mobile-search">
<div class="divider_10 nomargin mobileview"></div>
<form action="/dailymed/search.cfm">
<div class="searchNav">
<ul class="searchType">
<li class="all active"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-all-2" value="all"> <label for=
"labeltype-all-2">All Drugs</label></li>
<li class="human"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-human-2" value="human"> <label for=
"labeltype-human-2">Human Drugs</label></li>
<li class="animal"><input type="radio" class="hidden" name=
"labeltype" id="labeltype-animal-2" value="animal"> <label for=
"labeltype-animal-2">Animal Drugs</label></li>
</ul>
</div>
<div class="searchForm">
<div class="searchInput"><input id="searchToolsQuery" name="query"
tabindex="0" type="text" placeholder=
"Enter drug, NDC code, drug class, or Set ID" autocorrect="off"
autocapitalize="off"></div>
<input class="search" tabindex="0" title="Search" type="submit"
value="Search"></div>
</form>
<div class="divider"></div>
<nav class="bottomHeaderNav"><noscript>
<div class="tabletnav no-js">
<div class="col">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li>Search
<ul>
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Labels Archives</a></li>
<li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Index Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
</ul>
</div>
<div class="col">
<ul>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
</div>
</noscript>
<ul class="webview hasjs">
<li><a href="/dailymed/index.cfm" title="Home">Home</a></li>
<li><a href="#" title="News">News</a>
<ul class="sub-menu">
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm" title=
"FDA Guidances &amp; Info">FDA Guidances &amp; Info</a></li>
<li><a href="#" title=
"Structured Product Labeling (SPL) resources for industry professionals.">
NLM SPL Resources</a>
<ul class="sub-menu">
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li><a href="#" title="Application Development Support">Application
Development Support</a>
<ul class="sub-menu">
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm" title="Help">Help</a></li>
</ul>
<ul class="tabletview hasjs">
<li><a href="/dailymed/advanced-search.cfm" title=
"Advanced Search">Advanced Search</a></li>
<li class="viewmore"><a href="#" title="View More">View More</a>
<ul>
<li><span>News</span>
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li><span>Safety Reporting and Recalls</span>
<ul>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a></li>
<li><a href="//www.fda.gov/Safety/Recalls" target="_blank">FDA
Saftey Recalls</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li><span>NLM SPL Resources</span>
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">- All
Drug Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">- All
Indexing Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">- All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li><span>Application Development Support</span>
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">- Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">- Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm" title="Help">Help</a></li>
</ul>
</li>
<li class="mobileview viewmore" tabindex="0"><a title="View More"
href="#">More ways to search</a>
<ul>
<li tabindex="0"><a title="Browse Drug Classes" href=
"/dailymed/browse-drug-classes.cfm">Browse Drug Classes</a></li>
<li tabindex="0"><a title="Label Archives" href=
"/dailymed/archives/index.cfm">Label Archives</a></li>
<li tabindex="0"><a target="_blank" title="Tablet/Capsule ID Tool"
href="http://pillbox.nlm.nih.gov/">Tablet/Capsule ID Tool</a></li>
</ul>
</li>
</ul>
<ul class="mobileview hasjs">
<li><a href="/dailymed/advanced-search.cfm" title=
"Advanced Search">Advanced Search</a></li>
<li tabindex="0" class="viewmore"><a href="#" title=
"View More">View More</a>
<ul>
<li tabindex="0"><a href="/dailymed/browse-drug-classes.cfm" title=
"Browse Drug Classes">Browse Drug Classes</a></li>
<li tabindex="0"><a href="/dailymed/archives/index.cfm" title=
"Label Archives">Label Archives</a></li>
<li tabindex="0"><a href="http://pillbox.nlm.nih.gov/" title=
"Tablet/Capsule ID Tool" target="_blank">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
</ul>
</nav>
<div class="divider_10 nomargin"></div>
</div>
</div>
<div class="divider"></div>
</div>
</header>
<div id="skip-main-content"></div>
<div class="container">
<div class="main-content">
<div class="header long">
<div class="header-top">
<h1>Label: <span class="long-title">CYMBALTA- duloxetine
hydrochloride capsule, delayed release<br></span></h1>
</div>
<ul class="tools">
<li class="rss"><a href="#modal-label-rss" class="modal-open">Label
RSS</a></li>
<li class="share">Share <noscript>: JavaScript needed for Sharing
tools</noscript> <!-- AddThis Button BEGIN -->
<div class=
"addthis_toolbox addthis_default_style addthis_16x16_style">
<a class="email-share" href=
"mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0ACYMBALTA%2D%20Duloxetine%20Hydrochloride%20Capsule%2C%20Delayed%20Release%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D2f7d4d67%2D10c1%2D4bf4%2Da7f2%2Dc185fbad64ba%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E"
title="Share by Email"></a> <a class="addthis_button_facebook"></a>
<a class="addthis_button_twitter"></a> <a class=
"at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share"
href=
"//www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed"
target="_blank" style="display: block;"><span style=
"left: -9999px; position: absolute;">Bookmark &amp;
Share</span><img style="width:17px" src=
"/dailymed/images/addthis-image.jpg"></a></div>
<script type="text/javascript">
var addthis_config = {"data_track_addressbar":false};
</script> <script type="text/javascript" src=
"//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5">
</script> <!-- AddThis Button END --></li>
</ul>
</div>
<div class="four columns sidebar" id="leftmenu">
<section>
<article>
<div class="w-photos">
<div class="mod drug-photos">
<h2><a>View Package Photos</a></h2>
<ul>
<li>
<ul>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=cymbalta-20mg-contain-60-8536.jpg&amp;setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="0"><img id="zoom_1" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=cymbalta-20mg-contain-60-8536.jpg&amp;setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba"
src=
"image.cfm?type=img&amp;name=cymbalta-20mg-contain-60-8536.jpg&amp;setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba"
data-photo-type="package"> </a></li>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=cymbalta-30mg-contain-30-8938.jpg&amp;setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="1"><img id="zoom_2" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=cymbalta-30mg-contain-30-8938.jpg&amp;setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba"
src=
"image.cfm?type=img&amp;name=cymbalta-30mg-contain-30-8938.jpg&amp;setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba"
data-photo-type="package"> </a></li>
</ul>
</li>
</ul>
<h4 class="more closed">VIEW MORE</h4>
<div class="show-more">
<ul>
<li>
<ul>
<li class="img package-photo"><a href=
"image.cfm?type=img&amp;name=cymbalta-60mg-contain-30-1932.jpg&amp;setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba"
class="thumbnail" title="Package Photo" data-photo-type="package"
data-slideorder="2"><img id="zoom_3" title="Package Photo" alt=
"Package Photo" data-zoom-image=
"image.cfm?type=img&amp;name=cymbalta-60mg-contain-30-1932.jpg&amp;setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba"
src=
"image.cfm?type=img&amp;name=cymbalta-60mg-contain-30-1932.jpg&amp;setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba"
data-photo-type="package"> </a></li>
</ul>
</li>
</ul>
</div>
</div>
<div class="mod drug-photos">
<h2><a>VIEW DRUG PHOTOS</a></h2>
<div class="no-pill-photo-warning-drug-info">DailyMed is no longer
displaying pill images from RxImage. For more information, <a href=
"#no-pill-photo-warning-modal" class="modal-open">click
here</a>.</div>
</div>
</div>
<div class="mod-wrap">
<div class="mod blue-list page-jump">
<h2><a href="#drug-information">Drug Label Info</a></h2>
</div>
<div class="mod blue-list orange">
<h2><a href="#">Safety</a></h2>
<ul>
<li><a class="tip" rel="tooltip" title=
"A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects."
href="#boxedwarning">Boxed Warnings</a></li>
<li><a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a></li>
<li><a href="http://www.fda.gov/Safety/Recalls/" target=
"_blank">FDA Safety Recalls</a></li>
<li><a href=
"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22Duloxetine%22+%29"
target="_blank">Presence in Breast Milk</a></li>
</ul>
</div>
<div class="mod blue-list">
<h2><a href="#">Related Resources</a></h2>
<ul>
<li><a href=
"//vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&amp;query=Duloxetine"
target="_blank">Medline Plus</a></li>
<li><a href=
"//www.clinicaltrials.gov/ct/search?submit=Search&amp;term=Duloxetine"
target="blank">Clinical Trials</a></li>
<li><a href="#" id="pubmed-menu">PubMed</a>
<ul>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=Duloxetine[All%20Fields]"
title="Link opens new window for All Citations" target="pubmed">All
Citations</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=Duloxetine/AE"
title="Link opens new window for Adverse Effects" target=
"pubmed">Adverse Effects</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=Duloxetine/TU"
title="Link opens new window for Therapeutic Use" target=
"pubmed">Therapeutic Use</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=Duloxetine/PD"
title="Link opens new window for Pharmacology" target=
"pubmed">Pharmacology</a></li>
<li><a href=
"//www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=Duloxetine[All%20Fields]%20AND%20Clinical%20Trial[ptyp]"
title="Link opens new window for Clinical Trials" target=
"pubmed">Clinical Trials</a></li>
</ul>
</li>
<li><a href=
"http://www.drugbank.ca/search?utf8=%E2%9C%93&amp;query=APRD00060&amp;search_type=drugs&amp;button="
target="_blank">Biochemical Data Summary</a></li>
</ul>
</div>
<div class="mod blue-list">
<h2><a href="#">More Info For This Drug</a></h2>
<ul>
<li><a href="#modal-label-archives" class="modal-open">View Label
Archives</a></li>
<li><a href="#modal-rx-norm" class="modal-open">RxNorm</a></li>
<li><a href="#modal-label-rss" class="modal-open">Get Label RSS
Feed</a></li>
</ul>
</div>
</div>
</article>
</section>
</div>
<div class="content-wide">
<article>
<ul class="drug-information">
<li><strong><a class="tip" rel="tooltip" title=
"&lt;b&gt;NDC (National Drug Code)&lt;/b&gt; - Each drug product is assigned this unique number which can be found on the drug's outer packaging."
href="#">NDC Code(s):</a></strong> <span id=
"item-code-s">0002-3235-60, 0002-3240-01, 0002-3240-07,
0002-3240-30, <a class="view-more show-js" href="#">view
more</a></span>
<div class="more-codes"><span id="item-code-s"><span>0002-3240-33,
0002-3240-90, 0002-3270-01, 0002-3270-04, 0002-3270-30,
0002-3270-33</span></span></div>
</li>
<li><strong>Packager:</strong> Eli Lilly and Company</li>
</ul>
<ul class="drug-information">
<li><strong>Category:</strong> <span id="category" class=
"orangetext">HUMAN PRESCRIPTION DRUG LABEL</span></li>
<li><strong>DEA Schedule:</strong> <span id=
"dea-schedule">None</span></li>
<li><strong>Marketing Status:</strong> <span id=
"marketing-status">New Drug Application</span></li>
</ul>
<div id="drug-information" class="toggle">
<h2><a id="druglabel"></a>Drug Label Information</h2>
<p class="date">Updated June 18, 2015</p>
<p class="orangetext">If you are a consumer or patient please visit
<a class="audience-context-switch consumer" href=
"/dailymed/drugInfo.cfm?setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba&amp;audience=consumer">
this version.</a></p>
<ul class="tools">
<li class="download">Download DRUG LABEL INFO: <a download=""
class="pdf" href=
"/dailymed/getFile.cfm?setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba&amp;type=pdf&amp;name=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba"
target="_blank">PDF</a> <a download="" class="xml" href=
"/dailymed/getFile.cfm?setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba&amp;type=zip&amp;name=CYMBALTA"
target="_blank">XML</a></li>
<li class="medguide">Medication Guide: <a href=
"/dailymed/medguide.cfm?setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba"
target="_blank">HTML</a></li>
<li class="print"><a href=
"/dailymed/fda/fdaDrugXsl.cfm?setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba&amp;type=display"
target="_blank">Print Drug Label Info</a></li>
</ul>
<div class="drug-label-sections">
<div class="control-nav show-js"><a class="open-all" href="#">View
All Sections</a><a class="close-all" href="#">Close All
Sections</a></div>
<ul>
<li id="boxedwarning"><a href="#">BOXED WARNING</a><a class=" tip"
rel="tooltip" href="#" title=
"A boxed warning is the strongest warning that the FDA requires, and signifies that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects.">(What
is this?)</a>
<div class="Warning toggle-content open"><a name="s2" id="s2"></a>
<a name="section-1" id="section-1"></a>
<h1>WARNING: SUICIDAL THOUGHTS AND BEHAVIORS</h1>
<p class="First"><span class="Bold">Antidepressants increased the
risk of suicidal thoughts and behavior in children, adolescents,
and young adults in short-term studies. These studies did not show
an increase in the risk of suicidal thoughts and behavior with
antidepressant use in patients over age 24; there was a reduction
in risk with antidepressant use in patients aged 65 and
older</span> <span class="Bold Italics">[see Warnings and
Precautions (<a href="#s22">5.1</a>)]</span>.</p>
<p><span class="Bold">In patients of all ages who are started on
antidepressant therapy, monitor closely for worsening, and for
emergence of suicidal thoughts and behaviors. Advise families and
caregivers of the need for close observation and communication with
the prescriber</span> <span class="Bold Italics">[see Warnings and
Precautions (<a href="#s22">5.1</a>)]</span>.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">HIGHLIGHTS OF PRESCRIBING INFORMATION</a>
<div id="Highlights" class=" Highlights toggle-content closed">
<div class="HighlightsDisclaimer">These highlights do not include
all the information needed to use CYMBALTA safely and effectively.
See full prescribing information for CYMBALTA.<br>
CYMBALTA (Duloxetine Delayed-Release Capsules) for Oral Use.<br>
Initial U.S. Approval: 2004</div>
<div class="Warning">
<div>
<h1 class="Warning"><span class="Bold">WARNING: SUICIDALTHOUGHTS
AND BEHAVIORS</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing
information for complete boxed warning.</span></h1>
<ul class="Disc">
<li><span class="Bold">Increased risk of suicidal thinking and
behavior in children, adolescents, and young adults taking
antidepressants (<a href="#s22">5.1</a>)</span></li>
<li><span class="Bold">Monitor for worsening and emergence of
suicidal thoughts and behaviors (<a href=
"#s22">5.1</a>)</span></li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<table width="100%">
<colgroup>
<col align="left" width="5.067%">
<col align="left" width="81.600%">
<col align="left" width="13.333%"></colgroup>
<tbody class="Headless">
<tr>
<td align="left" colspan="2" valign="top">Boxed Warning: Suicidal
Thoughts and Behaviors</td>
<td align="right" valign="top">10/2014</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Indications and Usage
(<a href="#s3">1</a>)</td>
<td align="right" valign="top">10/2014</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Dosage and
Administration:</td>
<td align="right" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top">Dosage for Treatment of Generalized
Anxiety Disorder (<a href="#s6">2.2</a>)</td>
<td align="right" valign="top">10/2014</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Contraindications:</td>
<td align="right" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top">Uncontrolled Narrow-Angle Glaucoma
(4.2) Removed</td>
<td align="right" valign="top">07/2014</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Warnings and
Precautions:</td>
<td align="right" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top">Orthostatic Hypotension, Falls and
Syncope (<a href="#s24">5.3</a>)</td>
<td align="right" valign="top">11/2014</td>
</tr>
<tr>
<td align="left" valign="top"></td>
<td align="left" valign="top">Angle-Closure Glaucoma (<a href=
"#s30">5.9</a>)</td>
<td align="right" valign="top">07/2014</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">CYMBALTA<span class="Sup">®</span> is a
serotonin and norepinephrine reuptake inhibitor (SNRI) indicated
for:</p>
<ul class="Disc">
<li>Major Depressive Disorder (MDD) (<a href="#s3">1</a>)</li>
<li>Generalized Anxiety Disorder (GAD) (<a href="#s3">1</a>)</li>
<li>Diabetic Peripheral Neuropathic Pain (DPNP) (<a href=
"#s3">1</a>)</li>
<li>Fibromyalgia (FM) (<a href="#s3">1</a>)</li>
<li>Chronic Musculoskeletal Pain (<a href="#s3">1</a>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<ul class="Disc">
<li>Take CYMBALTA once daily, with or without food. Swallow
CYMBALTA whole; do not crush or chew, do not open capsule. Take a
missed dose as soon as it is remembered. Do not take two doses of
CYMBALTA at the same time. (<a href="#s4">2</a>)</li>
</ul>
<table width="100%">
<colgroup>
<col align="left" width="31.842%">
<col align="left" width="19.295%">
<col align="left" width="26.743%">
<col align="left" width="22.119%"></colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Indication</span></td>
<td class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Starting Dose</span></td>
<td class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Target Dose</span></td>
<td class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Maximum Dose</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">MDD
(<a href="#s5">2.1</a>)</td>
<td class="Botrule Rrule" align="left" valign="top">40 mg/day to 60
mg/day</td>
<td class="Botrule Rrule" align="left" valign="top">Acute
Treatment: 40 mg/day (20 mg twice daily) to 60 mg/day (once daily
or as 30 mg twice daily); Maintenance Treatment: 60 mg/day</td>
<td class="Botrule Rrule" align="left" valign="top">120 mg/day</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">GAD (<a href=
"#s6">2.2</a>)</td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Adults</td>
<td class="Rrule" align="left" valign="top">60 mg/day</td>
<td class="Rrule" align="left" valign="top">60 mg/day (once
daily)</td>
<td class="Rrule" align="left" valign="top">120 mg/day</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Elderly</td>
<td class="Rrule" align="left" valign="top">30 mg/day</td>
<td class="Rrule" align="left" valign="top">60 mg/day (once
daily)</td>
<td class="Rrule" align="left" valign="top">120 mg/day</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Children
and Adolescents (7 to 17 years of age)</td>
<td class="Botrule Rrule" align="left" valign="top">30 mg/day</td>
<td class="Botrule Rrule" align="left" valign="top">30 to 60 mg/day
(once daily)</td>
<td class="Botrule Rrule" align="left" valign="top">120 mg/day</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">DPNP
(<a href="#s10">2.3</a>)</td>
<td class="Botrule Rrule" align="left" valign="top">60 mg/day</td>
<td class="Botrule Rrule" align="left" valign="top">60 mg/day (once
daily)</td>
<td class="Botrule Rrule" align="left" valign="top">60 mg/day</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">FM
(<a href="#s11">2.4</a>)</td>
<td class="Botrule Rrule" align="left" valign="top">30 mg/day</td>
<td class="Botrule Rrule" align="left" valign="top">60 mg/day (once
daily)</td>
<td class="Botrule Rrule" align="left" valign="top">60 mg/day</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Chronic
Musculoskeletal Pain (<a href="#s12">2.5</a>)</td>
<td class="Botrule Rrule" align="left" valign="top">30 mg/day</td>
<td class="Botrule Rrule" align="left" valign="top">60 mg/day (once
daily)</td>
<td class="Botrule Rrule" align="left" valign="top">60 mg/day</td>
</tr>
</tbody>
</table>
<ul class="Disc">
<li>Some patients may benefit from starting at 30 mg once daily
(<a href="#s4">2</a>)</li>
<li>There is no evidence that doses greater than 60 mg/day confers
additional benefit, while some adverse reactions were observed to
be dose-dependent (<a href="#s4">2</a>)</li>
<li>Discontinuing CYMBALTA: Gradually reduce dosage to avoid
discontinuation symptoms (<a href="#s16">2.7</a>, <a href=
"#s28">5.7</a>)</li>
<li>Hepatic Impairment: Avoid use in patients with chronic liver
disease or cirrhosis (<a href="#s43">5.14</a>)</li>
<li>Renal Impairment: Avoid use in patients with severe renal
impairment, GFR &lt;30 mL/min (<a href="#s43">5.14</a>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">20 mg, 30 mg, and 60 mg delayed-release
capsules (<a href="#s19">3</a>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<ul class="Disc">
<li>Serotonin Syndrome and MAOIs: Do not use MAOIs intended to
treat psychiatric disorders with CYMBALTA or within 5 days of
stopping treatment with CYMBALTA. Do not use CYMBALTA within 14
days of stopping an MAOI intended to treat psychiatric disorders.
In addition, do not start CYMBALTA in a patient who is being
treated with linezolid or intravenous methylene blue (<a href=
"#s20">4</a>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<ul class="Disc">
<li>Hepatotoxicity: Hepatic failure, sometimes fatal, has been
reported in patients treated with CYMBALTA. CYMBALTA should be
discontinued in patients who develop jaundice or other evidence of
clinically significant liver dysfunction and should not be resumed
unless another cause can be established. CYMBALTA should not be
prescribed to patients with substantial alcohol use or evidence of
chronic liver disease (<a href="#s23">5.2</a>)</li>
<li>Orthostatic Hypotension, Falls and Syncope: Cases have been
reported with CYMBALTA therapy (<a href="#s24">5.3</a>)</li>
<li>Serotonin Syndrome: Serotonin syndrome has been reported with
SSRIs and SNRIs, including with CYMBALTA, both when taken alone,
but especially when co-administered with other serotonergic agents
(including triptans, tricyclic antidepressants, fentanyl, lithium,
tramadol, tryptophan, buspirone and St. John's Wort). If such
symptoms occur, discontinue CYMBALTA and initiate supportive
treatment. If concomitant use of CYMBALTA with other serotonergic
drugs is clinically warranted, patients should be made aware of a
potential increased risk for serotonin syndrome, particularly
during treatment initiation and dose increases (<a href=
"#s25">5.4</a>)</li>
<li>Abnormal Bleeding: CYMBALTA may increase the risk of bleeding
events. Patients should be cautioned about the risk of bleeding
associated with the concomitant use of CYMBALTA and NSAIDs,
aspirin, or other drugs that affect coagulation (<a href=
"#s26">5.5</a>, <a href="#s82">7.4</a>)</li>
<li>Severe Skin Reactions: Severe skin reactions, including
erythema multiforme and Stevens-Johnson Syndrome (SJS), can occur
with CYMBALTA. CYMBALTA should be discontinued at the first
appearance of blisters, peeling rash, mucosal erosions, or any
other sign of hypersensitivity if no other etiology can be
identified. (<a href="#s27">5.6</a>)</li>
<li>Discontinuation: May result in symptoms, including dizziness,
headache, nausea, diarrhea, paresthesia, irritability, vomiting,
insomnia, anxiety, hyperhidrosis, and fatigue (<a href=
"#s28">5.7</a>)</li>
<li>Activation of mania or hypomania has occurred (<a href=
"#s29">5.8</a>)</li>
<li>Angle-Closure Glaucoma: Angle-closure glaucoma has occurred in
patients with untreated anatomically narrow angles treated with
antidepressants. (<a href="#s30">5.9</a>)</li>
<li>Seizures: Prescribe with care in patients with a history of
seizure disorder (<a href="#s31">5.10</a>)</li>
<li>Blood Pressure: Monitor blood pressure prior to initiating
treatment and periodically throughout treatment (<a href=
"#s32">5.11</a>)</li>
<li>Inhibitors of CYP1A2 or Thioridazine: Should not administer
with CYMBALTA (<a href="#s33">5.12</a>)</li>
<li>Hyponatremia: Cases of hyponatremia have been reported
(<a href="#s42">5.13</a>)</li>
<li>Glucose Control in Diabetes: In diabetic peripheral neuropathic
pain patients, small increases in fasting blood glucose, and
HbA<span class="Sub">1c</span> have been observed (<a href=
"#s43">5.14</a>)</li>
<li>Conditions that Slow Gastric Emptying: Use cautiously in these
patients (<a href="#s43">5.14</a>)</li>
<li>Urinary Hesitation and Retention (<a href="#s47">5.15</a>)</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disc">
<li>Most common adverse reactions (≥5% and at least twice the
incidence of placebo patients): nausea, dry mouth, somnolence,
constipation, decreased appetite, and hyperhidrosis (<a href=
"#s60">6.3</a>).</li>
</ul>
<p class="Highlighta"><span class="Bold">To report SUSPECTED
ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx
(1-800-545-5979) or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.</span></p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<ul class="Disc">
<li>Potent inhibitors of CYP1A2 should be avoided (<a href=
"#s79">7.1</a>).</li>
<li>Potent inhibitors of CYP2D6 may increase CYMBALTA
concentrations (<a href="#s80">7.2</a>).</li>
<li>CYMBALTA is a moderate inhibitor of CYP2D6 (<a href=
"#s87">7.9</a>).</li>
</ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC
POPULATIONS</span></h1>
<div>
<ul class="Disc">
<li>Pregnancy: Based on animal data may cause fetal harm (<a href=
"#s97">8.1</a>)</li>
<li>Nursing Mothers: Exercise caution when administered to a
nursing woman (<a href="#s104">8.3</a>)</li>
</ul>
</div>
</div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING
INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 6/2015</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">FULL PRESCRIBING INFORMATION: CONTENTS*</a>
<div id="Index" class=" Index toggle-content closed">
<h1><a href="#section-1" class="toc">WARNING: SUICIDAL THOUGHTS AND
BEHAVIORS</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND
USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND
ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosage for Treatment of
Major Depressive Disorder</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosage for Treatment of
Generalized Anxiety Disorder</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dosage for Treatment of
Diabetic Peripheral Neuropathic Pain</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Dosage for Treatment of
Fibromyalgia</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Dosage for Treatment of
Chronic Musculoskeletal Pain</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Dosing in Special
Populations</a></h2>
<h2><a href="#section-2.7" class="toc">2.7 Discontinuing
CYMBALTA</a></h2>
<h2><a href="#section-2.8" class="toc">2.8 Switching a Patient to
or from a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat
Psychiatric Disorders</a></h2>
<h2><a href="#section-2.9" class="toc">2.9 Use of CYMBALTA with
Other MAOIs such as Linezolid or Methylene Blue</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND
STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND
PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Suicidal Thoughts and
Behaviors in Children, Adolescents, and Young Adults</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Hepatotoxicity</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Orthostatic Hypotension,
Falls and Syncope</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Serotonin
Syndrome</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Abnormal
Bleeding</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Severe Skin
Reactions</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Discontinuation of
Treatment with CYMBALTA</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Activation of
Mania/Hypomania</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Angle-Closure
Glaucoma</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 Seizures</a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Effect on Blood
Pressure</a></h2>
<h2><a href="#section-5.12" class="toc">5.12 Clinically Important
Drug Interactions</a></h2>
<h2><a href="#section-5.13" class="toc">5.13 Hyponatremia</a></h2>
<h2><a href="#section-5.14" class="toc">5.14 Use in Patients with
Concomitant Illness</a></h2>
<h2><a href="#section-5.15" class="toc">5.15 Urinary Hesitation and
Retention</a></h2>
<h2><a href="#section-5.16" class="toc">5.16 Laboratory
Tests</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Data
Sources</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Adverse Reactions
Reported as Reasons for Discontinuation of Treatment in Adult
Placebo-Controlled Trials</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Most Common Adult
Adverse Reactions</a></h2>
<h2><a href="#section-6.4" class="toc">6.4 Adverse Reactions
Occurring at an Incidence of 5% or More Among CYMBALTA-Treated
Patients in Adult Placebo-Controlled Trials</a></h2>
<h2><a href="#section-6.5" class="toc">6.5 Adverse Reactions
Occurring at an Incidence of 2% or More Among CYMBALTA-Treated
Patients in Adult Placebo-Controlled Trials</a></h2>
<h2><a href="#section-6.6" class="toc">6.6 Effects on Male and
Female Sexual Function in Adults</a></h2>
<h2><a href="#section-6.7" class="toc">6.7 Vital Sign Changes in
Adults</a></h2>
<h2><a href="#section-6.8" class="toc">6.8 Laboratory Changes in
Adults</a></h2>
<h2><a href="#section-6.9" class="toc">6.9 Electrocardiogram
Changes in Adults</a></h2>
<h2><a href="#section-6.10" class="toc">6.10 Other Adverse
Reactions Observed During the Premarketing and Postmarketing
Clinical Trial Evaluation of CYMBALTA in Adults</a></h2>
<h2><a href="#section-6.11" class="toc">6.11 Adverse Reactions
Observed in Children and Adolescent Placebo-Controlled Clinical
Trials</a></h2>
<h2><a href="#section-6.12" class="toc">6.12 Postmarketing
Spontaneous Reports</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Inhibitors of
CYP1A2</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Inhibitors of
CYP2D6</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Dual Inhibition of
CYP1A2 and CYP2D6</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Drugs that Interfere
with Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin)</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Lorazepam</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Temazepam</a></h2>
<h2><a href="#section-7.7" class="toc">7.7 Drugs that Affect
Gastric Acidity</a></h2>
<h2><a href="#section-7.8" class="toc">7.8 Drugs Metabolized by
CYP1A2</a></h2>
<h2><a href="#section-7.9" class="toc">7.9 Drugs Metabolized by
CYP2D6</a></h2>
<h2><a href="#section-7.10" class="toc">7.10 Drugs Metabolized by
CYP2C9</a></h2>
<h2><a href="#section-7.11" class="toc">7.11 Drugs Metabolized by
CYP3A</a></h2>
<h2><a href="#section-7.12" class="toc">7.12 Drugs Metabolized by
CYP2C19</a></h2>
<h2><a href="#section-7.13" class="toc">7.13 Monoamine Oxidase
Inhibitors (MAOIs)</a></h2>
<h2><a href="#section-7.14" class="toc">7.14 Serotonergic
Drugs</a></h2>
<h2><a href="#section-7.15" class="toc">7.15 Alcohol</a></h2>
<h2><a href="#section-7.16" class="toc">7.16 CNS Drugs</a></h2>
<h2><a href="#section-7.17" class="toc">7.17 Drugs Highly Bound to
Plasma Protein</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC
POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Gender</a></h2>
<h2><a href="#section-8.6" class="toc">8.7 Smoking Status</a></h2>
<h2><a href="#section-8.7" class="toc">8.8 Race</a></h2>
<h2><a href="#section-8.8" class="toc">8.9 Hepatic
Impairment</a></h2>
<h2><a href="#section-8.9" class="toc">8.10 Severe Renal
Impairment</a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND
DEPENDENCE</a></h1>
<h2><a href="#section-9.1" class="toc">9.2 Abuse</a></h2>
<h2><a href="#section-9.2" class="toc">9.3 Dependence</a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h2><a href="#section-10.1" class="toc">10.1 Signs and
Symptoms</a></h2>
<h2><a href="#section-10.2" class="toc">10.2 Management of
Overdose</a></h2>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL
PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1 Mechanism of
Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2
Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3
Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NONCLINICAL
TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1 Carcinogenesis,
Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1 Major Depressive
Disorder</a></h2>
<h2><a href="#section-14.2" class="toc">14.2 Generalized Anxiety
Disorder</a></h2>
<h2><a href="#section-14.3" class="toc">14.3 Diabetic Peripheral
Neuropathic Pain</a></h2>
<h2><a href="#section-14.4" class="toc">14.4 Fibromyalgia</a></h2>
<h2><a href="#section-14.5" class="toc">14.5 Chronic
Musculoskeletal Pain</a></h2>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND
HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-15.2" class="toc">16.2 Storage and
Handling</a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING
INFORMATION</a></h1>
<dl class="Footnote">
<dt><a name="footnote-content" href="#footnote-reference-content"
id="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing
information are not listed.</dd>
</dl>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">1 INDICATIONS AND USAGE</a>
<div class="Section toggle-content closed" data-sectioncode=
"34067-9"><a name="s3" id="s3"></a> <a name="section-1" id=
"section-1"></a>
<p class="First">CYMBALTA<span class="Sup">®</span> is indicated
for the treatment of:</p>
<ul class="Disc">
<li>Major Depressive Disorder <span class="Italics">[see Clinical
Studies (<a href="#s137">14.1</a> )]</span></li>
<li>Generalized Anxiety Disorder <span class="Italics">[see
Clinical Studies (<a href="#s138">14.2</a> )]</span></li>
<li>Diabetic Peripheral Neuropathy <span class="Italics">[see
Clinical Studies (<a href="#s139">14.3</a> )]</span></li>
<li>Fibromyalgia <span class="Italics">[see Clinical Studies
(<a href="#s140">14.4</a> )]</span></li>
<li>Chronic Musculoskeletal Pain <span class="Italics">[see
Clinical Studies (<a href="#s141">14.5</a> )]</span></li>
</ul>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">2 DOSAGE AND ADMINISTRATION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34068-7"><a name="s4" id="s4"></a> <a name="section-2" id=
"section-2"></a>
<p class="First">Swallow CYMBALTA whole. Do not chew or crush. Do
not open the capsule and sprinkle its contents on food or mix with
liquids. All of these might affect the enteric coating. CYMBALTA
can be given without regard to meals. If a dose of CYMBALTA is
missed, take the missed dose as soon as it is remembered. If it is
almost time for the next dose, skip the missed dose and take the
next dose at the regular time. Do not take two doses of CYMBALTA at
the same time.</p>
<div class="Section" data-sectioncode="42229-5"><a name="s5" id=
"s5"></a> <a name="section-2.1" id="section-2.1"></a>
<h2>2.1 Dosage for Treatment of Major Depressive Disorder</h2>
<p class="First">Administer CYMBALTA at a total dose of 40 mg/day
(given as 20 mg twice daily) to 60 mg/day (given either once daily
or as 30 mg twice daily). For some patients, it may be desirable to
start at 30 mg once daily for 1 week, to allow patients to adjust
to the medication before increasing to 60 mg once daily. While a
120 mg/day dose was shown to be effective, there is no evidence
that doses greater than 60 mg/day confer any additional benefits.
The safety of doses above 120 mg/day has not been adequately
evaluated. Periodically reassess to determine the need for
maintenance treatment and the appropriate dose for such treatment
<span class="Italics">[see Clinical Studies (<a href=
"#s137">14.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s6" id=
"s6"></a> <a name="section-2.2" id="section-2.2"></a>
<h2>2.2 Dosage for Treatment of Generalized Anxiety Disorder</h2>
<div class="Section" data-sectioncode="42229-5"><a name="s7" id=
"s7"></a> <a name="section-2.2.1" id="section-2.2.1"></a>
<p class="First"><span class="Underline">Adults</span> — For most
patients, initiate CYMBALTA 60 mg once daily. For some patients, it
may be desirable to start at 30 mg once daily for 1 week, to allow
patients to adjust to the medication before increasing to 60 mg
once daily. While a 120 mg once daily dose was shown to be
effective, there is no evidence that doses greater than 60 mg/day
confer additional benefit. Nevertheless, if a decision is made to
increase the dose beyond 60 mg once daily, increase dose in
increments of 30 mg once daily. The safety of doses above 120 mg
once daily has not been adequately evaluated. Periodically reassess
to determine the continued need for maintenance treatment and the
appropriate dose for such treatment <span class="Italics">[see
Clinical Studies (<a href="#s138">14.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s8" id=
"s8"></a> <a name="section-2.2.2" id="section-2.2.2"></a>
<p class="First" style="border-left:1px solid;"><span class=
"Underline">Elderly</span> — Initiate CYMBALTA at a dose of 30 mg
once daily for 2 weeks before considering an increase to the target
dose of 60 mg. Thereafter, patients may benefit from doses above 60
mg once daily. If a decision is made to increase the dose beyond 60
mg once daily, increase dose in increments of 30 mg once daily. The
maximum dose studied was 120 mg per day. Safety of doses above 120
mg once daily has not been adequately evaluated <span class=
"Italics">[see Clinical Studies (<a href=
"#s138">14.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s9" id=
"s9"></a> <a name="section-2.2.3" id="section-2.2.3"></a>
<p class="First" style="border-left:1px solid;"><span class=
"Underline">Children and Adolescents (7 to 17 years of age)</span>
— Initiate CYMBALTA at a dose of 30 mg once daily for 2 weeks
before considering an increase to 60 mg. The recommended dose range
is 30 to 60 mg once daily. Some patients may benefit from doses
above 60 mg once daily. If a decision is made to increase the dose
beyond 60 mg once daily, increase dose in increments of 30 mg once
daily. The maximum dose studied was 120 mg per day. The safety of
doses above 120 mg once daily has not been evaluated <span class=
"Italics">[see Clinical Studies (<a href=
"#s138">14.2</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s10" id=
"s10"></a> <a name="section-2.3" id="section-2.3"></a>
<h2>2.3 Dosage for Treatment of Diabetic Peripheral Neuropathic
Pain</h2>
<p class="First">Administer CYMBALTA 60 mg once daily. There is no
evidence that doses higher than 60 mg confer additional significant
benefit and the higher dose is clearly less well tolerated
<span class="Italics">[see Clinical Studies (<a href=
"#s139">14.3</a>)]</span>. For patients for whom tolerability is a
concern, a lower starting dose may be considered.</p>
<p>Since diabetes is frequently complicated by renal disease,
consider a lower starting dose and gradual increase in dose for
patients with renal impairment <span class="Italics">[see Dosage
and Administration (<a href="#s13">2.6</a>), Use in Specific
Populations (<a href="#s116">8.10</a>), and Clinical Pharmacology
(<a href="#s127">12.3</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s11" id=
"s11"></a> <a name="section-2.4" id="section-2.4"></a>
<h2>2.4 Dosage for Treatment of Fibromyalgia</h2>
<p class="First">Administer CYMBALTA 60 mg once daily. Begin
treatment at 30 mg once daily for 1 week, to allow patients to
adjust to the medication before increasing to 60 mg once daily.
Some patients may respond to the starting dose. There is no
evidence that doses greater than 60 mg/day confer additional
benefit, even in patients who do not respond to a 60 mg dose, and
higher doses are associated with a higher rate of adverse reactions
<span class="Italics">[see Clinical Studies (<a href=
"#s140">14.4</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s12" id=
"s12"></a> <a name="section-2.5" id="section-2.5"></a>
<h2>2.5 Dosage for Treatment of Chronic Musculoskeletal Pain</h2>
<p class="First">Administer CYMBALTA 60 mg once daily. Begin
treatment at 30 mg for one week, to allow patients to adjust to the
medication before increasing to 60 mg once daily. There is no
evidence that higher doses confer additional benefit, even in
patients who do not respond to a 60 mg dose, and higher doses are
associated with a higher rate of adverse reactions <span class=
"Italics">[see Clinical Studies (<a href=
"#s141">14.5</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s13" id=
"s13"></a> <a name="section-2.6" id="section-2.6"></a>
<h2>2.6 Dosing in Special Populations</h2>
<div class="Section" data-sectioncode="42229-5"><a name="s14" id=
"s14"></a> <a name="section-2.6.1" id="section-2.6.1"></a>
<p class="First"><span class="Underline">Hepatic Impairment</span>
— Avoid use in patients with chronic liver disease or cirrhosis
<span class="Italics">[see Warnings and Precautions (<a href=
"#s43">5.14</a>) and Use in Specific Populations (<a href=
"#s115">8.9</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s15" id=
"s15"></a> <a name="section-2.6.2" id="section-2.6.2"></a>
<p class="First"><span class="Underline">Severe Renal
Impairment</span> — Avoid use in patients with severe renal
impairment, GFR &lt;30 mL/min <span class="Italics">[see Warnings
and Precautions (<a href="#s43">5.14</a>) and Use in Specific
Populations (<a href="#s116">8.10</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s16" id=
"s16"></a> <a name="section-2.7" id="section-2.7"></a>
<h2>2.7 Discontinuing CYMBALTA</h2>
<p class="First">Adverse reactions after discontinuation of
CYMBALTA, after abrupt or tapered discontinuation, include:
dizziness, headache, nausea, diarrhea, paresthesia, irritability,
vomiting, insomnia, anxiety, hyperhidrosis, and fatigue. A gradual
reduction in dosage rather than abrupt cessation is recommended
whenever possible <span class="Italics">[see Warnings and
Precautions (<a href="#s28">5.7</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s17" id=
"s17"></a> <a name="section-2.8" id="section-2.8"></a>
<h2>2.8 Switching a Patient to or from a Monoamine Oxidase
Inhibitor (MAOI) Intended to Treat Psychiatric Disorders</h2>
<p class="First">At least 14 days should elapse between
discontinuation of an MAOI intended to treat psychiatric disorders
and initiation of therapy with CYMBALTA. Conversely, at least 5
days should be allowed after stopping CYMBALTA before starting an
MAOI intended to treat psychiatric disorders <span class=
"Italics">[see Contraindications (<a href=
"#s20">4</a>)].</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s18" id=
"s18"></a> <a name="section-2.9" id="section-2.9"></a>
<h2>2.9 Use of CYMBALTA with Other MAOIs such as Linezolid or
Methylene Blue</h2>
<p class="First">Do not start CYMBALTA in a patient who is being
treated with linezolid or intravenous methylene blue because there
is an increased risk of serotonin syndrome. In a patient who
requires more urgent treatment of a psychiatric condition, other
interventions, including hospitalization, should be considered
<span class="Italics">[see Contraindications (<a href=
"#s20">4</a>)].</span></p>
<p>In some cases, a patient already receiving CYMBALTA therapy may
require urgent treatment with linezolid or intravenous methylene
blue. If acceptable alternatives to linezolid or intravenous
methylene blue treatment are not available and the potential
benefits of linezolid or intravenous methylene blue treatment are
judged to outweigh the risks of serotonin syndrome in a particular
patient, CYMBALTA should be stopped promptly, and linezolid or
intravenous methylene blue can be administered. The patient should
be monitored for symptoms of serotonin syndrome for 5 days or until
24 hours after the last dose of linezolid or intravenous methylene
blue, whichever comes first. Therapy with CYMBALTA may be resumed
24 hours after the last dose of linezolid or intravenous methylene
blue <span class="Italics">[see Warnings and Precautions (<a href=
"#s25">5.4</a>)]</span>.</p>
<p>The risk of administering methylene blue by non-intravenous
routes (such as oral tablets or by local injection) or in
intravenous doses much lower than 1 mg/kg with CYMBALTA is unclear.
The clinician should, nevertheless, be aware of the possibility of
emergent symptoms of serotonin syndrome with such use <span class=
"Italics">[see Warnings and Precautions (<a href=
"#s25">5.4</a>)]</span>.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">3 DOSAGE FORMS AND STRENGTHS</a>
<div class="Section toggle-content closed" data-sectioncode=
"43678-2"><a name="s19" id="s19"></a> <a name="section-3" id=
"section-3"></a>
<p class="First">CYMBALTA is available as delayed release
capsules:</p>
<p>20 mg opaque green capsules imprinted with “Lilly 3235 20mg”</p>
<p>30 mg opaque white and blue capsules imprinted with “Lilly 3240
30mg”</p>
<p>60 mg opaque green and blue capsules imprinted with “Lilly 3270
60mg”</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">4 CONTRAINDICATIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34070-3"><a name="s20" id="s20"></a> <a name="section-4" id=
"section-4"></a>
<p class="First">Monoamine Oxidase Inhibitors (MAOIs) — The use of
MAOIs intended to treat psychiatric disorders with CYMBALTA or
within 5 days of stopping treatment with CYMBALTA is
contraindicated because of an increased risk of serotonin syndrome.
The use of CYMBALTA within 14 days of stopping an MAOI intended to
treat psychiatric disorders is also contraindicated <span class=
"Italics">[see Dosage and Administration (<a href="#s17">2.8</a>)
and Warnings and Precautions (<a href="#s25">5.4</a>)]</span>.</p>
<p>Starting CYMBALTA in a patient who is being treated with MAOIs
such as linezolid or intravenous methylene blue is also
contraindicated because of an increased risk of serotonin syndrome
<span class="Italics">[see Dosage and Administration (<a href=
"#s18">2.9</a>) and Warnings and Precautions (<a href=
"#s25">5.4</a>)]</span>.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">5 WARNINGS AND PRECAUTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"43685-7"><a name="s21" id="s21"></a> <a name="section-5" id=
"section-5"></a>
<div class="Section" data-sectioncode="42229-5"><a name="s22" id=
"s22"></a> <a name="section-5.1" id="section-5.1"></a>
<h2>5.1 Suicidal Thoughts and Behaviors in Children, Adolescents,
and Young Adults</h2>
<p class="First">Patients with major depressive disorder (MDD),
both adult and pediatric, may experience worsening of their
depression and/or the emergence of suicidal ideation and behavior
(suicidality) or unusual changes in behavior, whether or not they
are taking antidepressant medications, and this risk may persist
until significant remission occurs. Suicide is a known risk of
depression and certain other psychiatric disorders, and these
disorders themselves are the strongest predictors of suicide. There
has been a long-standing concern, however, that antidepressants may
have a role in inducing worsening of depression and the emergence
of suicidality in certain patients during the early phases of
treatment.</p>
<p>Pooled analyses of short-term placebo-controlled trials of
antidepressant drugs (SSRIs and others) showed that these drugs
increase the risk of suicidal thinking and behavior (suicidality)
in children, adolescents, and young adults (ages 18-24) with major
depressive disorder (MDD) and other psychiatric disorders.
Short-term studies did not show an increase in the risk of
suicidality with antidepressants compared to placebo in adults
beyond age 24; there was a reduction with antidepressants compared
to placebo in adults aged 65 and older.</p>
<p>The pooled analyses of placebo-controlled trials in children and
adolescents with MDD, obsessive compulsive disorder (OCD), or other
psychiatric disorders included a total of 24 short-term trials of 9
antidepressant drugs in over 4400 patients. The pooled analyses of
placebo-controlled trials in adults with MDD or other psychiatric
disorders included a total of 295 short-term trials (median
duration of 2 months) of 11 antidepressant drugs in over 77,000
patients. There was considerable variation in risk of suicidality
among drugs, but a tendency toward an increase in the younger
patients for almost all drugs studied. There were differences in
absolute risk of suicidality across the different indications, with
the highest incidence in MDD. The risk of differences (drug vs
placebo), however, were relatively stable within age strata and
across indications. These risk differences (drug-placebo difference
in the number of cases of suicidality per 1000 patients treated)
are provided in <a href="#t1">Table 1</a>.</p>
<a name="t1" id="t1"></a>
<div class="scrollingtable">
<table width="100%">
<caption><span>Table 1</span></caption>
<colgroup>
<col align="left" width="50.000%">
<col align="left" width="50.000%"></colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign=
"top"><span class="Bold">Age Range</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Drug-Placebo Difference in Number of Cases of
Suicidality per 1000 Patients Treated</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">Increases
Compared to Placebo</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
&lt;18</td>
<td class="Botrule Rrule" align="center" valign="top">14 additional
cases</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
18-24</td>
<td class="Botrule Rrule" align="center" valign="top">5 additional
cases</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top">Decreases
Compared to Placebo</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top">
25-64</td>
<td class="Botrule Rrule" align="center" valign="top">1 fewer
case</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">
≥65</td>
<td class="Botrule Rrule" align="center" valign="top">6 fewer
cases</td>
</tr>
</tbody>
</table>
</div>
<p>No suicides occurred in any of the pediatric trials. There were
suicides in the adult trials, but the number was not sufficient to
reach any conclusion about drug effect on suicide.</p>
<p>It is unknown whether the suicidality risk extends to
longer-term use, i.e., beyond several months. However, there is
substantial evidence from placebo-controlled maintenance trials in
adults with depression that the use of antidepressants can delay
the recurrence of depression.</p>
<p><span class="Bold">All patients being treated with
antidepressants for any indication should be monitored
appropriately and observed closely for clinical worsening,
suicidality, and unusual changes in behavior, especially during the
initial few months of a course of drug therapy, or at times of dose
changes, either increases or decreases.</span></p>
<p>The following symptoms, anxiety, agitation, panic attacks,
insomnia, irritability, hostility, aggressiveness, impulsivity,
akathisia (psychomotor restlessness), hypomania, and mania, have
been reported in adult and pediatric patients being treated with
antidepressants for major depressive disorder as well as for other
indications, both psychiatric and nonpsychiatric. Although a causal
link between the emergence of such symptoms and either the
worsening of depression and/or the emergence of suicidal impulses
has not been established, there is concern that such symptoms may
represent precursors to emerging suicidality.</p>
<p>Consideration should be given to changing the therapeutic
regimen, including possibly discontinuing the medication, in
patients whose depression is persistently worse, or who are
experiencing emergent suicidality or symptoms that might be
precursors to worsening depression or suicidality, especially if
these symptoms are severe, abrupt in onset, or were not part of the
patient's presenting symptoms.</p>
<p>If the decision has been made to discontinue treatment,
medication should be tapered, as rapidly as is feasible, but with
recognition that discontinuation can be associated with certain
symptoms <span class="Italics">[see Dosage and Administration
(<a href="#s16">2.7</a>) and Warnings and Precautions (<a href=
"#s28">5.7</a>) for descriptions of the risks of discontinuation of
CYMBALTA]</span>.</p>
<p><span class="Bold">Families and caregivers of patients being
treated with antidepressants for major depressive disorder or other
indications, both psychiatric and nonpsychiatric, should be alerted
about the need to monitor patients for the emergence of agitation,
irritability, unusual changes in behavior, and the other symptoms
described above, as well as the emergence of suicidality, and to
report such symptoms immediately to health care providers. Such
monitoring should include daily observation by families and
caregivers. Prescriptions for CYMBALTA should be written for the
smallest quantity of capsules consistent with good patient
management, in order to reduce the risk of overdose.</span></p>
<p><span class="Bold">Screening Patients for Bipolar
Disorder</span> — A major depressive episode may be the initial
presentation of bipolar disorder. It is generally believed (though
not established in controlled trials) that treating such an episode
with an antidepressant alone may increase the likelihood of
precipitation of a mixed/manic episode in patients at risk for
bipolar disorder. Whether any of the symptoms described above
represent such a conversion is unknown. However, prior to
initiating treatment with an antidepressant, patients with
depressive symptoms should be adequately screened to determine if
they are at risk for bipolar disorder; such screening should
include a detailed psychiatric history, including a family history
of suicide, bipolar disorder, and depression. It should be noted
that CYMBALTA is not approved for use in treating bipolar
depression.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s23" id=
"s23"></a> <a name="section-5.2" id="section-5.2"></a>
<h2>5.2 Hepatotoxicity</h2>
<p class="First">There have been reports of hepatic failure,
sometimes fatal, in patients treated with CYMBALTA. These cases
have presented as hepatitis with abdominal pain, hepatomegaly, and
elevation of transaminase levels to more than twenty times the
upper limit of normal with or without jaundice, reflecting a mixed
or hepatocellular pattern of liver injury. CYMBALTA should be
discontinued in patients who develop jaundice or other evidence of
clinically significant liver dysfunction and should not be resumed
unless another cause can be established.</p>
<p>Cases of cholestatic jaundice with minimal elevation of
transaminase levels have also been reported. Other postmarketing
reports indicate that elevated transaminases, bilirubin, and
alkaline phosphatase have occurred in patients with chronic liver
disease or cirrhosis.</p>
<p>CYMBALTA increased the risk of elevation of serum transaminase
levels in development program clinical trials. Liver transaminase
elevations resulted in the discontinuation of 0.3% (92/34,756) of
CYMBALTA-treated patients. In most patients, the median time to
detection of the transaminase elevation was about two months. In
adult placebo-controlled trials in any indication, for patients
with normal and abnormal baseline ALT values, elevation of ALT
&gt;3 times the upper limit of normal occurred in 1.25%
(144/11,496) of CYMBALTA-treated patients compared to 0.45%
(39/8716) of placebo-treated patients. In adult placebo-controlled
studies using a fixed dose design, there was evidence of a dose
response relationship for ALT and AST elevation of &gt;3 times the
upper limit of normal and &gt;5 times the upper limit of normal,
respectively.</p>
<p>Because it is possible that CYMBALTA and alcohol may interact to
cause liver injury or that CYMBALTA may aggravate pre-existing
liver disease, CYMBALTA should not be prescribed to patients with
substantial alcohol use or evidence of chronic liver disease.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s24" id=
"s24"></a> <a name="section-5.3" id="section-5.3"></a>
<h2 style="border-left:1px solid;">5.3 Orthostatic Hypotension,
Falls and Syncope</h2>
<p class="First" style="border-left:1px solid;">Orthostatic
hypotension, falls and syncope have been reported with therapeutic
doses of CYMBALTA. Syncope and orthostatic hypotension tend to
occur within the first week of therapy but can occur at any time
during CYMBALTA treatment, particularly after dose increases. The
risk of falling appears to be related to the degree of orthostatic
decrease in blood pressure as well as other factors that may
increase the underlying risk of falls.</p>
<p style="border-left:1px solid;">In an analysis of patients from
all placebo-controlled trials, patients treated with CYMBALTA
reported a higher rate of falls compared to patients treated with
placebo. Risk appears to be related to the presence of orthostatic
decrease in blood pressure. The risk of blood pressure decreases
may be greater in patients taking concomitant medications that
induce orthostatic hypotension (such as antihypertensives) or are
potent CYP1A2 inhibitors <span class="Italics">[see Warnings and
Precautions (<a href="#s33">5.12</a>) and Drug Interactions
(<a href="#s79">7.1</a>)]</span> and in patients taking CYMBALTA at
doses above 60 mg daily. Consideration should be given to dose
reduction or discontinuation of CYMBALTA in patients who experience
symptomatic orthostatic hypotension, falls and/or syncope during
CYMBALTA therapy.</p>
<p style="border-left:1px solid;">Risk of falling also appeared to
be proportional to a patient's underlying risk for falls and
appeared to increase steadily with age. As elderly patients tend to
have a higher underlying risk for falls due to a higher prevalence
of risk factors such as use of multiple medications, medical
comorbidities and gait disturbances, the impact of increasing age
by itself is unclear. Falls with serious consequences including
bone fractures and hospitalizations have been reported <span class=
"Italics">[see Adverse Reactions (<a href="#s74">6.10</a>) and
Patient Counseling Information (<a href=
"#s147">17</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s25" id=
"s25"></a> <a name="section-5.4" id="section-5.4"></a>
<h2>5.4 Serotonin Syndrome</h2>
<p class="First">The development of a potentially life-threatening
serotonin syndrome has been reported with SNRIs and SSRIs,
including CYMBALTA, alone but particularly with concomitant use of
other serotonergic drugs (including triptans, tricyclic
antidepressants, fentanyl, lithium, tramadol, tryptophan,
buspirone, and St. John's Wort) and with drugs that impair
metabolism of serotonin (in particular, MAOIs, both those intended
to treat psychiatric disorders and also others, such as linezolid
and intravenous methylene blue).</p>
<p>Serotonin syndrome symptoms may include mental status changes
(e.g., agitation, hallucinations, delirium, and coma), autonomic
instability (e.g., tachycardia, labile blood pressure, dizziness,
diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g.,
tremor, rigidity, myoclonus, hyperreflexia, incoordination),
seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting,
diarrhea). Patients should be monitored for the emergence of
serotonin syndrome.</p>
<p>The concomitant use of CYMBALTA with MAOIs intended to treat
psychiatric disorders is contraindicated. CYMBALTA should also not
be started in a patient who is being treated with MAOIs such as
linezolid or intravenous methylene blue. All reports with methylene
blue that provided information on the route of administration
involved intravenous administration in the dose range of 1 mg/kg to
8 mg/kg. No reports involved the administration of methylene blue
by other routes (such as oral tablets or local tissue injection) or
at lower doses. There may be circumstances when it is necessary to
initiate treatment with an MAOI such as linezolid or intravenous
methylene blue in a patient taking CYMBALTA. CYMBALTA should be
discontinued before initiating treatment with the MAOI <span class=
"Italics">[see Dosage and Administration (<a href="#s17">2.8</a>,
<a href="#s18">2.9</a>), and Contraindications (<a href=
"#s20">4</a>)].</span></p>
<p>If concomitant use of CYMBALTA with other serotonergic drugs
including triptans, tricyclic antidepressants, fentanyl, lithium,
tramadol, buspirone, tryptophan and St. John's Wort is clinically
warranted, patients should be made aware of a potential increased
risk for serotonin syndrome, particularly during treatment
initiation and dose increases. Treatment with CYMBALTA and any
concomitant serotonergic agents, should be discontinued immediately
if the above events occur and supportive symptomatic treatment
should be initiated.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s26" id=
"s26"></a> <a name="section-5.5" id="section-5.5"></a>
<h2>5.5 Abnormal Bleeding</h2>
<p class="First">SSRIs and SNRIs, including CYMBALTA, may increase
the risk of bleeding events. Concomitant use of aspirin,
nonsteroidal anti-inflammatory drugs, warfarin, and other
anti-coagulants may add to this risk. Case reports and
epidemiological studies (case-control and cohort design) have
demonstrated an association between use of drugs that interfere
with serotonin reuptake and the occurrence of gastrointestinal
bleeding. Bleeding events related to SSRIs and SNRIs use have
ranged from ecchymoses, hematomas, epistaxis, and petechiae to
life-threatening hemorrhages.</p>
<p>Patients should be cautioned about the risk of bleeding
associated with the concomitant use of CYMBALTA and NSAIDs,
aspirin, or other drugs that affect coagulation.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s27" id=
"s27"></a> <a name="section-5.6" id="section-5.6"></a>
<h2>5.6 Severe Skin Reactions</h2>
<p class="First">Severe skin reactions, including erythema
multiforme and Stevens-Johnson Syndrome (SJS), can occur with
CYMBALTA. The reporting rate of SJS associated with CYMBALTA use
exceeds the general population background incidence rate for this
serious skin reaction (1 to 2 cases per million person years). The
reporting rate is generally accepted to be an underestimate due to
underreporting.</p>
<p>CYMBALTA should be discontinued at the first appearance of
blisters, peeling rash, mucosal erosions, or any other sign of
hypersensitivity if no other etiology can be identified.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s28" id=
"s28"></a> <a name="section-5.7" id="section-5.7"></a>
<h2>5.7 Discontinuation of Treatment with CYMBALTA</h2>
<p class="First">Discontinuation symptoms have been systematically
evaluated in patients taking CYMBALTA. Following abrupt or tapered
discontinuation in adult placebo-controlled clinical trials, the
following symptoms occurred at 1% or greater and at a significantly
higher rate in CYMBALTA-treated patients compared to those
discontinuing from placebo: dizziness, headache, nausea, diarrhea,
paresthesia, irritability, vomiting, insomnia, anxiety,
hyperhidrosis, and fatigue.</p>
<p>During marketing of other SSRIs and SNRIs (serotonin and
norepinephrine reuptake inhibitors), there have been spontaneous
reports of adverse events occurring upon discontinuation of these
drugs, particularly when abrupt, including the following: dysphoric
mood, irritability, agitation, dizziness, sensory disturbances
(e.g., paresthesias such as electric shock sensations), anxiety,
confusion, headache, lethargy, emotional lability, insomnia,
hypomania, tinnitus, and seizures. Although these events are
generally self-limiting, some have been reported to be severe.</p>
<p>Patients should be monitored for these symptoms when
discontinuing treatment with CYMBALTA. A gradual reduction in the
dose rather than abrupt cessation is recommended whenever possible.
If intolerable symptoms occur following a decrease in the dose or
upon discontinuation of treatment, then resuming the previously
prescribed dose may be considered. Subsequently, the physician may
continue decreasing the dose but at a more gradual rate
<span class="Italics">[see Dosage and Administration (<a href=
"#s16">2.7</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s29" id=
"s29"></a> <a name="section-5.8" id="section-5.8"></a>
<h2>5.8 Activation of Mania/Hypomania</h2>
<p class="First">In adult placebo-controlled trials in patients
with major depressive disorder, activation of mania or hypomania
was reported in 0.1% (4/3779) of CYMBALTA-treated patients and
0.04% (1/2536) of placebo-treated patients. No activation of mania
or hypomania was reported in DPNP, GAD, fibromyalgia, or chronic
musculoskeletal pain placebo-controlled trials. Activation of mania
or hypomania has been reported in a small proportion of patients
with mood disorders who were treated with other marketed drugs
effective in the treatment of major depressive disorder. As with
these other agents, CYMBALTA should be used cautiously in patients
with a history of mania.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s30" id=
"s30"></a> <a name="section-5.9" id="section-5.9"></a>
<h2 style="border-left:1px solid;">5.9 Angle-Closure Glaucoma</h2>
<p class="First" style="border-left:1px solid;">The pupillary
dilation that occurs following use of many antidepressant drugs
including CYMBALTA may trigger an angle closure attack in a patient
with anatomically narrow angles who does not have a patent
iridectomy.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s31" id=
"s31"></a> <a name="section-5.10" id="section-5.10"></a>
<h2>5.10 Seizures</h2>
<p class="First">CYMBALTA has not been systematically evaluated in
patients with a seizure disorder, and such patients were excluded
from clinical studies. In adult placebo-controlled clinical trials,
seizures/convulsions occurred in 0.02% (3/12,722) of patients
treated with CYMBALTA and 0.01% (1/9513) of patients treated with
placebo. CYMBALTA should be prescribed with care in patients with a
history of a seizure disorder.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s32" id=
"s32"></a> <a name="section-5.11" id="section-5.11"></a>
<h2>5.11 Effect on Blood Pressure</h2>
<p class="First">In adult placebo-controlled clinical trials across
indications from baseline to endpoint, CYMBALTA treatment was
associated with mean increases of 0.5 mm Hg in systolic blood
pressure and 0.8 mm Hg in diastolic blood pressure compared to mean
decreases of 0.6 mm Hg systolic and 0.3 mm Hg diastolic in
placebo-treated patients. There was no significant difference in
the frequency of sustained (3 consecutive visits) elevated blood
pressure. In a clinical pharmacology study designed to evaluate the
effects of CYMBALTA on various parameters, including blood pressure
at supratherapeutic doses with an accelerated dose titration, there
was evidence of increases in supine blood pressure at doses up to
200 mg twice daily. At the highest 200 mg twice daily dose, the
increase in mean pulse rate was 5.0 to 6.8 beats and increases in
mean blood pressure were 4.7 to 6.8 mm Hg (systolic) and 4.5 to 7
mm Hg (diastolic) up to 12 hours after dosing.</p>
<p>Blood pressure should be measured prior to initiating treatment
and periodically measured throughout treatment <span class=
"Italics">[see Adverse Reactions (<a href=
"#s71">6.7</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s33" id=
"s33"></a> <a name="section-5.12" id="section-5.12"></a>
<h2>5.12 Clinically Important Drug Interactions</h2>
<p class="First">Both CYP1A2 and CYP2D6 are responsible for
CYMBALTA metabolism.</p>
<div class="Section" data-sectioncode="42229-5"><a name="s34" id=
"s34"></a> <a name="section-5.12.1" id="section-5.12.1"></a>
<p class="First"><span class="Underline">Potential for Other Drugs
to Affect CYMBALTA</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s35" id=
"s35"></a> <a name="section-5.12.2" id="section-5.12.2"></a>
<p class="First"><span class="Italics">CYP1A2 Inhibitors</span> —
Co-administration of CYMBALTA with potent CYP1A2 inhibitors should
be avoided <span class="Italics">[see Drug Interactions (<a href=
"#s79">7.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s36" id=
"s36"></a> <a name="section-5.12.3" id="section-5.12.3"></a>
<p class="First"><span class="Italics">CYP2D6 Inhibitors</span> —
Because CYP2D6 is involved in CYMBALTA metabolism, concomitant use
of CYMBALTA with potent inhibitors of CYP2D6 would be expected to,
and does, result in higher concentrations (on average of 60%) of
CYMBALTA <span class="Italics">[see Drug Interactions (<a href=
"#s80">7.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s37" id=
"s37"></a> <a name="section-5.12.4" id="section-5.12.4"></a>
<p class="First"><span class="Underline">Potential for CYMBALTA to
Affect Other Drugs</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s38" id=
"s38"></a> <a name="section-5.12.5" id="section-5.12.5"></a>
<p class="First"><span class="Italics">Drugs Metabolized by
CYP2D6</span> — Co-administration of CYMBALTA with drugs that are
extensively metabolized by CYP2D6 and that have a narrow
therapeutic index, including certain antidepressants (tricyclic
antidepressants [TCAs], such as nortriptyline, amitriptyline, and
imipramine), phenothiazines and Type 1C antiarrhythmics (e.g.,
propafenone, flecainide), should be approached with caution. Plasma
TCA concentrations may need to be monitored and the dose of the TCA
may need to be reduced if a TCA is co-administered with CYMBALTA.
Because of the risk of serious ventricular arrhythmias and sudden
death potentially associated with elevated plasma levels of
thioridazine, CYMBALTA and thioridazine should not be
co-administered <span class="Italics">[see Drug Interactions
(<a href="#s87">7.9</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s39" id=
"s39"></a> <a name="section-5.12.6" id="section-5.12.6"></a>
<p class="First"><span class="Underline">Other Clinically Important
Drug Interactions</span></p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s40" id=
"s40"></a> <a name="section-5.12.7" id="section-5.12.7"></a>
<p class="First"><span class="Italics">Alcohol</span> — Use of
CYMBALTA concomitantly with heavy alcohol intake may be associated
with severe liver injury. For this reason, CYMBALTA should not be
prescribed for patients with substantial alcohol use <span class=
"Italics">[see Warnings and Precautions (<a href="#s23">5.2</a>)
and Drug Interactions (<a href="#s93">7.15</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s41" id=
"s41"></a> <a name="section-5.12.8" id="section-5.12.8"></a>
<p class="First"><span class="Italics">CNS Acting Drugs</span> —
Given the primary CNS effects of CYMBALTA, it should be used with
caution when it is taken in combination with or substituted for
other centrally acting drugs, including those with a similar
mechanism of action <span class="Italics">[see Warnings and
Precautions (<a href="#s33">5.12</a>) and Drug Interactions
(<a href="#s94">7.16</a>)]</span>.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s42" id=
"s42"></a> <a name="section-5.13" id="section-5.13"></a>
<h2>5.13 Hyponatremia</h2>
<p class="First">Hyponatremia may occur as a result of treatment
with SSRIs and SNRIs, including CYMBALTA. In many cases, this
hyponatremia appears to be the result of the syndrome of
inappropriate antidiuretic hormone secretion (SIADH). Cases with
serum sodium lower than 110 mmol/L have been reported and appeared
to be reversible when CYMBALTA was discontinued. Elderly patients
may be at greater risk of developing hyponatremia with SSRIs and
SNRIs. Also, patients taking diuretics or who are otherwise volume
depleted may be at greater risk <span class="Italics">[see Use in
Specific Populations (<a href="#s111">8.5</a>)]</span>.
Discontinuation of CYMBALTA should be considered in patients with
symptomatic hyponatremia and appropriate medical intervention
should be instituted.</p>
<p>Signs and symptoms of hyponatremia include headache, difficulty
concentrating, memory impairment, confusion, weakness, and
unsteadiness, which may lead to falls. More severe and/or acute
cases have been associated with hallucination, syncope, seizure,
coma, respiratory arrest, and death.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s43" id=
"s43"></a> <a name="section-5.14" id="section-5.14"></a>
<h2>5.14 Use in Patients with Concomitant Illness</h2>
<p class="First">Clinical experience with CYMBALTA in patients with
concomitant systemic illnesses is limited. There is no information
on the effect that alterations in gastric motility may have on the
stability of CYMBALTA's enteric coating. In extremely acidic
conditions, CYMBALTA, unprotected by the enteric coating, may
undergo hydrolysis to form naphthol. Caution is advised in using
CYMBALTA in patients with conditions that may slow gastric emptying
(e.g., some diabetics).</p>
<p>CYMBALTA has not been systematically evaluated in patients with
a recent history of myocardial infarction or unstable coronary
artery disease. Patients with these diagnoses were generally
excluded from clinical studies during the product's premarketing
testing.</p>
<div class="Section" data-sectioncode="42229-5"><a name="s44" id=
"s44"></a> <a name="section-5.14.1" id="section-5.14.1"></a>
<p class="First"><span class="Underline">Hepatic Impairment</span>
— Avoid use in patients with chronic liver disease or cirrhosis
<span class="Italics">[see Dosage and Administration (<a href=
"#s13">2.6</a>), Warnings and Precautions (<a href="#s23">5.2</a>),
and Use in Specific Populations (<a href=
"#s115">8.9</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s45" id=
"s45"></a> <a name="section-5.14.2" id="section-5.14.2"></a>
<p class="First"><span class="Underline">Severe Renal
Impairment</span> — Avoid use in patients with severe renal
impairment, GFR &lt;30 mL/min. Increased plasma concentration of
CYMBALTA, and especially of its metabolites, occur in patients with
end-stage renal disease (requiring dialysis) <span class=
"Italics">[see Dosage and Administration (<a href="#s13">2.6</a>)
and Use in Specific Populations (<a href=
"#s116">8.10</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s46" id=
"s46"></a> <a name="section-5.14.3" id="section-5.14.3"></a>
<p class="First"><span class="Underline">Glycemic Control in
Patients with Diabetes</span> — As observed in DPNP trials,
CYMBALTA treatment worsens glycemic control in some patients with
diabetes. In three clinical trials of CYMBALTA for the management
of neuropathic pain associated with diabetic peripheral neuropathy,
the mean duration of diabetes was approximately 12 years, the mean
baseline fasting blood glucose was 176 mg/dL, and the mean baseline
hemoglobin A<span class="Sub">1c</span> (HbA<span class=
"Sub">1c</span>) was 7.8%. In the 12-week acute treatment phase of
these studies, CYMBALTA was associated with a small increase in
mean fasting blood glucose as compared to placebo. In the extension
phase of these studies, which lasted up to 52 weeks, mean fasting
blood glucose increased by 12 mg/dL in the CYMBALTA group and
decreased by 11.5 mg/dL in the routine care group. HbA<span class=
"Sub">1c</span> increased by 0.5% in the CYMBALTA and by 0.2% in
the routine care groups.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s47" id=
"s47"></a> <a name="section-5.15" id="section-5.15"></a>
<h2>5.15 Urinary Hesitation and Retention</h2>
<p class="First">CYMBALTA is in a class of drugs known to affect
urethral resistance. If symptoms of urinary hesitation develop
during treatment with CYMBALTA, consideration should be given to
the possibility that they might be drug-related.</p>
<p>In post marketing experience, cases of urinary retention have
been observed. In some instances of urinary retention associated
with CYMBALTA use, hospitalization and/or catheterization has been
needed.</p>
</div>
<div class="Section" data-sectioncode="34075-2"><a name="s48" id=
"s48"></a> <a name="section-5.16" id="section-5.16"></a>
<h2>5.16 Laboratory Tests</h2>
<p class="First">No specific laboratory tests are recommended.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">6 ADVERSE REACTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34084-4"><a name="s49" id="s49"></a> <a name="section-6" id=
"section-6"></a>
<p class="First">The following serious adverse reactions are
described below and elsewhere in the labeling:</p>
<ul class="Disc">
<li>Suicidal Thoughts and Behaviors in Children, Adolescents and
Young Adults <span class="Italics">[see <a href="#s2">Boxed
Warning</a> and Warnings and Precautions (<a href=
"#s22">5.1</a>)]</span></li>
<li>Hepatotoxicity <span class="Italics">[see Warnings and
Precautions (<a href="#s23">5.2</a>)]</span></li>
<li>Orthostatic Hypotension, Falls and Syncope <span class=
"Italics">[see Warnings and Precautions (<a href=
"#s24">5.3</a>)]</span></li>
<li>Serotonin Syndrome <span class="Italics">[see Warnings and
Precautions (<a href="#s25">5.4</a>)]</span></li>
<li>Abnormal Bleeding <span class="Italics">[see Warnings and
Precautions (<a href="#s26">5.5</a>)]</span></li>
<li>Severe Skin Reactions <span class="Italics">[see Warnings and
Precautions (<a href="#s27">5.6</a>)]</span></li>
<li>Discontinuation of Treatment with CYMBALTA <span class=
"Italics">[see Warnings and Precautions (<a href=
"#s28">5.7</a>)]</span></li>
<li>Activation of Mania/Hypomania <span class="Italics">[see
Warnings and Precautions (<a href="#s29">5.8</a>)]</span></li>
<li>Angle-Closure Glaucoma <span class="Italics">[see Warnings and
Precautions (<a href="#s30">5.9</a>)]</span></li>
<li>Seizures <span class="Italics">[see Warnings and Precautions
(<a href="#s31">5.10</a>)]</span></li>
<li>Effect on Blood Pressure <span class="Italics">[see Warnings
and Precautions (<a href="#s32">5.11</a>)]</span></li>
<li>Clinically Important Drug Interactions <span class=
"Italics">[see Warnings and Precautions (<a href=
"#s33">5.12</a>)]</span></li>
<li>Hyponatremia <span class="Italics">[see Warnings and
Precautions (<a href="#s42">5.13</a>)]</span></li>
<li>Urinary Hesitation and Retention <span class="Italics">[see
Warnings and Precautions (<a href="#s47">5.15</a>)]</span></li>
</ul>
<div class="Section" data-sectioncode="42229-5"><a name="s50" id=
"s50"></a> <a name="section-6.1" id="section-6.1"></a>
<h2>6.1 Clinical Trial Data Sources</h2>
<p class="First">Because clinical trials are conducted under widely
varying conditions, adverse reaction rates observed in the clinical
trials of a drug cannot be directly compared to rates in the
clinical trials of another drug and may not reflect the rates
observed in practice.</p>
<p>The stated frequencies of adverse reactions represent the
proportion of individuals who experienced, at least once, a
treatment-emergent adverse reaction of the type listed. A reaction
was considered treatment-emergent if it occurred for the first time
or worsened while receiving therapy following baseline evaluation.
Reactions reported during the studies were not necessarily caused
by the therapy, and the frequencies do not reflect investigator
impression (assessment) of causality.</p>
<div class="Section" data-sectioncode="42229-5"><a name="s51" id=
"s51"></a> <a name="section-6.1.1" id="section-6.1.1"></a>
<p class="First"><span class="Underline">Adults</span> — The data
described below reflect exposure to CYMBALTA in placebo-controlled
trials for MDD (N=3779), GAD (N=1018), OA (N=503), CLBP (N=600),
DPNP (N=906), and FM (N=1294). The population studied was 17 to 89
years of age; 65.7%, 60.8%, 60.6%, 42.9%, and 94.4% female; and
81.8%, 72.6%, 85.3%, 74.0%, and 85.7% Caucasian for MDD, GAD, OA
and CLBP, DPNP, and FM, respectively. Most patients received doses
of a total of 60 to 120 mg per day <span class="Italics">[see
Clinical Studies (<a href="#s133">14</a>)]</span>.The data below do
not include results of the trial examining the efficacy of CYMBALTA
in patients ≥ 65 years old for the treatment of generalized anxiety
disorder; however, the adverse reactions observed in this geriatric
sample were generally similar to adverse reactions in the overall
adult population.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s52" id=
"s52"></a> <a name="section-6.1.2" id="section-6.1.2"></a>
<p class="First"><span class="Underline">Children and
Adolescents</span> — The data described below reflect exposure to
CYMBALTA in pediatric, 10-week, placebo-controlled trials for MDD
(N=341) and GAD (N=135). The population studied (N=476) was 7 to 17
years of age with 42.4% children age 7 to 11 years of age, 50.6%
female, and 68.6% white. Patients received 30-120 mg per day during
placebo-controlled acute treatment studies. Additional data come
from the overall total of 822 pediatric patients (age 7 to 17 years
of age) with 41.7% children age 7 to 11 years of age and 51.8%
female exposed to CYMBALTA in MDD and GAD clinical trials up to
36-weeks in length, in which most patients received 30-120 mg per
day.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s53" id=
"s53"></a> <a name="section-6.2" id="section-6.2"></a>
<h2>6.2 Adverse Reactions Reported as Reasons for Discontinuation
of Treatment in Adult Placebo-Controlled Trials</h2>
<div class="Section" data-sectioncode="42229-5"><a name="s54" id=
"s54"></a> <a name="section-6.2.1" id="section-6.2.1"></a>
<p class="First"><span class="Underline">Major Depressive
Disorder</span> — Approximately 8.4% (319/3779) of the patients who
received CYMBALTA in placebo-controlled trials for MDD discontinued
treatment due to an adverse reaction, compared with 4.6% (117/2536)
of the patients receiving placebo. Nausea (CYMBALTA 1.1%, placebo
0.4%) was the only common adverse reaction reported as a reason for
discontinuation and considered to be drug-related (i.e.,
discontinuation occurring in at least 1% of the CYMBALTA-treated
patients and at a rate of at least twice that of placebo).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s55" id=
"s55"></a> <a name="section-6.2.2" id="section-6.2.2"></a>
<p class="First"><span class="Underline">Generalized Anxiety
Disorder</span> — Approximately 13.7% (139/1018) of the patients
who received CYMBALTA in placebo-controlled trials for GAD
discontinued treatment due to an adverse reaction, compared with
5.0% (38/767) for placebo. Common adverse reactions reported as a
reason for discontinuation and considered to be drug-related (as
defined above) included nausea (CYMBALTA 3.3%, placebo 0.4%), and
dizziness (CYMBALTA 1.3%, placebo 0.4%).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s56" id=
"s56"></a> <a name="section-6.2.3" id="section-6.2.3"></a>
<p class="First"><span class="Underline">Diabetic Peripheral
Neuropathic Pain</span> — Approximately 12.9% (117/906) of the
patients who received CYMBALTA in placebo-controlled trials for
DPNP discontinued treatment due to an adverse reaction, compared
with 5.1% (23/448) for placebo. Common adverse reactions reported
as a reason for discontinuation and considered to be drug-related
(as defined above) included nausea (CYMBALTA 3.5%, placebo 0.7%),
dizziness (CYMBALTA 1.2%, placebo 0.4%), and somnolence (CYMBALTA
1.1%, placebo 0.0%).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s57" id=
"s57"></a> <a name="section-6.2.4" id="section-6.2.4"></a>
<p class="First"><span class="Underline">Fibromyalgia</span> —
Approximately 17.5% (227/1294) of the patients who received
CYMBALTA in 3 to 6 month placebo-controlled trials for FM
discontinued treatment due to an adverse reaction, compared with
10.1% (96/955) for placebo. Common adverse reactions reported as a
reason for discontinuation and considered to be drug-related (as
defined above) included nausea (CYMBALTA 2.0%, placebo 0.5%),
headache (CYMBALTA 1.2%, placebo 0.3%), somnolence (CYMBALTA 1.1%,
placebo 0.0%), and fatigue (CYMBALTA 1.1%, placebo 0.1%).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s58" id=
"s58"></a> <a name="section-6.2.5" id="section-6.2.5"></a>
<p class="First"><span class="Underline">Chronic Pain due to
Osteoarthritis</span> — Approximately 15.7% (79/503) of the
patients who received CYMBALTA in 13-week, placebo-controlled
trials for chronic pain due to OA discontinued treatment due to an
adverse reaction, compared with 7.3% (37/508) for placebo. Common
adverse reactions reported as a reason for discontinuation and
considered to be drug-related (as defined above) included nausea
(CYMBALTA 2.2%, placebo 1.0%).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s59" id=
"s59"></a> <a name="section-6.2.6" id="section-6.2.6"></a>
<p class="First"><span class="Underline">Chronic Low Back
Pain</span> — Approximately 16.5% (99/600) of the patients who
received CYMBALTA in 13-week, placebo-controlled trials for CLBP
discontinued treatment due to an adverse reaction, compared with
6.3% (28/441) for placebo. Common adverse reactions reported as a
reason for discontinuation and considered to be drug-related (as
defined above) included nausea (CYMBALTA 3.0%, placebo 0.7%), and
somnolence (CYMBALTA 1.0%, placebo 0.0%).</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s60" id=
"s60"></a> <a name="section-6.3" id="section-6.3"></a>
<h2>6.3 Most Common Adult Adverse Reactions</h2>
<div class="Section" data-sectioncode="42229-5"><a name="s61" id=
"s61"></a> <a name="section-6.3.1" id="section-6.3.1"></a>
<p class="First"><span class="Underline">Pooled Trials for all
Approved Indications</span> — The most commonly observed adverse
reactions in CYMBALTA-treated patients (incidence of at least 5%
and at least twice the incidence in placebo patients) were nausea,
dry mouth, somnolence, constipation, decreased appetite, and
hyperhidrosis.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s62" id=
"s62"></a> <a name="section-6.3.2" id="section-6.3.2"></a>
<p class="First"><span class="Underline">Diabetic Peripheral
Neuropathic Pain</span> — The most commonly observed adverse
reactions in CYMBALTA-treated patients (as defined above) were
nausea, somnolence, decreased appetite, constipation,
hyperhidrosis, and dry mouth.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s63" id=
"s63"></a> <a name="section-6.3.3" id="section-6.3.3"></a>
<p class="First"><span class="Underline">Fibromyalgia</span> — The
most commonly observed adverse reactions in CYMBALTA-treated
patients (as defined above) were nausea, dry mouth, constipation,
somnolence, decreased appetite, hyperhidrosis, and agitation.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s64" id=
"s64"></a> <a name="section-6.3.4" id="section-6.3.4"></a>
<p class="First"><span class="Underline">Chronic Pain due to
Osteoarthritis</span> — The most commonly observed adverse
reactions in CYMBALTA-treated patients (as defined above) were
nausea, fatigue, constipation, dry mouth, insomnia, somnolence, and
dizziness.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s65" id=
"s65"></a> <a name="section-6.3.5" id="section-6.3.5"></a>
<p class="First"><span class="Underline">Chronic Low Back
Pain</span> — The most commonly observed adverse reactions in
CYMBALTA-treated patients (as defined above) were nausea, dry
mouth, insomnia, somnolence, constipation, dizziness, and
fatigue.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s66" id=
"s66"></a> <a name="section-6.4" id="section-6.4"></a>
<h2>6.4 Adverse Reactions Occurring at an Incidence of 5% or More
Among CYMBALTA-Treated Patients in Adult Placebo-Controlled
Trials</h2>
<p class="First"><a href="#t2">Table 2</a> gives the incidence of
treatment-emergent adverse reactions in placebo-controlled trials
for approved indications that occurred in 5% or more of patients
treated with CYMBALTA and with an incidence greater than
placebo.</p>
<a name="t2" id="t2"></a>
<div class="scrollingtable">
<table width="100%">
<caption><span>Table 2: Treatment-Emergent Adverse Reactions:
Incidence of 5% or More and Greater than Placebo in
Placebo-Controlled Trials of Approved Indications<span class=
"Sup">a</span></span></caption>
<colgroup>
<col align="left" width="33.333%">
<col align="left" width="33.333%">
<col align="left" width="33.333%"></colgroup>
<tfoot>
<tr class="First">
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">a</span> The inclusion
of an event in the table is determined based on the percentages
before rounding; however, the percentages displayed in the table
are rounded to the nearest integer.</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">b</span> Also includes
asthenia.</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">c</span> Events for
which there was a significant dose-dependent relationship in
fixed-dose studies, excluding three MDD studies which did not have
a placebo lead-in period or dose titration.</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">d</span> Also includes
initial insomnia, middle insomnia, and early morning awakening.</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">e</span> Also includes
hypersomnia and sedation.</p>
</td>
</tr>
<tr class="Last">
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">f</span> Also includes
abdominal discomfort, abdominal pain lower, abdominal pain upper,
abdominal tenderness, and gastrointestinal pain.</p>
</td>
</tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2"
valign="top"><span class="Bold">Percentage of Patients Reporting
Reaction</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">Adverse Reaction</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class=
"Bold">CYMBALTA<br>
(N=8100)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class=
"Bold">Placebo<br>
(N=5655)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
Nausea<span class="Sup">c</span></td>
<td class="Botrule Rrule" align="center" valign="middle">23</td>
<td class="Botrule Rrule" align="center" valign="middle">8</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
Headache</td>
<td class="Botrule Rrule" align="center" valign="middle">14</td>
<td class="Botrule Rrule" align="center" valign="middle">12</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">Dry
mouth</td>
<td class="Botrule Rrule" align="center" valign="middle">13</td>
<td class="Botrule Rrule" align="center" valign="middle">5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
Somnolence<span class="Sup">e</span></td>
<td class="Botrule Rrule" align="center" valign="middle">10</td>
<td class="Botrule Rrule" align="center" valign="middle">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
Fatigue<span class="Sup">b,c</span></td>
<td class="Botrule Rrule" align="center" valign="middle">9</td>
<td class="Botrule Rrule" align="center" valign="middle">5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
Insomnia<span class="Sup">d</span></td>
<td class="Botrule Rrule" align="center" valign="middle">9</td>
<td class="Botrule Rrule" align="center" valign="middle">5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
Constipation<span class="Sup">c</span></td>
<td class="Botrule Rrule" align="center" valign="middle">9</td>
<td class="Botrule Rrule" align="center" valign="middle">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
Dizziness<span class="Sup">c</span></td>
<td class="Botrule Rrule" align="center" valign="middle">9</td>
<td class="Botrule Rrule" align="center" valign="middle">5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
Diarrhea</td>
<td class="Botrule Rrule" align="center" valign="middle">9</td>
<td class="Botrule Rrule" align="center" valign="middle">6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
Decreased appetite<span class="Sup">c</span></td>
<td class="Botrule Rrule" align="center" valign="middle">7</td>
<td class="Botrule Rrule" align="center" valign="middle">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle">
Hyperhidrosis<span class="Sup">c</span></td>
<td class="Botrule Rrule" align="center" valign="middle">6</td>
<td class="Botrule Rrule" align="center" valign="middle">1</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="middle">
Abdominal pain<span class="Sup">f</span></td>
<td class="Botrule Rrule" align="center" valign="middle">5</td>
<td class="Botrule Rrule" align="center" valign="middle">4</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s67" id=
"s67"></a> <a name="section-6.5" id="section-6.5"></a>
<h2>6.5 Adverse Reactions Occurring at an Incidence of 2% or More
Among CYMBALTA-Treated Patients in Adult Placebo-Controlled
Trials</h2>
<div class="Section" data-sectioncode="42229-5"><a name="s68" id=
"s68"></a> <a name="section-6.5.1" id="section-6.5.1"></a>
<p class="First"><span class="Underline">Pooled MDD and GAD
Trials</span> — <a href="#t3">Table 3</a> gives the incidence of
treatment-emergent adverse reactions in MDD and GAD
placebo-controlled trials for approved indications that occurred in
2% or more of patients treated with CYMBALTA and with an incidence
greater than placebo.</p>
<a name="t3" id="t3"></a>
<div class="scrollingtable">
<table width="100%">
<caption><span>Table 3: Treatment-Emergent Adverse Reactions:
Incidence of 2% or More and Greater than Placebo in MDD and GAD
Placebo-Controlled Trials<span class=
"Sup">a,b</span></span></caption>
<colgroup>
<col align="left" width="44.975%">
<col align="left" width="27.125%">
<col align="left" width="26.925%">
<col align="left" width="10%"></colgroup>
<tfoot>
<tr class="First">
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">a</span> The inclusion
of an event in the table is determined based on the percentages
before rounding; however, the percentages displayed in the table
are rounded to the nearest integer.</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">b</span> For GAD, there
were no adverse events that were significantly different between
treatments in adults ≥65 years that were also not significant in
the adults &lt;65 years.</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">c</span> Events for
which there was a significant dose-dependent relationship in
fixed-dose studies, excluding three MDD studies which did not have
a placebo lead-in period or dose titration.</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">d</span> Also includes
abdominal pain upper, abdominal pain lower, abdominal tenderness,
abdominal discomfort, and gastrointestinal pain</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">e</span> Also includes
asthenia</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">f</span> Also includes
hypersomnia and sedation</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">g</span> Also includes
initial insomnia, middle insomnia, and early morning awakening</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">h</span> Also includes
feeling jittery, nervousness, restlessness, tension and psychomotor
hyperactivity</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">i</span> Also includes
loss of libido</p>
</td>
</tr>
<tr class="Last">
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">j</span> Also includes
anorgasmia</p>
</td>
</tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="middle"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3"
valign="top"><span class="Bold">Percentage of Patients Reporting
Reaction</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">System Organ Class / Adverse
Reaction</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">CYMBALTA<br>
(N=4797)</span></td>
<td class="Botrule Rrule Toprule" align="center" valign="top">
<span class="Bold">Placebo<br>
(N=3303)</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Cardiac Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
Palpitations</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Eye Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Vision
blurred</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Gastrointestinal Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">
Nausea<span class="Sup">c</span></td>
<td class="Rrule" align="center" valign="top">23</td>
<td class="Rrule" align="center" valign="top">8</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Dry mouth</td>
<td class="Rrule" align="center" valign="top">14</td>
<td class="Rrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">
Constipation<span class="Sup">c</span></td>
<td class="Rrule" align="center" valign="top">9</td>
<td class="Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Diarrhea</td>
<td class="Rrule" align="center" valign="top">9</td>
<td class="Rrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Abdominal
pain<span class="Sup">d</span></td>
<td class="Rrule" align="center" valign="top">5</td>
<td class="Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
Vomiting</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">General Disorders and Administration Site
Conditions</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
Fatigue<span class="Sup">e</span></td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Metabolism and Nutrition Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Decreased
appetite<span class="Sup">c</span></td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Nervous System Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Headache</td>
<td class="Rrule" align="center" valign="top">14</td>
<td class="Rrule" align="center" valign="top">14</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">
Dizziness<span class="Sup">c</span></td>
<td class="Rrule" align="center" valign="top">9</td>
<td class="Rrule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">
Somnolence<span class="Sup">f</span></td>
<td class="Rrule" align="center" valign="top">9</td>
<td class="Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
Tremor</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Psychiatric Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">
Insomnia<span class="Sup">g</span></td>
<td class="Rrule" align="center" valign="top">9</td>
<td class="Rrule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">
Agitation<span class="Sup">h</span></td>
<td class="Rrule" align="center" valign="top">4</td>
<td class="Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Anxiety</td>
<td class="Rrule" align="center" valign="top">3</td>
<td class="Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Reproductive System and Breast Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Erectile
dysfunction</td>
<td class="Rrule" align="center" valign="top">4</td>
<td class="Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
Ejaculation delayed<span class="Sup">c</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Libido
decreased<span class="Sup">i</span></td>
<td class="Rrule" align="center" valign="top">3</td>
<td class="Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Orgasm
abnormal<span class="Sup">j</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Respiratory, Thoracic, and Mediastinal Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
Yawning</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Skin and Subcutaneous Tissue Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
Hyperhidrosis</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s69" id=
"s69"></a> <a name="section-6.5.2" id="section-6.5.2"></a>
<p class="First"><span class="Underline">DPNP, FM, OA, and
CLBP</span> — <a href="#t4">Table 4</a> gives the incidence of
treatment-emergent adverse events that occurred in 2% or more of
patients treated with CYMBALTA (determined prior to rounding) in
the premarketing acute phase of DPNP, FM, OA, and CLBP
placebo-controlled trials and with an incidence greater than
placebo.</p>
<a name="t4" id="t4"></a>
<div class="scrollingtable">
<table width="100%">
<caption><span>Table 4: Treatment-Emergent Adverse Reactions:
Incidence of 2% or More and Greater than Placebo in DPNP, FM, OA,
and CLBP Placebo-Controlled Trials<span class=
"Sup">a</span></span></caption>
<colgroup>
<col align="left" width="45.082%">
<col align="left" width="27.876%">
<col align="left" width="27.042%"></colgroup>
<tfoot>
<tr class="First">
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">a</span> The inclusion
of an event in the table is determined based on the percentages
before rounding; however, the percentages displayed in the table
are rounded to the nearest integer.</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">b</span> Incidence of
120 mg/day is significantly greater than the incidence for 60
mg/day.</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">c</span> Also includes
abdominal discomfort, abdominal pain lower, abdominal pain upper,
abdominal tenderness and gastrointestinal pain</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">d</span> Also includes
asthenia</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">e</span> Also includes
myalgia and neck pain</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">f</span> Also includes
hypersomnia and sedation</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">g</span> Also includes
hypoaesthesia, hypoaesthesia facial, genital hypoaesthesia and
paraesthesia oral</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">h</span> Also includes
initial insomnia, middle insomnia, and early morning awakening.</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">i</span> Also includes
feeling jittery, nervousness, restlessness, tension and psychomotor
hyperactivity</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">j</span> Also includes
ejaculation failure</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">k</span> Also includes
hot flush</p>
</td>
</tr>
<tr class="Last">
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">l</span> Also includes
blood pressure diastolic increased, blood pressure systolic
increased, diastolic hypertension, essential hypertension,
hypertension, hypertensive crisis, labile hypertension, orthostatic
hypertension, secondary hypertension, and systolic hypertension</p>
</td>
</tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="middle"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2"
valign="top"><span class="Bold">Percentage of Patients Reporting
Reaction</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">System Organ Class / Adverse
Reaction</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class=
"Bold">CYMBALTA<br>
(N=3303)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class=
"Bold">Placebo</span><br>
<span class="Bold">(N=2352)</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Gastrointestinal Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Nausea</td>
<td class="Rrule" align="center" valign="top">23</td>
<td class="Rrule" align="center" valign="top">7</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Dry
Mouth<span class="Sup">b</span></td>
<td class="Rrule" align="center" valign="top">11</td>
<td class="Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">
Constipation<span class="Sup">b</span></td>
<td class="Rrule" align="center" valign="top">10</td>
<td class="Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Diarrhea</td>
<td class="Rrule" align="center" valign="top">9</td>
<td class="Rrule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Abdominal
Pain<span class="Sup">c</span></td>
<td class="Rrule" align="center" valign="top">5</td>
<td class="Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Vomiting</td>
<td class="Rrule" align="center" valign="top">3</td>
<td class="Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
Dyspepsia</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">General Disorders and Administration Site
Conditions</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
Fatigue<span class="Sup">d</span></td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Infections and Infestations</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">
Nasopharyngitis</td>
<td class="Rrule" align="center" valign="top">4</td>
<td class="Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Upper Respiratory
Tract Infection</td>
<td class="Rrule" align="center" valign="top">3</td>
<td class="Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
Influenza</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Metabolism and Nutrition Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Decreased
Appetite<span class="Sup">b</span></td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Musculoskeletal and Connective Tissue</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Musculoskeletal
Pain<span class="Sup">e</span></td>
<td class="Rrule" align="center" valign="top">3</td>
<td class="Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Muscle
Spasms</td>
<td class="Rrule" align="center" valign="top">2</td>
<td class="Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Nervous System Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Headache</td>
<td class="Rrule" align="center" valign="top">13</td>
<td class="Rrule" align="center" valign="top">8</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">
Somnolence<span class="Sup">b,f</span></td>
<td class="Rrule" align="center" valign="top">11</td>
<td class="Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Dizziness</td>
<td class="Rrule" align="center" valign="top">9</td>
<td class="Rrule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">
Paraesthesia<span class="Sup">g</span></td>
<td class="Rrule" align="center" valign="top">2</td>
<td class="Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
Tremor<span class="Sup">b</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Psychiatric Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">
Insomnia<span class="Sup">b,h</span></td>
<td class="Rrule" align="center" valign="top">10</td>
<td class="Rrule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
Agitation<span class="Sup">i</span></td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Reproductive System and Breast Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Erectile
Dysfunction<span class="Sup">b</span></td>
<td class="Rrule" align="center" valign="top">4</td>
<td class="Rrule" align="center" valign="top">&lt;1</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
Ejaculation Disorder<span class="Sup">j</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">&lt;1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Respiratory, Thoracic, and Mediastinal Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Cough</td>
<td class="Rrule" align="center" valign="top">2</td>
<td class="Rrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Skin and Subcutaneous Tissue Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
Hyperhidrosis</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Vascular Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">
Flushing<span class="Sup">k</span></td>
<td class="Rrule" align="center" valign="top">3</td>
<td class="Rrule" align="center" valign="top">1</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Blood
pressure increased<span class="Sup">l</span></td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s70" id=
"s70"></a> <a name="section-6.6" id="section-6.6"></a>
<h2>6.6 Effects on Male and Female Sexual Function in Adults</h2>
<p class="First">Changes in sexual desire, sexual performance and
sexual satisfaction often occur as manifestations of psychiatric
disorders or diabetes, but they may also be a consequence of
pharmacologic treatment. Because adverse sexual reactions are
presumed to be voluntarily underreported, the Arizona Sexual
Experience Scale (ASEX), a validated measure designed to identify
sexual side effects, was used prospectively in 4 MDD
placebo-controlled trials. In these trials, as shown in <a href=
"#t5">Table 5</a> below, patients treated with CYMBALTA experienced
significantly more sexual dysfunction, as measured by the total
score on the ASEX, than did patients treated with placebo. Gender
analysis showed that this difference occurred only in males. Males
treated with CYMBALTA experienced more difficulty with ability to
reach orgasm (ASEX Item 4) than males treated with placebo. Females
did not experience more sexual dysfunction on CYMBALTA than on
placebo as measured by ASEX total score. Negative numbers signify
an improvement from a baseline level of dysfunction, which is
commonly seen in depressed patients. Physicians should routinely
inquire about possible sexual side effects.</p>
<a name="t5" id="t5"></a>
<div class="scrollingtable">
<table width="100%">
<caption><span>Table 5: Mean Change in ASEX Scores by Gender in MDD
Placebo-Controlled Trials</span></caption>
<colgroup>
<col align="left" width="38.568%">
<col align="left" width="16.343%">
<col align="left" width="14.703%">
<col align="left" width="14.703%">
<col align="left" width="15.683%"></colgroup>
<tfoot>
<tr class="First">
<td align="left" colspan="5" valign="top">
<p class="First Footnote"><span class="Sup">a</span> n=Number of
patients with non-missing change score for ASEX total</p>
</td>
</tr>
<tr>
<td align="left" colspan="5" valign="top">
<p class="First Footnote"><span class="Sup">b</span> p=0.013 versus
placebo</p>
</td>
</tr>
<tr class="Last">
<td align="left" colspan="5" valign="top">
<p class="First Footnote"><span class="Sup">c</span> p&lt;0.001
versus placebo</p>
</td>
</tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2"
valign="top"><span class="Bold">Male Patients</span><span class=
"Bold"><span class="Sup">a</span></span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2"
valign="top"><span class="Bold">Female Patients</span><span class=
"Bold"><span class="Sup">a</span></span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" valign="top"><span class=
"Bold">CYMBALTA<br>
(n=175)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class=
"Bold">Placebo<br>
(n=83)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class=
"Bold">CYMBALTA<br>
(n=241)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class=
"Bold">Placebo<br>
(n=126)</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">ASEX Total (Items
1-5)</td>
<td class="Rrule" align="center" valign="top">0.56<span class=
"Sup">b</span></td>
<td class="Rrule" align="center" valign="top">-1.07</td>
<td class="Rrule" align="center" valign="top">-1.15</td>
<td class="Rrule" align="center" valign="top">-1.07</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Item 1 — Sex
drive</td>
<td class="Rrule" align="center" valign="top">-0.07</td>
<td class="Rrule" align="center" valign="top">-0.12</td>
<td class="Rrule" align="center" valign="top">-0.32</td>
<td class="Rrule" align="center" valign="top">-0.24</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Item 2 —
Arousal</td>
<td class="Rrule" align="center" valign="top">0.01</td>
<td class="Rrule" align="center" valign="top">-0.26</td>
<td class="Rrule" align="center" valign="top">-0.21</td>
<td class="Rrule" align="center" valign="top">-0.18</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Item 3 — Ability
to achieve erection (men); Lubrication (women)</td>
<td class="Rrule" align="center" valign="top">0.03</td>
<td class="Rrule" align="center" valign="top">-0.25</td>
<td class="Rrule" align="center" valign="top">-0.17</td>
<td class="Rrule" align="center" valign="top">-0.18</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Item 4 — Ease of
reaching orgasm</td>
<td class="Rrule" align="center" valign="top">0.40<span class=
"Sup">c</span></td>
<td class="Rrule" align="center" valign="top">-0.24</td>
<td class="Rrule" align="center" valign="top">-0.09</td>
<td class="Rrule" align="center" valign="top">-0.13</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Item 5 —
Orgasm satisfaction</td>
<td class="Botrule Rrule" align="center" valign="top">0.09</td>
<td class="Botrule Rrule" align="center" valign="top">-0.13</td>
<td class="Botrule Rrule" align="center" valign="top">-0.11</td>
<td class="Botrule Rrule" align="center" valign="top">-0.17</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s71" id=
"s71"></a> <a name="section-6.7" id="section-6.7"></a>
<h2>6.7 Vital Sign Changes in Adults</h2>
<p class="First">In placebo-controlled clinical trials across
approved indications for change from baseline to endpoint, CYMBALTA
treatment was associated with mean increases of 0.23 mm Hg in
systolic blood pressure and 0.73 mm Hg in diastolic blood pressure
compared to mean decreases of 1.09 mm Hg systolic and 0.55 mm Hg
diastolic in placebo-treated patients. There was no significant
difference in the frequency of sustained (3 consecutive visits)
elevated blood pressure <span class="Italics">[see Warnings and
Precautions (<a href="#s24">5.3</a>, <a href=
"#s32">5.11</a>)]</span>.</p>
<p>CYMBALTA treatment, for up to 26 weeks in placebo-controlled
trials across approved indications, typically caused a small
increase in heart rate for change from baseline to endpoint
compared to placebo of up to 1.37 beats per minute (increase of
1.20 beats per minute in CYMBALTA - treated patients, decrease of
0.17 beats per minute in placebo-treated patients).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s72" id=
"s72"></a> <a name="section-6.8" id="section-6.8"></a>
<h2>6.8 Laboratory Changes in Adults</h2>
<p class="First">CYMBALTA treatment in placebo-controlled clinical
trials across approved indications, was associated with small mean
increases from baseline to endpoint in ALT, AST, CPK, and alkaline
phosphatase; infrequent, modest, transient, abnormal values were
observed for these analytes in CYMBALTA-treated patients when
compared with placebo-treated patients <span class="Italics">[see
Warnings and Precautions (<a href="#s23">5.2</a>)]</span>. High
bicarbonate, cholesterol, and abnormal (high or low) potassium,
were observed more frequently in CYMBALTA treated patients compared
to placebo.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s73" id=
"s73"></a> <a name="section-6.9" id="section-6.9"></a>
<h2>6.9 Electrocardiogram Changes in Adults</h2>
<p class="First">The effect of CYMBALTA 160 mg and 200 mg
administered twice daily to steady state was evaluated in a
randomized, double-blinded, two-way crossover study in 117 healthy
female subjects. No QT interval prolongation was detected. CYMBALTA
appears to be associated with concentration-dependent but not
clinically meaningful QT shortening.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s74" id=
"s74"></a> <a name="section-6.10" id="section-6.10"></a>
<h2>6.10 Other Adverse Reactions Observed During the Premarketing
and Postmarketing Clinical Trial Evaluation of CYMBALTA in
Adults</h2>
<p class="First">Following is a list of treatment-emergent adverse
reactions reported by patients treated with CYMBALTA in clinical
trials. In clinical trials of all indications, 34,756 patients were
treated with CYMBALTA. Of these, 26.9% (9337) took CYMBALTA for at
least 6 months, and 12.4% (4317) for at least one year. The
following listing is not intended to include reactions (1) already
listed in previous tables or elsewhere in labeling, (2) for which a
drug cause was remote, (3) which were so general as to be
uninformative, (4) which were not considered to have significant
clinical implications, or (5) which occurred at a rate equal to or
less than placebo.</p>
<p>Reactions are categorized by body system according to the
following definitions: frequent adverse reactions are those
occurring in at least 1/100 patients; infrequent adverse reactions
are those occurring in 1/100 to 1/1000 patients; rare reactions are
those occurring in fewer than 1/1000 patients.</p>
<p><span class="Bold">Cardiac Disorders</span> — <span class=
"Italics">Frequent:</span> palpitations; <span class=
"Italics">Infrequent:</span> myocardial infarction and
tachycardia.</p>
<p><span class="Bold">Ear and Labyrinth Disorders</span> —
<span class="Italics">Frequent:</span> vertigo; <span class=
"Italics">Infrequent:</span> ear pain and tinnitus.</p>
<p><span class="Bold">Endocrine Disorders</span> — <span class=
"Italics">Infrequent:</span> hypothyroidism.</p>
<p><span class="Bold">Eye Disorders</span> — <span class=
"Italics">Frequent:</span> vision blurred; <span class=
"Italics">Infrequent:</span> diplopia, dry eye, and visual
impairment.</p>
<p><span class="Bold">Gastrointestinal Disorders</span> —
<span class="Italics">Frequent:</span> flatulence; <span class=
"Italics">Infrequent:</span> dysphagia, eructation, gastritis,
gastrointestinal hemorrhage, halitosis, and stomatitis;
<span class="Italics">Rare:</span> gastric ulcer.</p>
<p><span class="Bold">General Disorders and Administration Site
Conditions</span> — <span class="Italics">Frequent:</span>
chills/rigors; <span class="Italics">Infrequent:</span> falls,
feeling abnormal, feeling hot and/or cold, malaise, and thirst;
<span class="Italics">Rare:</span> gait disturbance.</p>
<p><span class="Bold">Infections and Infestations</span> —
<span class="Italics">Infrequent:</span> gastroenteritis and
laryngitis.</p>
<p><span class="Bold">Investigations</span> — <span class=
"Italics">Frequent:</span> weight increased, weight decreased;
<span class="Italics">Infrequent:</span> blood cholesterol
increased.</p>
<p><span class="Bold">Metabolism and Nutrition Disorders</span> —
<span class="Italics">Infrequent:</span> dehydration and
hyperlipidemia; <span class="Italics">Rare:</span>
dyslipidemia.</p>
<p><span class="Bold">Musculoskeletal and Connective Tissue
Disorders</span> — <span class="Italics">Frequent:</span>
musculoskeletal pain; <span class="Italics">Infrequent:</span>
muscle tightness and muscle twitching.</p>
<p><span class="Bold">Nervous System Disorders</span> —
<span class="Italics">Frequent:</span> dysgeusia, lethargy, and
paraesthesia/hypoesthesia; <span class="Italics">Infrequent:</span>
disturbance in attention, dyskinesia, myoclonus, and poor quality
sleep; <span class="Italics">Rare:</span> dysarthria.</p>
<p><span class="Bold">Psychiatric Disorders</span> — <span class=
"Italics">Frequent:</span> abnormal dreams and sleep disorder;
<span class="Italics">Infrequent:</span> apathy, bruxism,
disorientation/confusional state, irritability, mood swings, and
suicide attempt; <span class="Italics">Rare:</span> completed
suicide.</p>
<p><span class="Bold">Renal and Urinary Disorders</span> —
<span class="Italics">Frequent</span>: urinary frequency;
<span class="Italics">Infrequent:</span> dysuria, micturition
urgency, nocturia, polyuria, and urine odor abnormal.</p>
<p><span class="Bold">Reproductive System and Breast
Disorders</span> — <span class="Italics">Frequent:</span>
anorgasmia/orgasm abnormal; <span class=
"Italics">Infrequent:</span> menopausal symptoms, sexual
dysfunction, and testicular pain; <span class=
"Italics">Rare:</span> menstrual disorder.</p>
<p><span class="Bold">Respiratory, Thoracic and Mediastinal
Disorders</span> — <span class="Italics">Frequent:</span> yawning,
oropharyngeal pain; <span class="Italics">Infrequent:</span> throat
tightness.</p>
<p><span class="Bold">Skin and Subcutaneous Tissue Disorders</span>
— <span class="Italics">Frequent:</span> pruritus; <span class=
"Italics">Infrequent:</span> cold sweat, dermatitis contact,
erythema, increased tendency to bruise, night sweats, and
photosensitivity reaction; <span class="Italics">Rare:</span>
ecchymosis.</p>
<p><span class="Bold">Vascular Disorders</span> — <span class=
"Italics">Frequent:</span> hot flush; <span class=
"Italics">Infrequent:</span> flushing, orthostatic hypotension, and
peripheral coldness.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s75" id=
"s75"></a> <a name="section-6.11" id="section-6.11"></a>
<h2>6.11 Adverse Reactions Observed in Children and Adolescent
Placebo-Controlled Clinical Trials</h2>
<p class="First">The adverse drug reaction profile observed in
pediatric clinical trials (children and adolescents) was consistent
with the adverse drug reaction profile observed in adult clinical
trials. The specific adverse drug reactions observed in adult
patients can be expected to be observed in pediatric patients
(children and adolescents) <span class="Italics">[see Adverse
Reactions (<a href="#s67">6.5</a>)]</span>. The most common (≥5%
and twice placebo) adverse reactions observed in pediatric clinical
trials include: nausea, diarrhea, decreased weight, and
dizziness.</p>
<p><a href="#t6">Table 6</a> provides the incidence of
treatment-emergent adverse reactions in MDD and GAD pediatric
placebo-controlled trials that occurred in greater than 2% of
patients treated with CYMBALTA and with an incidence greater than
placebo.</p>
<a name="t6" id="t6"></a>
<div class="scrollingtable">
<table width="100%">
<caption><span>Table 6: Treatment-Emergent Adverse Reactions:
Incidence of 2% or More and Greater than Placebo in three 10-week
Pediatric Placebo-Controlled Trials<span class=
"Sup">a</span></span></caption>
<colgroup>
<col align="left" width="45.467%">
<col align="left" width="27.267%">
<col align="left" width="27.267%"></colgroup>
<tfoot>
<tr class="First">
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">a</span> The inclusion
of an event in the table is determined based on the percentages
before rounding; however, the percentages displayed in the table
are rounded to the nearest integer.</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">b</span> Also includes
abdominal pain upper, abdominal pain lower, abdominal tenderness,
abdominal discomfort, and gastrointestinal pain.</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">c</span> Also includes
asthenia.</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">d</span> Frequency
based on weight measurement meeting potentially clinically
significant threshold of ≥3.5% weight loss (N=467 CYMBALTA; N=354
Placebo).</p>
</td>
</tr>
<tr>
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">e</span> Also includes
hypersomnia and sedation.</p>
</td>
</tr>
<tr class="Last">
<td align="left" colspan="3" valign="top">
<p class="First Footnote"><span class="Sup">f</span> Also includes
initial insomnia, insomnia, middle insomnia, and terminal
insomnia.</p>
</td>
</tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="middle"></td>
<td class="Botrule Rrule Toprule" align="center" colspan="2"
valign="top"><span class="Bold">Percentage of Pediatric Patients
Reporting Reaction</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
<span class="Bold">System Organ Class/Adverse Reaction</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class=
"Bold">CYMBALTA<br>
(N=476)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class=
"Bold">Placebo<br>
(N=362)</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Gastrointestinal Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Nausea</td>
<td class="Rrule" align="center" valign="top">18</td>
<td class="Rrule" align="center" valign="top">8</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Abdominal
Pain<span class="Sup">b</span></td>
<td class="Rrule" align="center" valign="top">13</td>
<td class="Rrule" align="center" valign="top">10</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Vomiting</td>
<td class="Rrule" align="center" valign="top">9</td>
<td class="Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Diarrhea</td>
<td class="Rrule" align="center" valign="top">6</td>
<td class="Rrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Dry
Mouth</td>
<td class="Botrule Rrule" align="center" valign="top">2</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">General Disorders and Administration Site
Conditions</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
Fatigue<span class="Sup">c</span></td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Investigations</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Decreased
Weight<span class="Sup">d</span></td>
<td class="Botrule Rrule" align="center" valign="top">14</td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Metabolism and Nutrition Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Decreased
Appetite</td>
<td class="Botrule Rrule" align="center" valign="top">10</td>
<td class="Botrule Rrule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Nervous System Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Headache</td>
<td class="Rrule" align="center" valign="top">18</td>
<td class="Rrule" align="center" valign="top">13</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">
Somnolence<span class="Sup">e</span></td>
<td class="Rrule" align="center" valign="top">11</td>
<td class="Rrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
Dizziness</td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Psychiatric Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">
Insomnia<span class="Sup">f</span></td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
<td class="Botrule Rrule" align="center" valign="top">4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class=
"Bold">Respiratory, Thoracic, and Mediastinal Disorders</span></td>
<td class="Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Oropharyngeal
Pain</td>
<td class="Rrule" align="center" valign="top">4</td>
<td class="Rrule" align="center" valign="top">2</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">
Cough</td>
<td class="Botrule Rrule" align="center" valign="top">3</td>
<td class="Botrule Rrule" align="center" valign="top">1</td>
</tr>
</tbody>
</table>
</div>
<p>Other adverse reactions that occurred at an incidence of less
than 2% but were reported by more CYMBALTA treated patients than
placebo treated patients and are associated CYMBALTA treatment:
abnormal dreams (including nightmare), anxiety, flushing (including
hot flush), hyperhidrosis, palpitations, pulse increased, and
tremor.</p>
<p>Discontinuation-emergent symptoms have been reported when
stopping CYMBALTA. The most commonly reported symptoms following
discontinuation of CYMBALTA in pediatric clinical trials have
included headache, dizziness, insomnia, and abdominal pain
<span class="Italics">[see Warnings and Precautions (<a href=
"#s28">5.7</a>) and Adverse Reactions (<a href=
"#s53">6.2</a>)]</span>.</p>
<div class="Section" data-sectioncode="42229-5"><a name="s76" id=
"s76"></a> <a name="section-6.11.1" id="section-6.11.1"></a>
<p class="First"><span class="Underline">Growth (Height and
Weight)</span> — Decreased appetite and weight loss have been
observed in association with the use of SSRIs and SNRIs. Pediatric
patients treated with CYMBALTA in clinical trials experienced a
0.1kg mean decrease in weight at 10 weeks, compared with a mean
weight gain of approximately 0.9 kg in placebo-treated patients.
The proportion of patients who experienced a clinically significant
decrease in weight (≥3.5%) was greater in the CYMBALTA group than
in the placebo group (14% and 6%, respectively). Subsequently, over
the 4- to 6-month uncontrolled extension periods, CYMBALTA-treated
patients on average trended toward recovery to their expected
baseline weight percentile based on population data from age- and
sex-matched peers. In studies up to 9 months, CYMBALTA-treated
pediatric patients experienced an increase in height of 1.7 cm on
average (2.2 cm increase in children [7 to 11 years of age] and 1.3
cm increase in adolescents [12 to 17 years of age]). While height
increase was observed during these studies, a mean decrease of 1%
in height percentile was observed (decrease of 2% in children [7 to
11 years of age] and increase of 0.3% in adolescents [12 to 17
years of age]). Weight and height should be monitored regularly in
children and adolescents treated with CYMBALTA.</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s77" id=
"s77"></a> <a name="section-6.12" id="section-6.12"></a>
<h2>6.12 Postmarketing Spontaneous Reports</h2>
<p class="First">The following adverse reactions have been
identified during post approval use of CYMBALTA. Because these
reactions are reported voluntarily from a population of uncertain
size, it is not always possible to reliably estimate their
frequency or establish a causal relationship to drug exposure.</p>
<p>Adverse reactions reported since market introduction that were
temporally related to CYMBALTA therapy and not mentioned elsewhere
in labeling include: anaphylactic reaction, aggression and anger
(particularly early in treatment or after treatment
discontinuation), angioneurotic edema, angle-closure glaucoma,
colitis (microscopic or unspecified), cutaneous vasculitis
(sometimes associated with systemic involvement), extrapyramidal
disorder, galactorrhea, gynecological bleeding, hallucinations,
hyperglycemia, hyperprolactinemia, hypersensitivity, hypertensive
crisis, muscle spasm, rash, restless legs syndrome, seizures upon
treatment discontinuation, supraventricular arrhythmia, tinnitus
(upon treatment discontinuation), trismus, and urticaria.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">7 DRUG INTERACTIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"34073-7"><a name="s78" id="s78"></a> <a name="section-7" id=
"section-7"></a>
<p class="First">Both CYP1A2 and CYP2D6 are responsible for
duloxetine metabolism.</p>
<div class="Section" data-sectioncode="42229-5"><a name="s79" id=
"s79"></a> <a name="section-7.1" id="section-7.1"></a>
<h2>7.1 Inhibitors of CYP1A2</h2>
<p class="First">When duloxetine 60 mg was co-administered with
fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to male subjects
(n=14) duloxetine AUC was increased approximately 6-fold, the
C<span class="Sub">max</span> was increased about 2.5-fold, and
duloxetine t<span class="Sub">1/2</span> was increased
approximately 3-fold. Other drugs that inhibit CYP1A2 metabolism
include cimetidine and quinolone antimicrobials such as
ciprofloxacin and enoxacin <span class="Italics">[see Warnings and
Precautions (<a href="#s33">5.12</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s80" id=
"s80"></a> <a name="section-7.2" id="section-7.2"></a>
<h2>7.2 Inhibitors of CYP2D6</h2>
<p class="First">Concomitant use of duloxetine (40 mg once daily)
with paroxetine (20 mg once daily) increased the concentration of
duloxetine AUC by about 60%, and greater degrees of inhibition are
expected with higher doses of paroxetine. Similar effects would be
expected with other potent CYP2D6 inhibitors (e.g., fluoxetine,
quinidine) <span class="Italics">[see Warnings and Precautions
(<a href="#s33">5.12</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s81" id=
"s81"></a> <a name="section-7.3" id="section-7.3"></a>
<h2>7.3 Dual Inhibition of CYP1A2 and CYP2D6</h2>
<p class="First">Concomitant administration of duloxetine 40 mg
twice daily with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to
CYP2D6 poor metabolizer subjects (n=14) resulted in a 6-fold
increase in duloxetine AUC and C<span class="Sub">max</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s82" id=
"s82"></a> <a name="section-7.4" id="section-7.4"></a>
<h2>7.4 Drugs that Interfere with Hemostasis (e.g., NSAIDs,
Aspirin, and Warfarin)</h2>
<p class="First">Serotonin release by platelets plays an important
role in hemostasis. Epidemiological studies of the case-control and
cohort design that have demonstrated an association between use of
psychotropic drugs that interfere with serotonin reuptake and the
occurrence of upper gastrointestinal bleeding have also shown that
concurrent use of an NSAID or aspirin may potentiate this risk of
bleeding. Altered anticoagulant effects, including increased
bleeding, have been reported when SSRIs or SNRIs are
co-administered with warfarin. Concomitant administration of
warfarin (2-9 mg once daily) under steady state conditions with
duloxetine 60 or 120 mg once daily for up to 14 days in healthy
subjects (n=15) did not significantly change INR from baseline
(mean INR changes ranged from 0.05 to +0.07). The total warfarin
(protein bound plus free drug) pharmacokinetics (AUC<span class=
"Sub">τ,ss</span>, C<span class="Sub">max,ss</span> or
t<span class="Sub">max,ss</span>) for both R- and S-warfarin were
not altered by duloxetine. Because of the potential effect of
duloxetine on platelets, patients receiving warfarin therapy should
be carefully monitored when duloxetine is initiated or discontinued
<span class="Italics">[see Warnings and Precautions (<a href=
"#s26">5.5</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s83" id=
"s83"></a> <a name="section-7.5" id="section-7.5"></a>
<h2>7.5 Lorazepam</h2>
<p class="First">Under steady-state conditions for duloxetine (60
mg Q 12 hours) and lorazepam (2 mg Q 12 hours), the
pharmacokinetics of duloxetine were not affected by
co-administration.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s84" id=
"s84"></a> <a name="section-7.6" id="section-7.6"></a>
<h2>7.6 Temazepam</h2>
<p class="First">Under steady-state conditions for duloxetine (20
mg qhs) and temazepam (30 mg qhs), the pharmacokinetics of
duloxetine were not affected by co-administration.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s85" id=
"s85"></a> <a name="section-7.7" id="section-7.7"></a>
<h2>7.7 Drugs that Affect Gastric Acidity</h2>
<p class="First">CYMBALTA has an enteric coating that resists
dissolution until reaching a segment of the gastrointestinal tract
where the pH exceeds 5.5. In extremely acidic conditions, CYMBALTA,
unprotected by the enteric coating, may undergo hydrolysis to form
naphthol. Caution is advised in using CYMBALTA in patients with
conditions that may slow gastric emptying (e.g., some diabetics).
Drugs that raise the gastrointestinal pH may lead to an earlier
release of duloxetine. However, co-administration of CYMBALTA with
aluminum- and magnesium-containing antacids (51 mEq) or CYMBALTA
with famotidine, had no significant effect on the rate or extent of
duloxetine absorption after administration of a 40 mg oral dose. It
is unknown whether the concomitant administration of proton pump
inhibitors affects duloxetine absorption <span class="Italics">[see
Warnings and Precautions (<a href="#s43">5.14</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s86" id=
"s86"></a> <a name="section-7.8" id="section-7.8"></a>
<h2>7.8 Drugs Metabolized by CYP1A2</h2>
<p class="First"><span class="Italics">In vitro</span> drug
interaction studies demonstrate that duloxetine does not induce
CYP1A2 activity. Therefore, an increase in the metabolism of CYP1A2
substrates (e.g., theophylline, caffeine) resulting from induction
is not anticipated, although clinical studies of induction have not
been performed. Duloxetine is an inhibitor of the CYP1A2 isoform in
<span class="Italics">in vitro</span> studies, and in two clinical
studies the average (90% confidence interval) increase in
theophylline AUC was 7% (1%-15%) and 20% (13%-27%) when
co-administered with duloxetine (60 mg twice daily).</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s87" id=
"s87"></a> <a name="section-7.9" id="section-7.9"></a>
<h2>7.9 Drugs Metabolized by CYP2D6</h2>
<p class="First">Duloxetine is a moderate inhibitor of CYP2D6. When
duloxetine was administered (at a dose of 60 mg twice daily) in
conjunction with a single 50 mg dose of desipramine, a CYP2D6
substrate, the AUC of desipramine increased 3-fold <span class=
"Italics">[see Warnings and Precautions (<a href=
"#s33">5.12</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s88" id=
"s88"></a> <a name="section-7.10" id="section-7.10"></a>
<h2>7.10 Drugs Metabolized by CYP2C9</h2>
<p class="First">Results of <span class="Italics">in vitro</span>
studies demonstrate that duloxetine does not inhibit activity. In a
clinical study, the pharmacokinetics of S-warfarin, a CYP2C9
substrate, were not significantly affected by duloxetine
<span class="Italics">[see Drug Interactions (<a href=
"#s82">7.4</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s89" id=
"s89"></a> <a name="section-7.11" id="section-7.11"></a>
<h2>7.11 Drugs Metabolized by CYP3A</h2>
<p class="First">Results of <span class="Italics">in vitro</span>
studies demonstrate that duloxetine does not inhibit or induce
CYP3A activity. Therefore, an increase or decrease in the
metabolism of CYP3A substrates (e.g., oral contraceptives and other
steroidal agents) resulting from induction or inhibition is not
anticipated, although clinical studies have not been performed.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s90" id=
"s90"></a> <a name="section-7.12" id="section-7.12"></a>
<h2>7.12 Drugs Metabolized by CYP2C19</h2>
<p class="First">Results of <span class="Italics">in vitro</span>
studies demonstrate that duloxetine does not inhibit CYP2C19
activity at therapeutic concentrations. Inhibition of the
metabolism of CYP2C19 substrates is therefore not anticipated,
although clinical studies have not been performed.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s91" id=
"s91"></a> <a name="section-7.13" id="section-7.13"></a>
<h2>7.13 Monoamine Oxidase Inhibitors (MAOIs)</h2>
<p class="First"><span class="Italics">[See Dosage and
Administration (<a href="#s17">2.8</a>, <a href="#s18">2.9</a>),
Contraindications (<a href="#s20">4</a>), and Warnings and
Precautions (<a href="#s25">5.4</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s92" id=
"s92"></a> <a name="section-7.14" id="section-7.14"></a>
<h2>7.14 Serotonergic Drugs</h2>
<p class="First"><span class="Italics">[See Dosage and
Administration (<a href="#s17">2.8</a>, <a href="#s18">2.9</a>),
Contraindications (<a href="#s20">4</a>), and Warnings and
Precautions (<a href="#s25">5.4</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s93" id=
"s93"></a> <a name="section-7.15" id="section-7.15"></a>
<h2>7.15 Alcohol</h2>
<p class="First">When CYMBALTA and ethanol were administered
several hours apart so that peak concentrations of each would
coincide, CYMBALTA did not increase the impairment of mental and
motor skills caused by alcohol.</p>
<p>In the CYMBALTA clinical trials database, three CYMBALTA-treated
patients had liver injury as manifested by ALT and total bilirubin
elevations, with evidence of obstruction. Substantial intercurrent
ethanol use was present in each of these cases, and this may have
contributed to the abnormalities seen <span class="Italics">[see
Warnings and Precautions (<a href="#s23">5.2</a>, <a href=
"#s33">5.12</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s94" id=
"s94"></a> <a name="section-7.16" id="section-7.16"></a>
<h2>7.16 CNS Drugs</h2>
<p class="First"><span class="Italics">[See Warnings and
Precautions (<a href="#s33">5.12</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s95" id=
"s95"></a> <a name="section-7.17" id="section-7.17"></a>
<h2>7.17 Drugs Highly Bound to Plasma Protein</h2>
<p class="First">Because duloxetine is highly bound to plasma
protein, administration of CYMBALTA to a patient taking another
drug that is highly protein bound may cause increased free
concentrations of the other drug, potentially resulting in adverse
reactions. However, co-administration of duloxetine (60 or 120 mg)
with warfarin (2-9 mg), a highly protein-bound drug, did not result
in significant changes in INR and in the pharmacokinetics of either
total S-or total R-warfarin (protein bound plus free drug)
<span class="Italics">[see Drug Interactions (<a href=
"#s82">7.4</a>)]</span>.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">8 USE IN SPECIFIC POPULATIONS</a>
<div class="Section toggle-content closed" data-sectioncode=
"43684-0"><a name="s96" id="s96"></a> <a name="section-8" id=
"section-8"></a>
<div class="Section" data-sectioncode="42228-7"><a name="s97" id=
"s97"></a> <a name="section-8.1" id="section-8.1"></a>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectioncode="42229-5"><a name="s98" id=
"s98"></a> <a name="section-8.1.1" id="section-8.1.1"></a>
<p class="First"><span class="Underline">Pregnancy Category
C</span></p>
<p><span class="Italics">Pregnancy Exposure Registry</span> — There
is a pregnancy registry that monitors the pregnancy outcomes in
women exposed to CYMBALTA during pregnancy. To enroll, contact the
CYMBALTA Pregnancy Registry at 1-866-814-6975 or
www.cymbaltapregnancyregistry.com.</p>
<p><span class="Italics">Risk Summary</span> — There are no
adequate and well-controlled studies of CYMBALTA administration in
pregnant women. In animal studies with duloxetine, fetal weights
were decreased but there was no evidence of teratogenicity in
pregnant rats and rabbits at oral doses administered during the
period of organogenesis up to 4 and 7 times the maximum recommended
human dose (MRHD) of 120 mg/day, respectively. When duloxetine was
administered orally to pregnant rats throughout gestation and
lactation, pup weights at birth and pup survival to 1 day
postpartum were decreased at a dose 2 times the MRHD. At this dose,
pup behaviors consistent with increased reactivity, such as
increased startle response to noise and decreased habituation of
locomotor activity were observed. Post-weaning growth was not
adversely affected. CYMBALTA should be used in pregnancy only if
the potential benefit justifies the potential risk to the
fetus.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s100" id=
"s100"></a> <a name="section-8.1.2" id="section-8.1.2"></a>
<p class="First"><span class="Underline">Clinical
Considerations</span></p>
<p><span class="Italics">Fetal/Neonatal Adverse Reaction</span> —
Neonates exposed during pregnancy to serotonin - norepinephrine
reuptake inhibitors (SNRIs) or selective serotonin reuptake
inhibitors (SSRIs) have developed complications requiring prolonged
hospitalization, respiratory support, and tube feeding which can
arise immediately upon delivery. Reported clinical findings have
included respiratory distress, cyanosis, apnea, seizures,
temperature instability, feeding difficulty, vomiting,
hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor,
jitteriness, irritability, and constant crying. These features are
consistent with either a direct toxic effect of the SNRIs or SSRIs,
or possibly, a drug discontinuation syndrome. It should be noted
that, in some cases, the clinical picture is consistent with
serotonin syndrome <span class="Italics">[see Warnings and
Precautions (<a href="#s25">5.4</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s101" id=
"s101"></a> <a name="section-8.1.3" id="section-8.1.3"></a>
<p class="First"><span class="Underline">Data</span></p>
<p><span class="Italics">Animal Data</span> — In animal
reproduction studies, duloxetine has been shown to have adverse
effects on embryo/fetal and postnatal development.</p>
<p>When duloxetine was administered orally to pregnant rats and
rabbits during the period of organogenesis, there was no evidence
of teratogenicity at doses up to 45 mg/kg/day (4 times the maximum
recommended human dose (MRHD) of 120 mg/day on a mg/m<span class=
"Sup">2</span> basis, in rat; 7 times the MRHD in rabbit). However,
fetal weights were decreased at this dose, with a no-effect dose of
10 mg/kg/day approximately equal to the MRHD in rats; 2 times the
MRHD in rabbits).</p>
<p>When duloxetine was administered orally to pregnant rats
throughout gestation and lactation, the survival of pups to 1 day
postpartum and pup body weights at birth and during the lactation
period were decreased at a dose of 30 mg/kg/day (2 times the MRHD);
the no-effect dose was 10 mg/kg/day. Furthermore, behaviors
consistent with increased reactivity, such as increased startle
response to noise and decreased habituation of locomotor activity,
were observed in pups following maternal exposure to 30 mg/kg/day.
Post-weaning growth and reproductive performance of the progeny
were not affected adversely by maternal duloxetine treatment.</p>
</div>
</div>
<div class="Section" data-sectioncode="34080-2"><a name="s104" id=
"s104"></a> <a name="section-8.2" id="section-8.2"></a>
<h2>8.3 Nursing Mothers</h2>
<div class="Section" data-sectioncode="42229-5"><a name="s105" id=
"s105"></a> <a name="section-8.2.1" id="section-8.2.1"></a>
<p class="First">Risk Summary</p>
<p>CYMBALTA is present in human milk. In a published study,
lactating women who were weaning their infants were given CYMBALTA.
At steady state, the concentration of CYMBALTA in breast milk was
approximately 25% that of maternal plasma. The estimated daily
infant dose was approximately 0.14% of the maternal dose. The
developmental and health benefits of human milk feeding should be
considered along with the mother's clinical need for CYMBALTA and
any potential adverse effects on the milk-fed child from the drug
or from the underlying maternal condition. Exercise caution when
CYMBALTA is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s106" id=
"s106"></a> <a name="section-8.2.2" id="section-8.2.2"></a>
<p class="First">Data</p>
<p>The disposition of CYMBALTA was studied in 6 lactating women who
were at least 12 weeks postpartum and had elected to wean their
infants. The women were given 40 mg of CYMBALTA twice daily for 3.5
days. The peak concentration measured in breast milk occurred at a
median of 3 hours after the dose. The amount of CYMBALTA in breast
milk was approximately 7 mcg/day while on that dose; the estimated
daily infant dose was approximately 2 mcg/kg/day. The presence of
CYMBALTA metabolites in breast milk was not examined.</p>
</div>
</div>
<div class="Section" data-sectioncode="34081-0"><a name="s107" id=
"s107"></a> <a name="section-8.3" id="section-8.3"></a>
<h2>8.4 Pediatric Use</h2>
<div class="Section" data-sectioncode="42229-5"><a name="s108" id=
"s108"></a> <a name="section-8.3.1" id="section-8.3.1"></a>
<p class="First"><span class="Underline">Generalized Anxiety
Disorder</span> — In pediatric patients aged 7 to 17 years,
efficacy was demonstrated in one 10-week, placebo-controlled trial.
The study included 272 pediatric patients with GAD of which 47%
were 7 to 11 years of age. CYMBALTA demonstrated superiority over
placebo as measured by greater improvement in the Pediatric Anxiety
Rating Scale (PARS) for GAD severity score <span class=
"Italics">[see Clinical Studies (<a href="#s138">14.2</a>)]</span>.
The safety and effectiveness in pediatric patients less than 7
years of age have not been established.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s109" id=
"s109"></a> <a name="section-8.3.2" id="section-8.3.2"></a>
<p class="First"><span class="Underline">Major Depressive
Disorder</span> — Efficacy was not demonstrated in two 10-week,
placebo-controlled trials with 800 pediatric patients with MDD, age
7-17. Neither CYMBALTA nor an active control (indicated for
treatment of pediatric depression) was superior to placebo. The
safety and effectiveness in pediatric patients less than 7 years of
age have not been established.</p>
<p>The most frequently observed adverse reactions in the clinical
trials included nausea, headache, decreased weight, and abdominal
pain. Decreased appetite and weight loss have been observed in
association with the use of SSRIs and SNRIs. Perform regular
monitoring of weight and growth in children and adolescents treated
with an SNRI such as CYMBALTA <span class="Italics">[see Adverse
Reactions (<a href="#s75">6.11</a>)]</span>.</p>
<p>Use of CYMBALTA in a child or adolescent must balance the
potential risks with the clinical need <span class="Italics">[see
<a href="#s2">Boxed Warning</a> and Warnings and Precautions
(<a href="#s22">5.1</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s110" id=
"s110"></a> <a name="section-8.3.3" id="section-8.3.3"></a>
<p class="First"><span class="Underline">Animal Data</span> —
Duloxetine administration to young rats from post-natal day 21
(weaning) through post-natal day 90 (adult) resulted in decreased
body weights that persisted into adulthood, but recovered when drug
treatment was discontinued; slightly delayed (~1.5 days) sexual
maturation in females, without any effect on fertility; and a delay
in learning a complex task in adulthood, which was not observed
after drug treatment was discontinued. These effects were observed
at the high dose of 45 mg/kg/day (2 times the MRHD, for a child);
the no-effect-level was 20 mg/kg/day (≈1 times the MRHD, for a
child).</p>
</div>
</div>
<div class="Section" data-sectioncode="34082-8"><a name="s111" id=
"s111"></a> <a name="section-8.4" id="section-8.4"></a>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the 2,418 patients in premarketing clinical
studies of CYMBALTA for MDD, 5.9% (143) were 65 years of age or
over. Of the 1041 patients in CLBP premarketing studies, 21.2%
(221) were 65 years of age or over. Of the 487 patients in OA
premarketing studies, 40.5% (197) were 65 years of age or over. Of
the 1,074 patients in the DPNP premarketing studies, 33% (357) were
65 years of age or over. Of the 1,761 patients in FM premarketing
studies, 7.9% (140) were 65 years of age or over. In the MDD, GAD,
DPNP, FM, OA, and CLBP studies, no overall differences in safety or
effectiveness were generally observed between these subjects and
younger subjects, and other reported clinical experience has not
identified differences in responses between the elderly and younger
patients, but greater sensitivity of some older individuals cannot
be ruled out. SSRIs and SNRIs, including CYMBALTA have been
associated with cases of clinically significant hyponatremia in
elderly patients, who may be at greater risk for this adverse event
<span class="Italics">[see Warnings and Precautions (<a href=
"#s42">5.13</a>)]</span>.</p>
<p>In an analysis of data from all placebo-controlled-trials,
patients treated with CYMBALTA reported a higher rate of falls
compared to patients treated with placebo. The increased risk
appears to be proportional to a patient's underlying risk for
falls. Underlying risk appears to increase steadily with age. As
elderly patients tend to have a higher prevalence of risk factors
for falls such as medications, medical comorbidities and gait
disturbances, the impact of increasing age by itself on falls
during treatment with CYMBALTA is unclear. Falls with serious
consequences including bone fractures and hospitalizations have
been reported <span class="Italics">[see Warnings and Precautions
(<a href="#s24">5.3</a>) and Adverse Reactions (<a href=
"#s74">6.10</a>)]</span>.</p>
<p>The pharmacokinetics of duloxetine after a single dose of 40 mg
were compared in healthy elderly females (65 to 77 years) and
healthy middle-age females (32 to 50 years). There was no
difference in the C<span class="Sub">max</span>, but the AUC of
duloxetine was somewhat (about 25%) higher and the half-life about
4 hours longer in the elderly females. Population pharmacokinetic
analyses suggest that the typical values for clearance decrease by
approximately 1% for each year of age between 25 to 75 years of
age; but age as a predictive factor only accounts for a small
percentage of between-patient variability. Dosage adjustment based
on the age of the patient is not necessary.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s112" id=
"s112"></a> <a name="section-8.5" id="section-8.5"></a>
<h2>8.6 Gender</h2>
<p class="First">Duloxetine's half-life is similar in men and
women. Dosage adjustment based on gender is not necessary.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s113" id=
"s113"></a> <a name="section-8.6" id="section-8.6"></a>
<h2>8.7 Smoking Status</h2>
<p class="First">Duloxetine bioavailability (AUC) appears to be
reduced by about one-third in smokers. Dosage modifications are not
recommended for smokers.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s114" id=
"s114"></a> <a name="section-8.7" id="section-8.7"></a>
<h2>8.8 Race</h2>
<p class="First">No specific pharmacokinetic study was conducted to
investigate the effects of race.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s115" id=
"s115"></a> <a name="section-8.8" id="section-8.8"></a>
<h2>8.9 Hepatic Impairment</h2>
<p class="First">Patients with clinically evident hepatic
impairment have decreased duloxetine metabolism and elimination.
After a single 20 mg dose of CYMBALTA, 6 cirrhotic patients with
moderate liver impairment (Child-Pugh Class B) had a mean plasma
duloxetine clearance about 15% that of age- and gender-matched
healthy subjects, with a 5-fold increase in mean exposure (AUC).
Although C<span class="Sub">max</span> was similar to normals in
the cirrhotic patients, the half-life was about 3 times longer
<span class="Italics">[see Dosage and Administration (<a href=
"#s13">2.6</a>) and Warnings and Precautions (<a href=
"#s43">5.14</a>)]</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s116" id=
"s116"></a> <a name="section-8.9" id="section-8.9"></a>
<h2>8.10 Severe Renal Impairment</h2>
<p class="First">Limited data are available on the effects of
duloxetine in patients with end-stage renal disease (ESRD). After a
single 60 mg dose of duloxetine, C<span class="Sub">max</span> and
AUC values were approximately 100% greater in patients with
end-stage renal disease receiving chronic intermittent hemodialysis
than in subjects with normal renal function. The elimination
half-life, however, was similar in both groups. The AUCs of the
major circulating metabolites, 4-hydroxy duloxetine glucuronide and
5-hydroxy, 6-methoxy duloxetine sulfate, largely excreted in urine,
were approximately 7- to 9-fold higher and would be expected to
increase further with multiple dosing. Population PK analyses
suggest that mild to moderate degrees of renal impairment
(estimated CrCl 30-80 mL/min) have no significant effect on
duloxetine apparent clearance <span class="Italics">[see Dosage and
Administration (<a href="#s13">2.6</a>) and Warnings and
Precautions (<a href="#s43">5.14</a>)]</span>.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">9 DRUG ABUSE AND DEPENDENCE</a>
<div class="Section toggle-content closed" data-sectioncode=
"42227-9"><a name="s117" id="s117"></a> <a name="section-9" id=
"section-9"></a>
<div class="Section" data-sectioncode="34086-9"><a name="s118" id=
"s118"></a> <a name="section-9.1" id="section-9.1"></a>
<h2>9.2 Abuse</h2>
<p class="First">In animal studies, duloxetine did not demonstrate
barbiturate-like (depressant) abuse potential.</p>
<p>While CYMBALTA has not been systematically studied in humans for
its potential for abuse, there was no indication of drug-seeking
behavior in the clinical trials. However, it is not possible to
predict on the basis of premarketing experience the extent to which
a CNS active drug will be misused, diverted, and/or abused once
marketed. Consequently, physicians should carefully evaluate
patients for a history of drug abuse and follow such patients
closely, observing them for signs of misuse or abuse of CYMBALTA
(e.g., development of tolerance, incrementation of dose,
drug-seeking behavior).</p>
</div>
<div class="Section" data-sectioncode="34087-7"><a name="s119" id=
"s119"></a> <a name="section-9.2" id="section-9.2"></a>
<h2>9.3 Dependence</h2>
<p class="First">In drug dependence studies, duloxetine did not
demonstrate dependence-producing potential in rats.</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">10 OVERDOSAGE</a>
<div class="Section toggle-content closed" data-sectioncode=
"34088-5"><a name="s120" id="s120"></a> <a name="section-10" id=
"section-10"></a>
<div class="Section" data-sectioncode="42229-5"><a name="s121" id=
"s121"></a> <a name="section-10.1" id="section-10.1"></a>
<h2>10.1 Signs and Symptoms</h2>
<p class="First">In postmarketing experience, fatal outcomes have
been reported for acute overdoses, primarily with mixed overdoses,
but also with duloxetine only, at doses as low as 1000 mg. Signs
and symptoms of overdose (duloxetine alone or with mixed drugs)
included somnolence, coma, serotonin syndrome, seizures, syncope,
tachycardia, hypotension, hypertension, and vomiting.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s122" id=
"s122"></a> <a name="section-10.2" id="section-10.2"></a>
<h2>10.2 Management of Overdose</h2>
<p class="First">There is no specific antidote to CYMBALTA, but if
serotonin syndrome ensues, specific treatment (such as with
cyproheptadine and/or temperature control) may be considered. In
case of acute overdose, treatment should consist of those general
measures employed in the management of overdose with any drug.</p>
<p>An adequate airway, oxygenation, and ventilation should be
assured, and cardiac rhythm and vital signs should be monitored.
Induction of emesis is not recommended. Gastric lavage with a
large-bore orogastric tube with appropriate airway protection, if
needed, may be indicated if performed soon after ingestion or in
symptomatic patients.</p>
<p>Activated charcoal may be useful in limiting absorption of
duloxetine from the gastrointestinal tract. Administration of
activated charcoal has been shown to decrease AUC and C<span class=
"Sub">max</span> by an average of one-third, although some subjects
had a limited effect of activated charcoal. Due to the large volume
of distribution of this drug, forced diuresis, dialysis,
hemoperfusion, and exchange transfusion are unlikely to be
beneficial.</p>
<p>In managing overdose, the possibility of multiple drug
involvement should be considered. A specific caution involves
patients who are taking or have recently taken CYMBALTA and might
ingest excessive quantities of a TCA. In such a case, decreased
clearance of the parent tricyclic and/or its active metabolite may
increase the possibility of clinically significant sequelae and
extend the time needed for close medical observation <span class=
"Italics">[see Warnings and Precautions (<a href="#s25">5.4</a>)
and Drug Interactions (<a href="#s78">7</a>)]</span>. The physician
should consider contacting a poison control center (1-800-222-1222
or www.poison.org) for additional information on the treatment of
any overdose. Telephone numbers for certified poison control
centers are listed in the <span class="Italics">Physicians' Desk
Reference</span> (PDR).</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">11 DESCRIPTION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34089-3"><a name="s123" id="s123"></a> <a name="section-11" id=
"section-11"></a>
<p class="First">CYMBALTA<span class="Sup">®</span> (duloxetine
delayed-release capsules) is a selective serotonin and
norepinephrine reuptake inhibitor (SSNRI) for oral administration.
Its chemical designation is (+)-(<span class=
"Italics">S</span>)-<span class=
"Italics">N</span>-methyl-γ-(1-naphthyloxy)-2-thiophenepropylamine
hydrochloride. The empirical formula is C<span class=
"Sub">18</span>H<span class="Sub">19</span>NOS•HCl, which
corresponds to a molecular weight of 333.88. The structural formula
is:</p>
<div class="Figure"><a name="f01" id="f01"></a> <img src=
"image.cfm?setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba&amp;name=cymbalta-01.jpg"
alt="Structural Formula "></div>
<p>Duloxetine hydrochloride is a white to slightly brownish white
solid, which is slightly soluble in water.</p>
<p>Each capsule contains enteric-coated pellets of 22.4, 33.7, or
67.3 mg of duloxetine hydrochloride equivalent to 20, 30, or 60 mg
of duloxetine, respectively. These enteric-coated pellets are
designed to prevent degradation of the drug in the acidic
environment of the stomach. Inactive ingredients include FD&amp;C
Blue No. 2, gelatin, hypromellose, hydroxypropyl methylcellulose
acetate succinate, sodium lauryl sulfate, sucrose, sugar spheres,
talc, titanium dioxide, and triethyl citrate. The 20 and 60 mg
capsules also contain iron oxide yellow.</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">12 CLINICAL PHARMACOLOGY</a>
<div class="Section toggle-content closed" data-sectioncode=
"34090-1"><a name="s124" id="s124"></a> <a name="section-12" id=
"section-12"></a>
<div class="Section" data-sectioncode="43679-0"><a name="s125" id=
"s125"></a> <a name="section-12.1" id="section-12.1"></a>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Although the exact mechanisms of the
antidepressant, central pain inhibitory and anxiolytic actions of
duloxetine in humans are unknown, these actions are believed to be
related to its potentiation of serotonergic and noradrenergic
activity in the CNS.</p>
</div>
<div class="Section" data-sectioncode="43681-6"><a name="s126" id=
"s126"></a> <a name="section-12.2" id="section-12.2"></a>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Preclinical studies have shown that duloxetine is
a potent inhibitor of neuronal serotonin and norepinephrine
reuptake and a less potent inhibitor of dopamine reuptake.
Duloxetine has no significant affinity for dopaminergic,
adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA
receptors <span class="Italics">in vitro</span>. Duloxetine does
not inhibit monoamine oxidase (MAO).</p>
<p>CYMBALTA is in a class of drugs known to affect urethral
resistance. If symptoms of urinary hesitation develop during
treatment with CYMBALTA, consideration should be given to the
possibility that they might be drug-related.</p>
</div>
<div class="Section" data-sectioncode="43682-4"><a name="s127" id=
"s127"></a> <a name="section-12.3" id="section-12.3"></a>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Duloxetine has an elimination half-life of about
12 hours (range 8 to 17 hours) and its pharmacokinetics are dose
proportional over the therapeutic range. Steady-state plasma
concentrations are typically achieved after 3 days of dosing.
Elimination of duloxetine is mainly through hepatic metabolism
involving two P450 isozymes, CYP1A2 and CYP2D6.</p>
<div class="Section" data-sectioncode="42229-5"><a name="s128" id=
"s128"></a> <a name="section-12.3.1" id="section-12.3.1"></a>
<p class="First"><span class="Underline">Absorption and
Distribution</span> — Orally administered duloxetine hydrochloride
is well absorbed. There is a median 2 hour lag until absorption
begins (T<span class="Sub">lag</span>), with maximal plasma
concentrations (C<span class="Sub">max</span>) of duloxetine
occurring 6 hours post dose. Food does not affect the C<span class=
"Sub">max</span> of duloxetine, but delays the time to reach peak
concentration from 6 to 10 hours and it marginally decreases the
extent of absorption (AUC) by about 10%. There is a 3 hour delay in
absorption and a one-third increase in apparent clearance of
duloxetine after an evening dose as compared to a morning dose.</p>
<p>The apparent volume of distribution averages about 1640 L.
Duloxetine is highly bound (&gt;90%) to proteins in human plasma,
binding primarily to albumin and α<span class="Sub">1</span>-acid
glycoprotein. The interaction between duloxetine and other highly
protein bound drugs has not been fully evaluated. Plasma protein
binding of duloxetine is not affected by renal or hepatic
impairment.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s129" id=
"s129"></a> <a name="section-12.3.2" id="section-12.3.2"></a>
<p class="First"><span class="Underline">Metabolism and
Elimination</span> — Biotransformation and disposition of
duloxetine in humans have been determined following oral
administration of <span class="Sup">14</span>C-labeled duloxetine.
Duloxetine comprises about 3% of the total radiolabeled material in
the plasma, indicating that it undergoes extensive metabolism to
numerous metabolites. The major biotransformation pathways for
duloxetine involve oxidation of the naphthyl ring followed by
conjugation and further oxidation. Both CYP1A2 and CYP2D6 catalyze
the oxidation of the naphthyl ring <span class="Italics">in
vitro</span>. Metabolites found in plasma include 4-hydroxy
duloxetine glucuronide and 5-hydroxy, 6-methoxy duloxetine sulfate.
Many additional metabolites have been identified in urine, some
representing only minor pathways of elimination. Only trace (&lt;1%
of the dose) amounts of unchanged duloxetine are present in the
urine. Most (about 70%) of the duloxetine dose appears in the urine
as metabolites of duloxetine; about 20% is excreted in the feces.
Duloxetine undergoes extensive metabolism, but the major
circulating metabolites have not been shown to contribute
significantly to the pharmacologic activity of duloxetine.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s130" id=
"s130"></a> <a name="section-12.3.3" id="section-12.3.3"></a>
<p class="First"><span class="Underline">Children and Adolescents
(ages 7 to 17 years)</span> — Duloxetine steady-state plasma
concentration was comparable in children (7 to 12 years of age),
adolescents (13 to 17 years of age) and adults. The average
steady-state duloxetine concentration was approximately 30% lower
in the pediatric population (children and adolescents) relative to
the adults. The model-predicted duloxetine steady state plasma
concentrations in children and adolescents were mostly within the
concentration range observed in adult patients and did not exceed
the concentration range in adults.</p>
</div>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">13 NONCLINICAL TOXICOLOGY</a>
<div class="Section toggle-content closed" data-sectioncode=
"43680-8"><a name="s131" id="s131"></a> <a name="section-13" id=
"section-13"></a>
<div class="Section" data-sectioncode="34083-6"><a name="s132" id=
"s132"></a> <a name="section-13.1" id="section-13.1"></a>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Underline">Carcinogenesis</span> —
Duloxetine was administered in the diet to mice and rats for 2
years.</p>
<div class="Section" data-sectioncode="42229-5"><a name="s133" id=
"s133"></a> <a name="section-13.1.1" id="section-13.1.1"></a>
<p class="First">In female mice receiving duloxetine at 140
mg/kg/day (6 times the maximum recommended human dose (MRHD) of 120
mg/day on a mg/m<span class="Sup">2</span> basis), there was an
increased incidence of hepatocellular adenomas and carcinomas. The
no-effect dose was 50 mg/kg/day (2 times the MRHD). Tumor incidence
was not increased in male mice receiving duloxetine at doses up to
100 mg/kg/day (4 times the MRHD).</p>
<p>In rats, dietary doses of duloxetine up to 27 mg/kg/day in
females (2 times the MRHD) and up to 36 mg/kg/day in males (3 times
the MRHD) did not increase the incidence of tumors.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s134" id=
"s134"></a> <a name="section-13.1.2" id="section-13.1.2"></a>
<p class="First"><span class="Underline">Mutagenesis</span> —
Duloxetine was not mutagenic in the <span class="Italics">in
vitro</span> bacterial reverse mutation assay (Ames test) and was
not clastogenic in an <span class="Italics">in vivo</span>
chromosomal aberration test in mouse bone marrow cells.
Additionally, duloxetine was not genotoxic in an <span class=
"Italics">in vitro</span> mammalian forward gene mutation assay in
mouse lymphoma cells or in an <span class="Italics">in vitro</span>
unscheduled DNA synthesis (UDS) assay in primary rat hepatocytes,
and did not induce sister chromatid exchange in Chinese hamster
bone marrow <span class="Italics">in vivo</span>.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s135" id=
"s135"></a> <a name="section-13.1.3" id="section-13.1.3"></a>
<p class="First"><span class="Underline">Impairment of
Fertility</span> — Duloxetine administered orally to either male or
female rats prior to and throughout mating at doses up to 45
mg/kg/day (4 times the MRHD) did not alter mating or fertility.</p>
</div>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">14 CLINICAL STUDIES</a>
<div class="Section toggle-content closed" data-sectioncode=
"34092-7"><a name="s136" id="s136"></a> <a name="section-14" id=
"section-14"></a>
<p class="First">The efficacy of CYMBALTA has been established in
the following adequate and well-controlled trials:</p>
<ul class="Disc">
<li>Major Depressive Disorder (MDD): 4 short-term and 1 maintenance
trial in adults <span class="Italics">[see Clinical Studies
(<a href="#s137">14.1</a>)]</span>.</li>
<li>Generalized Anxiety Disorder (GAD): 3 short-term trials in
adults, 1 maintenance trial in adults, and 1 short-term trial in
children and adolescents <span class="Italics">[see Clinical
Studies (<a href="#s138">14.2</a>)]</span>.</li>
<li>Diabetic Peripheral Neuropathic Pain (DPNP): Two 12-week trials
in adults <span class="Italics">[see Clinical Studies (<a href=
"#s139">14.3</a>)]</span>.</li>
<li>Fibromyalgia (FM): Two trials in adults (one of 3 months
duration and one of 6 months duration) <span class="Italics">[see
Clinical Studies (<a href="#s140">14.4</a>)]</span>.</li>
<li>Chronic Musculoskeletal Pain: Two 12- to 13-week trials in
adult patients with chronic low back pain (CLBP) and one 13-week
trial in adult patients with chronic pain due to osteoarthritis
<span class="Italics">[see Clinical Studies (<a href=
"#s141">14.5</a>)]</span>.</li>
</ul>
<div class="Section" data-sectioncode="42229-5"><a name="s137" id=
"s137"></a> <a name="section-14.1" id="section-14.1"></a>
<h2>14.1 Major Depressive Disorder</h2>
<p class="First">The efficacy of CYMBALTA as a treatment for
depression was established in 4 randomized, double-blind,
placebo-controlled, fixed-dose studies in adult outpatients (18 to
83 years) meeting DSM-IV criteria for major depression. In 2
studies, patients were randomized to CYMBALTA 60 mg once daily
(N=123 and N=128, respectively) or placebo (N=122 and N=139,
respectively) for 9 weeks; in the third study, patients were
randomized to CYMBALTA 20 or 40 mg twice daily (N=86 and N=91,
respectively) or placebo (N=89) for 8 weeks; in the fourth study,
patients were randomized to CYMBALTA 40 or 60 mg twice daily (N=95
and N=93, respectively) or placebo (N=93) for 8 weeks. There is no
evidence that doses greater than 60 mg/day confer additional
benefits.</p>
<p>In all 4 studies, CYMBALTA demonstrated superiority over placebo
as measured by improvement in the 17-item Hamilton Depression
Rating Scale (HAMD-17) total score (Studies 1-4 in <a href=
"#t7">Table 7</a>).</p>
<p>In all of these clinical studies, analyses of the relationship
between treatment outcome and age, gender, and race did not suggest
any differential responsiveness on the basis of these patient
characteristics.</p>
<a name="t7" id="t7"></a>
<div class="scrollingtable">
<table width="100%">
<caption><span>Table 7: Summary of the Primary Efficacy Results for
Studies in Major Depressive Disorder</span></caption>
<colgroup>
<col align="left" width="14.020%">
<col align="left" width="25.380%">
<col align="left" width="20.200%">
<col align="left" width="20.200%">
<col align="left" width="20.200%"></colgroup>
<tfoot>
<tr class="First">
<td align="left" colspan="5" valign="top">
<p class="First Footnote">SD: standard deviation; SE: standard
error; LS Mean: least-squares mean; CI: confidence interval, not
adjusted for multiplicity in trials where multiple dose groups were
included.</p>
</td>
</tr>
<tr>
<td align="left" colspan="5" valign="top">
<p class="First Footnote"><span class="Sup">a</span> Difference
(drug minus placebo) in least-squares mean change from
baseline.</p>
</td>
</tr>
<tr class="Last">
<td align="left" colspan="5" valign="top">
<p class="First Footnote"><span class="Sup">b</span> Doses
statistically significantly superior to placebo.</p>
</td>
</tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2"
valign="middle"><span class="Bold">Study Number</span></td>
<td class="Botrule Rrule Toprule" align="center" rowspan="2"
valign="middle"><span class="Bold">Treatment Group</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3"
valign="middle"><span class="Bold">Primary Efficacy Measure:
HAMD-17</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">Mean Baseline Score (SD)</span></td>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">LS Mean Change from Baseline (SE)</span></td>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">Placebo-subtracted Difference</span><span class=
"Bold"><span class="Sup">a</span></span> <span class="Bold">(95%
CI)</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="middle">Study 1</td>
<td class="Rrule" align="left" valign="middle">CYMBALTA (60
mg/day)<span class="Sup">b</span></td>
<td class="Rrule" align="center" valign="middle">21.5 (4.10)</td>
<td class="Rrule" align="center" valign="middle">-10.9 (0.70)</td>
<td class="Rrule" align="center" valign="middle">-4.9 (-6.8,
-2.9)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="middle"></td>
<td class="Botrule Rrule" align="left" valign="middle">Placebo</td>
<td class="Botrule Rrule" align="center" valign="middle">21.1
(3.71)</td>
<td class="Botrule Rrule" align="center" valign="middle">-6.1
(0.69)</td>
<td class="Botrule Rrule" align="center" valign="middle">--</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Study 2</td>
<td class="Rrule" align="left" valign="top">CYMBALTA (60
mg/day)<span class="Sup">b</span></td>
<td class="Rrule" align="center" valign="middle">20.3 (3.32)</td>
<td class="Rrule" align="center" valign="middle">-10.5 (0.71)</td>
<td class="Rrule" align="center" valign="middle">-2.2 (-4.0,
-0.3)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="middle">20.5
(3.42)</td>
<td class="Botrule Rrule" align="center" valign="middle">-8.3
(0.67)</td>
<td class="Botrule Rrule" align="center" valign="middle">--</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Study 3</td>
<td class="Rrule" align="left" valign="top">CYMBALTA (20 mg
BID)<span class="Sup">b</span></td>
<td class="Rrule" align="center" valign="middle">18.6 (5.85)</td>
<td class="Rrule" align="center" valign="middle">-7.4 (0.80)</td>
<td class="Rrule" align="center" valign="middle">-2.4 (-4.7,
-0.2)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">CYMBALTA (40 mg
BID)<span class="Sup">b</span></td>
<td class="Rrule" align="center" valign="middle">18.1 (4.52)</td>
<td class="Rrule" align="center" valign="middle">-8.6 (0.81)</td>
<td class="Rrule" align="center" valign="middle">-3.6 (-5.9,
-1.4)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="middle">17.2
(5.11)</td>
<td class="Botrule Rrule" align="center" valign="middle">-5.0
(0.81)</td>
<td class="Botrule Rrule" align="center" valign="middle">--</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Study 4</td>
<td class="Rrule" align="left" valign="top">CYMBALTA (40 mg
BID)<span class="Sup">b</span></td>
<td class="Rrule" align="center" valign="middle">19.9 (3.54)</td>
<td class="Rrule" align="center" valign="middle">-11.0 (0.49)</td>
<td class="Rrule" align="center" valign="middle">-2.2 (-3.6,
-0.9)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">CYMBALTA (60 mg
BID)<span class="Sup">b</span></td>
<td class="Rrule" align="center" valign="middle">20.2 (3.41)</td>
<td class="Rrule" align="center" valign="middle">-12.1 (0.49)</td>
<td class="Rrule" align="center" valign="middle">-3.3 (-4.7,
-1.9)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="middle">19.9
(3.58)</td>
<td class="Botrule Rrule" align="center" valign="middle">-8.8
(0.50)</td>
<td class="Botrule Rrule" align="center" valign="middle">--</td>
</tr>
</tbody>
</table>
</div>
<p>In another study, 533 patients meeting DSM-IV criteria for MDD
received CYMBALTA 60 mg once daily during an initial 12-week
open-label treatment phase. Two hundred and seventy-eight patients
who responded to open label treatment (defined as meeting the
following criteria at weeks 10 and 12: a HAMD-17 total score ≤9,
Clinical Global Impressions of Severity (CGI-S) ≤2, and not meeting
the DSM-IV criteria for MDD) were randomly assigned to continuation
of CYMBALTA at the same dose (N=136) or to placebo (N=142) for 6
months. Patients on CYMBALTA experienced a statistically
significantly longer time to relapse of depression than did
patients on placebo (Study 5 in <a href="#fig1">Figure 1</a>).
Relapse was defined as an increase in the CGI-S score of ≥2 points
compared with that obtained at week 12, as well as meeting the
DSM-IV criteria for MDD at 2 consecutive visits at least 2 weeks
apart, where the 2-week temporal criterion had to be satisfied at
only the second visit. The effectiveness of CYMBALTA in
hospitalized patients with major depressive disorder has not been
studied.<br>
<br></p>
<p class="MultiMediaCaption"><a name="fig1" id=
"fig1"></a><span class="Bold">Figure 1: Kaplan-Meier Estimation of
Cumulative Proportion of Patients with Relapse (MDD Study
5)</span></p>
<div class="Figure"><a name="f02" id="f02"></a> <img src=
"image.cfm?setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba&amp;name=cymbalta-18.jpg"
alt="Figure 1 "></div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s138" id=
"s138"></a> <a name="section-14.2" id="section-14.2"></a>
<h2>14.2 Generalized Anxiety Disorder</h2>
<p class="First">The efficacy of CYMBALTA in the treatment of
generalized anxiety disorder (GAD) was established in 1 fixed-dose
randomized, double-blind, placebo-controlled trial and 2
flexible-dose randomized, double-blind, placebo-controlled trials
in adult outpatients between 18 and 83 years of age meeting the
DSM-IV criteria for GAD.</p>
<p>In 1 flexible-dose study and in the fixed-dose study, the
starting dose was 60 mg once daily where down titration to 30 mg
once daily was allowed for tolerability reasons before increasing
it to 60 mg once daily. Fifteen percent of patients were down
titrated. One flexible-dose study had a starting dose of 30 mg once
daily for 1 week before increasing it to 60 mg once daily.</p>
<p>The 2 flexible-dose studies involved dose titration with
CYMBALTA doses ranging from 60 mg once daily to 120 mg once daily
(N=168 and N=162) compared to placebo (N=159 and N=161) over a
10-week treatment period. The mean dose for completers at endpoint
in the flexible-dose studies was 104.75 mg/day. The fixed-dose
study evaluated CYMBALTA doses of 60 mg once daily (N=168) and 120
mg once daily (N=170) compared to placebo (N=175) over a 9-week
treatment period. While a 120 mg/day dose was shown to be
effective, there is no evidence that doses greater than 60 mg/day
confer additional benefit.</p>
<p>In all 3 studies, CYMBALTA demonstrated superiority over placebo
as measured by greater improvement in the Hamilton Anxiety Scale
(HAM-A) total score (Studies 1-3 in <a href="#t8">Table 8</a>) and
by the Sheehan Disability Scale (SDS) global functional impairment
score. The SDS is a composite measurement of the extent emotional
symptoms disrupt patient functioning in 3 life domains:
work/school, social life/leisure activities, and family life/home
responsibilities.</p>
<p>In another study, 887 patients meeting DSM-IV-TR criteria for
GAD received CYMBALTA 60 mg to 120 mg once daily during an initial
26-week open-label treatment phase. Four hundred and twenty-nine
patients who responded to open-label treatment (defined as meeting
the following criteria at weeks 24 and 26: a decrease from baseline
HAM-A total score by at least 50% to a score no higher than 11, and
a Clinical Global Impressions of Improvement [CGI-Improvement]
score of 1 or 2) were randomly assigned to continuation of CYMBALTA
at the same dose (N=216) or to placebo (N=213) and were observed
for relapse. Of the patients randomized, 73% had been in a
responder status for at least 10 weeks. Relapse was defined as an
increase in CGI-Severity score at least 2 points to a score ≥4 and
a MINI (Mini-International Neuropsychiatric Interview) diagnosis of
GAD (excluding duration), or discontinuation due to lack of
efficacy. Patients taking CYMBALTA experienced a statistically
significantly longer time to relapse of GAD than did patients
taking placebo (Study 4 in <a href="#fig2">Figure 2</a>).</p>
<p>Subgroup analyses did not indicate that there were any
differences in treatment outcomes as a function of age or
gender.</p>
<p>The efficacy of CYMBALTA in the treatment of patients ≥65 years
of age with generalized anxiety disorder was established in one
10-week flexible-dose, randomized, double-blind, placebo-controlled
trial in adults ≥65 years of age meeting the DSM-IV criteria for
GAD. In this study, the starting dose was 30 mg once daily for 2
weeks before further dose increases in 30 mg increments at
treatment weeks 2, 4, and 7 up to 120 mg once daily were allowed
based on investigator judgment of clinical response and
tolerability. The mean dose for patients completing the 10-week
acute treatment phase was 50.95 mg. Patients treated with CYMBALTA
(N=151) demonstrated significantly greater improvement compared
with placebo (N=140) on mean change from baseline to endpoint as
measured by the Hamilton Anxiety Rating Scale total score (Study 5
in <a href="#t8">Table 8</a>).</p>
<p>The efficacy of CYMBALTA in the treatment of pediatric patients
7 to 17 years of age with generalized anxiety disorder (GAD) was
established in 1 flexible-dose randomized, double-blind,
placebo-controlled trial in pediatric outpatients with GAD (based
on DSM-IV criteria).</p>
<p>In this study, the starting dose was 30 mg once daily for 2
weeks. Further dose increases in 30 mg increments up to 120 mg once
daily were allowed based on investigator judgment of clinical
response and tolerability. The mean dose for patients completing
the 10-week treatment phase was 57.6 mg/day. In this study,
CYMBALTA (N=135) demonstrated superiority over placebo (N=137) from
baseline to endpoint as measured by greater improvement in the
Pediatric Anxiety Rating Scale (PARS) for GAD severity score (Study
6 in <a href="#t8">Table 8</a>).</p>
<a name="t8" id="t8"></a>
<div class="scrollingtable">
<table width="100%">
<caption><span>Table 8: Summary of the Primary Efficacy Results for
Studies in General Anxiety Disorder</span></caption>
<colgroup>
<col align="left" width="13.557%">
<col align="left" width="25.515%">
<col align="left" width="20.416%">
<col align="left" width="20.416%">
<col align="left" width="20.096%"></colgroup>
<tfoot>
<tr class="First">
<td align="left" colspan="5" valign="top">
<p class="First Footnote">SD: standard deviation; SE: standard
error; LS Mean: least-squares mean; CI: confidence interval, not
adjusted for multiplicity in trials where multiple dose groups were
included.</p>
</td>
</tr>
<tr>
<td align="left" colspan="5" valign="top">
<p class="First Footnote"><span class="Sup">a</span> Difference
(drug minus placebo) in least squares mean change from
baseline.</p>
</td>
</tr>
<tr class="Last">
<td align="left" colspan="5" valign="top">
<p class="First Footnote"><span class="Sup">b</span> Dose
statistically significantly superior to placebo.</p>
</td>
</tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2"
valign="top"><span class="Bold">Study Number</span></td>
<td class="Botrule Rrule Toprule" align="left" rowspan="2" valign=
"top"><span class="Bold">Treatment Group</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3"
valign="top"><span class="Bold">Primary Efficacy
Measure</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">Mean Baseline Score (SD)</span></td>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">LS Mean Change from Baseline (SE)</span></td>
<td class="Botrule Rrule" align="center" valign="middle">
<span class="Bold">Placebo-subtracted Difference</span><span class=
"Bold"><span class="Sup">a</span></span> <span class="Bold">(95%
CI)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="3" valign=
"top">Study 1<br>
(HAM-A)</td>
<td class="Botrule Rrule" align="left" valign="top">CYMBALTA (60
mg/day)<span class="Sup">b</span></td>
<td class="Botrule Rrule" align="center" valign="top">25.1
(7.18)</td>
<td class="Botrule Rrule" align="center" valign="top">-12.8
(0.68)</td>
<td class="Botrule Rrule" align="center" valign="top">-4.4 (-6.2,
-2.5)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">CYMBALTA (120
mg/day)<span class="Sup">b</span></td>
<td class="Botrule Rrule" align="center" valign="top">25.1
(7.24)</td>
<td class="Botrule Rrule" align="center" valign="top">-12.5
(0.67)</td>
<td class="Botrule Rrule" align="center" valign="top">-4.1 (-5.9,
-2.3)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="top">25.8
(7.66)</td>
<td class="Botrule Rrule" align="center" valign="top">-8.4
(0.67)</td>
<td class="Botrule Rrule" align="center" valign="top">--</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign=
"top">Study 2<br>
(HAM-A)</td>
<td class="Botrule Rrule" align="left" valign="top">CYMBALTA
(60-120 mg/day)<span class="Sup">b</span></td>
<td class="Botrule Rrule" align="center" valign="middle">22.5
(7.44)</td>
<td class="Botrule Rrule" align="center" valign="middle">-8.1
(0.70)</td>
<td class="Botrule Rrule" align="center" valign="middle">-2.2
(-4.2, -0.3)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="middle">23.5
(7.91)</td>
<td class="Botrule Rrule" align="center" valign="middle">-5.9
(0.70)</td>
<td class="Botrule Rrule" align="center" valign="middle">--</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign=
"top">Study 3<br>
(HAM-A)</td>
<td class="Botrule Rrule" align="left" valign="top">CYMBALTA
(60-120 mg/day)<span class="Sup">b</span></td>
<td class="Botrule Rrule" align="center" valign="middle">25.8
(5.66)</td>
<td class="Botrule Rrule" align="center" valign="middle">-11.8
(0.69)</td>
<td class="Botrule Rrule" align="center" valign="middle">-2.6
(-4.5, -0.7)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="middle">25.0
(5.82)</td>
<td class="Botrule Rrule" align="center" valign="middle">-9.2
(0.67)</td>
<td class="Botrule Rrule" align="center" valign="middle">--</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign=
"top">Study 5<br>
(Elderly)<br>
(HAM-A)</td>
<td class="Botrule Rrule" align="left" valign="top">CYMBALTA
(60-120 mg/day)<span class="Sup">b</span></td>
<td class="Botrule Rrule" align="center" valign="middle">24.6
(6.21)</td>
<td class="Botrule Rrule" align="center" valign="middle">-15.9
(0.63)</td>
<td class="Botrule Rrule" align="center" valign="middle">-4.2
(-5.9, -2.5)</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="middle">24.5
(7.05)</td>
<td class="Botrule Rrule" align="center" valign="middle">-11.7
(0.67)</td>
<td class="Botrule Rrule" align="center" valign="middle">--</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Study 6<br>
(Pediatric)</td>
<td class="Botrule Rrule" align="left" valign="top">CYMBALTA
(30-120 mg/day)<span class="Sup">b</span></td>
<td class="Botrule Rrule" align="center" valign="middle">17.5
(1.98)</td>
<td class="Botrule Rrule" align="center" valign="middle">-9.7
(0.50)</td>
<td class="Botrule Rrule" align="center" valign="middle">-2.7
(-4.0, -1.3)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">(PARS for
GAD)</td>
<td class="Botrule Rrule" align="left" valign="top">Placebo</td>
<td class="Botrule Rrule" align="center" valign="middle">17.4
(2.24)</td>
<td class="Botrule Rrule" align="center" valign="middle">-7.1
(0.50)</td>
<td class="Botrule Rrule" align="center" valign="middle">--</td>
</tr>
</tbody>
</table>
</div>
<p class="MultiMediaCaption"><a name="fig2" id=
"fig2"></a><span class="Bold">Figure 2: Kaplan-Meier Estimation of
Cumulative Proportion of Patients with Relapse (GAD Study
4)</span></p>
<div class="Figure"><a name="f03" id="f03"></a> <img src=
"image.cfm?setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba&amp;name=cymbalta-19.jpg"
alt="Figure 2 "></div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s139" id=
"s139"></a> <a name="section-14.3" id="section-14.3"></a>
<h2>14.3 Diabetic Peripheral Neuropathic Pain</h2>
<p class="First">The efficacy of CYMBALTA for the management of
neuropathic pain associated with diabetic peripheral neuropathy was
established in 2 randomized, 12-week, double-blind,
placebo-controlled, fixed-dose studies in adult patients having
diabetic peripheral neuropathic pain for at least 6 months. Study
DPNP-1 and Study DPNP-2 enrolled a total of 791 patients of whom
592 (75%) completed the studies. Patients enrolled had Type I or II
diabetes mellitus with a diagnosis of painful distal symmetrical
sensorimotor polyneuropathy for at least 6 months. The patients had
a baseline pain score of ≥4 on an 11-point scale ranging from 0 (no
pain) to 10 (worst possible pain). Patients were permitted up to 4
g of acetaminophen per day as needed for pain, in addition to
CYMBALTA. Patients recorded their pain daily in a diary.</p>
<p>Both studies compared CYMBALTA 60 mg once daily or 60 mg twice
daily with placebo. DPNP-1 additionally compared CYMBALTA 20 mg
with placebo. A total of 457 patients (342 CYMBALTA, 115 placebo)
were enrolled in DPNP-1 and a total of 334 patients (226 CYMBALTA,
108 placebo) were enrolled in DPNP-2. Treatment with CYMBALTA 60 mg
one or two times a day statistically significantly improved the
endpoint mean pain scores from baseline and increased the
proportion of patients with at least a 50% reduction in pain scores
from baseline. For various degrees of improvement in pain from
baseline to study endpoint, <a href="#f04">Figures 3</a> and
<a href="#f05">4</a> show the fraction of patients achieving that
degree of improvement. The figures are cumulative, so that patients
whose change from baseline is, for example, 50%, are also included
at every level of improvement below 50%. Patients who did not
complete the study were assigned 0% improvement. Some patients
experienced a decrease in pain as early as week 1, which persisted
throughout the study.</p>
<div class="Figure"><a name="f04" id="f04"></a> <img src=
"image.cfm?setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba&amp;name=cymbalta-02.jpg"
alt="Figure 3 ">
<p class="MultiMediaCaption">Figure 3: Percentage of Patients
Achieving Various Levels of Pain Relief as Measured by 24-Hour
Average Pain Severity - DPNP-1</p>
</div>
<div class="Figure"><a name="f05" id="f05"></a> <img src=
"image.cfm?setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba&amp;name=cymbalta-03.jpg"
alt="Figure 4 ">
<p class="MultiMediaCaption">Figure 4: Percentage of Patients
Achieving Various Levels of Pain Relief as Measured by 24-Hour
Average Pain Severity - DPNP-2</p>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s140" id=
"s140"></a> <a name="section-14.4" id="section-14.4"></a>
<h2>14.4 Fibromyalgia</h2>
<p class="First">The efficacy of CYMBALTA for the management of
fibromyalgia was established in two randomized, double-blind,
placebo-controlled, fixed-dose studies in adult patients meeting
the American College of Rheumatology criteria for fibromyalgia (a
history of widespread pain for 3 months, and pain present at 11 or
more of the 18 specific tender point sites). Study FM-1 was three
months in duration and enrolled female patients only. Study FM-2
was six months in duration and enrolled male and female patients.
Approximately 25% of participants had a comorbid diagnosis of major
depressive disorder (MDD). FM-1 and FM-2 enrolled a total of 874
patients of whom 541 (62%) completed the studies. The patients had
a baseline pain score of 6.5 on an 11-point scale ranging from 0
(no pain) to 10 (worse possible pain).</p>
<p>Both studies compared CYMBALTA 60 mg once daily or 120 mg daily
(given in divided doses in FM-1 and as a single daily dose in FM-2)
with placebo. FM-2 additionally compared CYMBALTA 20 mg with
placebo during the initial three months of a six-month study. A
total of 354 patients (234 CYMBALTA, 120 placebo) were enrolled in
FM-1 and a total of 520 patients (376 CYMBALTA, 144 placebo) were
enrolled in FM-2 (5% male, 95% female). Treatment with CYMBALTA 60
mg or 120 mg daily statistically significantly improved the
endpoint mean pain scores from baseline and increased the
proportion of patients with at least a 50% reduction in pain score
from baseline. Pain reduction was observed in patients both with
and without comorbid MDD. However, the degree of pain reduction may
be greater in patients with comorbid MDD. For various degrees of
improvement in pain from baseline to study endpoint, <a href=
"#f06">Figures 5</a> and <a href="#f07">6</a> show the fraction of
patients achieving that degree of improvement. The figures are
cumulative so that patients whose change from baseline is, for
example, 50%, are also included at every level of improvement below
50%. Patients who did not complete the study were assigned 0%
improvement. Some patients experienced a decrease in pain as early
as week 1, which persisted throughout the study. Improvement was
also demonstrated on measures of function (Fibromyalgia Impact
Questionnaires) and patient global impression of change (PGI).
Neither study demonstrated a benefit of 120 mg compared to 60 mg,
and a higher dose was associated with more adverse reactions and
premature discontinuations of treatment.</p>
<div class="Figure"><a name="f06" id="f06"></a> <img src=
"image.cfm?setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba&amp;name=cymbalta-13.jpg"
alt="Figure 5 ">
<p class="MultiMediaCaption">Figure 5: Percentage of Patients
Achieving Various Levels of Pain Relief as Measured by 24-Hour
Average Pain Severity - FM-1</p>
</div>
<div class="Figure"><a name="f07" id="f07"></a> <img src=
"image.cfm?setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba&amp;name=cymbalta-14.jpg"
alt="Figure 6 ">
<p class="MultiMediaCaption">Figure 6: Percentage of Patients
Achieving Various Levels of Pain Relief as Measured by 24-Hour
Average Pain Severity - FM-2</p>
</div>
<p>Additionally, the benefit of up-titration in non-responders to
CYMBALTA at 60 mg/day was evaluated in a separate study. Patients
were initially treated with CYMBALTA 60 mg once daily for eight
weeks in open-label fashion. Subsequently, completers of this phase
were randomized to double-blind treatment with CYMBALTA at either
60 mg once daily or 120 mg once daily. Those patients who were
considered non-responders, where response was defined as at least a
30% reduction in pain score from baseline at the end of the 8-week
treatment, were no more likely to meet response criteria at the end
of 60 weeks of treatment if blindly titrated to CYMBALTA 120 mg as
compared to those who were blindly continued on CYMBALTA 60 mg.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s141" id=
"s141"></a> <a name="section-14.5" id="section-14.5"></a>
<h2>14.5 Chronic Musculoskeletal Pain</h2>
<p class="First">CYMBALTA is indicated for the management of
chronic musculoskeletal pain. This has been established in studies
in patients with chronic low back pain and chronic pain due to
osteoarthritis.</p>
<div class="Section" data-sectioncode="42229-5"><a name="s142" id=
"s142"></a> <a name="section-14.5.1" id="section-14.5.1"></a>
<p class="First"><span class="Underline">Studies in Chronic Low
Back Pain</span></p>
<p>The efficacy of CYMBALTA in chronic low back pain (CLBP) was
assessed in two double-blind, placebo-controlled, randomized
clinical trials of 13-weeks duration (Study CLBP-1 and Study
CLBP-2), and one of 12-weeks duration (CLBP-3). CLBP-1 and CLBP-3
demonstrated efficacy of CYMBALTA in the treatment of chronic low
back pain. Patients in all studies had no signs of radiculopathy or
spinal stenosis.</p>
<div class="Section" data-sectioncode="42229-5"><a name="e142" id=
"e142"></a> <a name="section-14.5.1.1" id="section-14.5.1.1"></a>
<p class="First"><span class="Italics">Study CLBP-1</span>: Two
hundred thirty-six adult patients (N=115 on CYMBALTA, N=121 on
placebo) enrolled and 182 (77%) completed 13-week treatment phase.
After 7 weeks of treatment, CYMBALTA patients with less than 30%
reduction in average daily pain and who were able to tolerate
CYMBALTA 60 mg once daily had their dose of CYMBALTA, in a
double-blinded fashion, increased to 120 mg once daily for the
remainder of the study. Patients had a mean baseline pain rating of
6 on a numerical rating scale ranging from 0 (no pain) to 10 (worst
possible pain). After 13 weeks of treatment, patients taking
CYMBALTA 60-120 mg daily had a significantly greater pain reduction
compared to placebo. Randomization was stratified by the patients'
baseline NSAIDs-use status. Subgroup analyses did not indicate that
there were differences in treatment outcomes as a function of
NSAIDs use.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="e143" id=
"e143"></a> <a name="section-14.5.1.2" id="section-14.5.1.2"></a>
<p class="First"><span class="Italics">Study CLBP-2</span>: Four
hundred and four patients were randomized to receive fixed doses of
CYMBALTA daily or a matching placebo (N=59 on CYMBALTA 20 mg, N=116
on CYMBALTA 60 mg, N=112 on CYMBALTA 120 mg, N=117 on placebo) and
267 (66%) completed the entire 13-week study. After 13 weeks of
treatment, none of the three CYMBALTA doses showed a statistically
significant difference in pain reduction compared to placebo.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="e144" id=
"e144"></a> <a name="section-14.5.1.3" id="section-14.5.1.3"></a>
<p class="First"><span class="Italics">Study CLBP-3</span>: Four
hundred and one patients were randomized to receive fixed doses of
CYMBALTA 60 mg daily or placebo (N=198 on CYMBALTA, N=203 on
placebo), and 303 (76%) completed the study. Patients had a mean
baseline pain rating of 6 on a numerical rating scale ranging from
0 (no pain) to 10 (worst possible pain). After 12 weeks of
treatment, patients taking CYMBALTA 60 mg daily had significantly
greater pain reduction compared to placebo.</p>
<p>For various degrees of improvement in pain from baseline to
study endpoint, <a href="#f08">Figures 7</a> and <a href=
"#f09">8</a> show the fraction of patients in CLBP-1 and CLBP-3
achieving that degree of improvement. The figures are cumulative,
so that patients whose change from baseline is, for example, 50%,
are also included at every level of improvement below 50%. Patients
who did not complete the study were assigned the value of 0%
improvement.</p>
<div class="Figure"><a name="f08" id="f08"></a> <img src=
"image.cfm?setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba&amp;name=cymbalta-15.jpg"
alt="Figure 7 ">
<p class="MultiMediaCaption">Figure 7: Percentage of Patients
Achieving Various Levels of Pain Relief as Measured by 24-Hour
Average Pain Severity – CLBP-1</p>
</div>
<div class="Figure"><a name="f09" id="f09"></a> <img src=
"image.cfm?setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba&amp;name=cymbalta-16.jpg"
alt="Figure 8 ">
<p class="MultiMediaCaption">Figure 8: Percentage of Patients
Achieving Various Levels of Pain Relief as Measured by 24-Hour
Average Pain Severity – CLBP-3</p>
</div>
</div>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="s143" id=
"s143"></a> <a name="section-14.5.2" id="section-14.5.2"></a>
<p class="First"><span class="Underline">Studies in Chronic Pain
Due to Osteoarthritis</span></p>
<p>The efficacy of CYMBALTA in chronic pain due to osteoarthritis
was assessed in 2 double-blind, placebo-controlled, randomized
clinical trials of 13-weeks duration (Study OA-1 and Study OA-2).
All patients in both studies fulfilled the ACR clinical and
radiographic criteria for classification of idiopathic
osteoarthritis of the knee. Randomization was stratified by the
patients' baseline NSAIDs-use status. Patients assigned to CYMBALTA
started treatment in both studies at a dose of 30 mg once daily for
one week. After the first week, the dose of CYMBALTA was increased
to 60 mg once daily. After 7 weeks of treatment with CYMBALTA 60 mg
once daily, in OA-1 patients with sub-optimal response to treatment
(&lt;30% pain reduction) and tolerated CYMBALTA 60 mg once daily
had their dose increased to 120 mg. However, in OA-2, all patients,
regardless of their response to treatment after 7 weeks, were
re-randomized to either continue receiving CYMBALTA 60 mg once
daily or have their dose increased to 120 mg once daily for the
remainder of the study. Patients in the placebo treatment groups in
both studies received a matching placebo for the entire duration of
studies. For both studies, efficacy analyses were conducted using
13-week data from the combined CYMBALTA 60 mg and 120 mg once daily
treatment groups compared to the placebo group.</p>
<div class="Section" data-sectioncode="42229-5"><a name="e145" id=
"e145"></a> <a name="section-14.5.2.1" id="section-14.5.2.1"></a>
<p class="First"><span class="Italics">Study OA-1</span>: Two
hundred fifty-six patients (N=128 on CYMBALTA, N=128 on placebo)
enrolled and 204 (80%) completed the study. Patients had a mean
baseline pain rating of 6 on a numerical rating scale ranging from
0 (no pain) to 10 (worst possible pain). After 13 weeks of
treatment, patients taking CYMBALTA had significantly greater pain
reduction. Subgroup analyses did not indicate that there were
differences in treatment outcomes as a function of NSAIDs use.</p>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="e146" id=
"e146"></a> <a name="section-14.5.2.2" id="section-14.5.2.2"></a>
<p class="First"><span class="Italics">Study OA-2</span>: Two
hundred thirty-one patients (N=111 on CYMBALTA, N=120 on placebo)
enrolled and 173 (75%) completed the study. Patients had a mean
baseline pain of 6 on a numerical rating scale ranging from 0 (no
pain) to 10 (worst possible pain). After 13 weeks of treatment,
patients taking CYMBALTA did not show a significantly greater pain
reduction.</p>
<p>In Study OA-1, for various degrees of improvement in pain from
baseline to study endpoint, <a href="#f08">Figure 7</a> shows the
fraction of patients achieving that degree of improvement. The
figure is cumulative, so that patients whose change from baseline
is, for example, 50%, are also included at every level of
improvement below 50%. Patients who did not complete the study were
assigned the value of 0% improvement.</p>
<div class="Figure"><a name="f10" id="f10"></a> <img src=
"image.cfm?setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba&amp;name=cymbalta-17.jpg"
alt="Figure 9 ">
<p class="MultiMediaCaption">Figure 9: Percentage of Patients
Achieving Various Levels of Pain Relief as Measured by 24-Hour
Average Pain Severity – OA-1</p>
</div>
</div>
</div>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">16 HOW SUPPLIED/STORAGE AND HANDLING</a>
<div class="Section toggle-content closed" data-sectioncode=
"34069-5"><a name="s144" id="s144"></a> <a name="section-15" id=
"section-15"></a>
<div class="Section" data-sectioncode="34069-5"><a name="s145" id=
"s145"></a> <a name="section-15.1" id="section-15.1"></a>
<h2>16.1 How Supplied</h2>
<p class="First">CYMBALTA is available as delayed release capsules
in the following strengths, colors, imprints, and
presentations:</p>
<div class="scrollingtable">
<table width="100%">
<colgroup>
<col align="left" width="28.750%">
<col align="left" width="23.700%">
<col align="left" width="23.700%">
<col align="left" width="23.850%"></colgroup>
<tfoot>
<tr class="First">
<td align="left" colspan="4" valign="top">
<p class="First Footnote"><span class="Sup">a</span> equivalent to
duloxetine base</p>
</td>
</tr>
<tr class="Last">
<td align="left" colspan="4" valign="top">
<p class="First Footnote"><span class="Sup">†</span> Identi-Dose®
(unit dose medication, Lilly)</p>
</td>
</tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" rowspan="2"
valign="top"><span class="Bold">Features</span></td>
<td class="Botrule Rrule Toprule" align="center" colspan="3"
valign="top"><span class="Bold">Strengths</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><span class=
"Bold">20 mg</span><span class="Bold"><span class=
"Sup">a</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class=
"Bold">30 mg</span><span class="Bold"><span class=
"Sup">a</span></span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class=
"Bold">60 mg</span><span class="Bold"><span class=
"Sup">a</span></span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Body
color</td>
<td class="Botrule Rrule" align="center" valign="top">Opaque
green</td>
<td class="Botrule Rrule" align="center" valign="top">Opaque
white</td>
<td class="Botrule Rrule" align="center" valign="top">Opaque
green</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Cap
color</td>
<td class="Botrule Rrule" align="center" valign="top">Opaque
green</td>
<td class="Botrule Rrule" align="center" valign="top">Opaque
blue</td>
<td class="Botrule Rrule" align="center" valign="top">Opaque
blue</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Cap
imprint</td>
<td class="Botrule Rrule" align="center" valign="top">Lilly
3235</td>
<td class="Botrule Rrule" align="center" valign="top">Lilly
3240</td>
<td class="Botrule Rrule" align="center" valign="top">Lilly
3270</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Body
imprint</td>
<td class="Botrule Rrule" align="center" valign="top">20mg</td>
<td class="Botrule Rrule" align="center" valign="top">30mg</td>
<td class="Botrule Rrule" align="center" valign="top">60mg</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Capsule
number</td>
<td class="Botrule Rrule" align="center" valign="top">PU3235</td>
<td class="Botrule Rrule" align="center" valign="top">PU3240</td>
<td class="Botrule Rrule" align="center" valign="top">PU3270</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" colspan="4" valign=
"top">Presentations and NDC Codes</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Bottles
of 30</td>
<td class="Botrule Rrule" align="center" valign="top">NA</td>
<td class="Botrule Rrule" align="center" valign="top">
0002-3240-30</td>
<td class="Botrule Rrule" align="center" valign="top">
0002-3270-30</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Bottles
of 60</td>
<td class="Botrule Rrule" align="center" valign="top">
0002-3235-60</td>
<td class="Botrule Rrule" align="center" valign="top">NA</td>
<td class="Botrule Rrule" align="center" valign="top">NA</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Bottles
of 90</td>
<td class="Botrule Rrule" align="center" valign="top">NA</td>
<td class="Botrule Rrule" align="center" valign="top">
0002-3240-90</td>
<td class="Botrule Rrule" align="center" valign="top">NA</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Bottles
of 1000</td>
<td class="Botrule Rrule" align="center" valign="top">NA</td>
<td class="Botrule Rrule" align="center" valign="top">NA</td>
<td class="Botrule Rrule" align="center" valign="top">
0002-3270-04</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Blisters
ID†100</td>
<td class="Botrule Rrule" align="center" valign="top">NA</td>
<td class="Botrule Rrule" align="center" valign="top">
0002-3240-33</td>
<td class="Botrule Rrule" align="center" valign="top">
0002-3270-33</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectioncode="44425-7"><a name="s146" id=
"s146"></a> <a name="section-15.2" id="section-15.2"></a>
<h2>16.2 Storage and Handling</h2>
<p class="First">Store at 25°C (77°F); excursions permitted to
15-30°C (59-86°F) [<span class="Italics">see</span> USP Controlled
Room Temperature].</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">17 PATIENT COUNSELING INFORMATION</a>
<div class="Section toggle-content closed" data-sectioncode=
"34076-0"><a name="s147" id="s147"></a> <a name="section-16" id=
"section-16"></a>
<div class="Section" data-sectioncode="34076-0"><a name="s147a" id=
"s147a"></a> <a name="section-16.1" id="section-16.1"></a>
<p class="First">See FDA-approved patient labeling (<a href=
"#s148">Medication Guide</a>).</p>
<ul class="Disc">
<li><span class="Underline">Information on Medication Guide</span>
— Inform patients, their families, and their caregivers about the
benefits and risks associated with treatment with CYMBALTA and
counsel them in its appropriate use. A patient Medication Guide is
available for CYMBALTA. Instruct patients, their families, and
their caregivers to read the Medication Guide before starting
CYMBALTA and each time their prescription is renewed, and assist
them in understanding its contents. Give patients the opportunity
to discuss the contents of the Medication Guide and to obtain
answers to any questions they may have. The complete text of the
Medication Guide is reprinted at the end of this document.<br>
Advise patients of the following issues and ask them to alert their
prescriber if these occur while taking CYMBALTA.</li>
<li><span class="Underline">Suicidal Thoughts and Behaviors</span>
— Encourage patients, their families, and their caregivers to be
alert to the emergence of anxiety, agitation, panic attacks,
insomnia, irritability, hostility, aggressiveness, impulsivity,
akathisia (psychomotor restlessness), hypomania, mania, other
unusual changes in behavior, worsening of depression, and suicidal
ideation, especially early during antidepressant treatment and when
the dose is adjusted up or down.<br>
Advise families and caregivers of patients to observe for the
emergence of such symptoms on a day-to-day basis, since changes may
be abrupt. Such symptoms should be reported to the patient's
prescriber or health professional, especially if they are severe,
abrupt in onset, or were not part of the patient's presenting
symptoms. Symptoms such as these may be associated with an
increased risk for suicidal thinking and behavior and indicate a
need for very close monitoring and possibly changes in the
medication <span class="Italics">[see <a href="#s2">Boxed
Warning</a>, and Warnings and Precautions (<a href=
"#s22">5.1</a>)]</span>.</li>
<li><span>CYMBALTA should be swallowed whole and should not be
chewed or crushed, nor should the capsule be opened and its
contents be sprinkled on food or mixed with liquids. All of these
might affect the enteric coating.</span></li>
<li><span class="Underline">Continuing the Therapy
Prescribed</span> — While patients may notice improvement with
CYMBALTA therapy in 1 to 4 weeks, advise patients to continue
therapy as directed.</li>
<li><span class="Underline">Hepatotoxicity</span> — Inform patients
that severe liver problems, sometimes fatal, have been reported in
patients treated with CYMBALTA. Instruct patients to talk to their
healthcare provider if they develop itching, right upper belly
pain, dark urine, or yellow skin/eyes while taking CYMBALTA, which
may be signs of liver problems. Instruct patients to talk to their
healthcare provider about their alcohol consumption. Use of
CYMBALTA with heavy alcohol intake may be associated with severe
liver injury <span class="Italics">[see Warnings and Precautions
(<a href="#s23">5.2</a>)]</span>.</li>
<li><span class="Underline">Alcohol</span> — Although CYMBALTA does
not increase the impairment of mental and motor skills caused by
alcohol, use of CYMBALTA concomitantly with heavy alcohol intake
may be associated with severe liver injury. For this reason,
CYMBALTA should not be prescribed for patients with substantial
alcohol use <span class="Italics">[see Warnings and Precautions
(<a href="#s23">5.2</a>) and Drug Interactions (<a href=
"#s93">7.15</a>)]</span>.</li>
<li><span class="Underline">Orthostatic Hypotension, Falls and
Syncope</span> — Advise patients of the risk of orthostatic
hypotension, falls and syncope, especially during the period of
initial use and subsequent dose escalation, and in association with
the use of concomitant drugs that might potentiate the orthostatic
effect of CYMBALTA <span class="Italics">[see Warnings and
Precautions (<a href="#s24">5.3</a>)]</span>.</li>
<li><span class="Underline">Serotonin Syndrome</span> — Caution
patients about the risk of serotonin syndrome with the concomitant
use of CYMBALTA and other serotonergic agents including triptans,
tricyclic antidepressants, fentanyl, lithium, tramadol, buspirone,
tryptophan and St. John's Wort <span class="Italics">[see
Contraindications (<a href="#s20">4</a>), Warnings and Precautions
(<a href="#s25">5.4</a>), and Drug Interactions (<a href=
"#s92">7.14</a>)]</span>.<br>
Advise patients of the signs and symptoms associated with serotonin
syndrome that may include mental status changes (e.g., agitation,
hallucinations, delirium, and coma), autonomic instability (e.g.,
tachycardia, labile blood pressure, dizziness, diaphoresis,
flushing, hyperthermia), neuromuscular changes (e.g., tremor,
rigidity, myoclonus, hyperreflexia, incoordination), seizures,
and/or gastrointestinal symptoms (e.g., nausea, vomiting,
diarrhea). Caution patients to seek medical care immediately if
they experience these symptoms.</li>
<li><span class="Underline">Abnormal Bleeding</span> — Caution
patients about the concomitant use of CYMBALTA and NSAIDs, aspirin,
warfarin, or other drugs that affect coagulation since combined use
of psychotropic drugs that interfere with serotonin reuptake and
these agents has been associated with an increased risk of bleeding
<span class="Italics">[see Warnings and Precautions (<a href=
"#s26">5.5</a>)]</span>.</li>
<li><span class="Underline">Severe Skin Reactions</span> — Caution
patients that CYMBALTA may cause serious skin reactions. This may
need to be treated in a hospital and may be life-threatening.
Counsel patients to call their doctor right away or get emergency
help if they have skin blisters, peeling rash, sores in their
mouth, hives, or any other allergic reactions <span class=
"Italics">[see Warnings and Precautions (<a href=
"#s27">5.6</a>)]</span>.</li>
<li><span class="Underline">Discontinuation of Treatment</span> —
Instruct patients that discontinuation of CYMBALTA may be
associated with symptoms such as dizziness, headache, nausea,
diarrhea, paresthesia, irritability, vomiting, insomnia, anxiety,
hyperhidrosis, and fatigue, and should be advised not to alter
their dosing regimen, or stop taking CYMBALTA without consulting
their physician <span class="Italics">[see Warnings and Precautions
(<a href="#s28">5.7</a>)]</span>.</li>
<li><span class="Underline">Activation of Mania or Hypomania</span>
— Adequately screen patients with depressive symptoms for risk of
bipolar disorder (e.g. family history of suicide, bipolar disorder,
and depression) prior to initiating treatment with CYMBALTA. Advise
patients to report any signs or symptoms of a manic reaction such
as greatly increased energy, severe trouble sleeping, racing
thoughts, reckless behavior, talking more or faster than usual,
unusually grand ideas, and excessive happiness or irritability
<span class="Italics">[see Warnings and Precautions (<a href=
"#s29">5.8</a>)]</span>.</li>
<li><span class="Underline">Angle-Closure Glaucoma</span> — Advise
patients that taking CYMBALTA can cause mild pupillary dilation,
which in susceptible individuals, can lead to an episode of
angle-closure glaucoma. Pre-existing glaucoma is almost always
open-angle glaucoma because angle-closure glaucoma, when diagnosed,
can be treated definitively with iridectomy. Open-angle glaucoma is
not a risk factor for angle-closure glaucoma. Patients may wish to
be examined to determine whether they are susceptible to
angle-closure, and have a prophylactic procedure (e.g.,
iridectomy), if they are susceptible. <span class="Italics">[See
Warnings and Precautions (<a href="#s30">5.9</a>)]</span>.</li>
<li><span class="Underline">Seizures</span> — Advise patients to
inform their physician if they have a history of seizure disorder
<span class="Italics">[see Warnings and Precautions (<a href=
"#s31">5.10</a>)]</span>.</li>
<li><span class="Underline">Effects on Blood Pressure</span> —
Caution patients that CYMBALTA may cause an increase in blood
pressure <span class="Italics">[see Warnings and Precautions
(<a href="#s32">5.11</a>)]</span>.</li>
<li><span class="Underline">Concomitant Medications</span> — Advise
patients to inform their physicians if they are taking, or plan to
take, any prescription or over-the-counter medications, since there
is a potential for interactions <span class="Italics">[see Dosage
and Administration (<a href="#s17">2.8</a>, <a href=
"#s18">2.9</a>), Contraindications (<a href="#s20">4</a>), Warnings
and Precautions (<a href="#s25">5.4</a>, <a href="#s33">5.12</a>),
and Drug Interactions (<a href="#s78">7</a>)]</span>.</li>
<li><span class="Underline">Hyponatremia</span> — Advise patients
that hyponatremia has been reported as a result of treatment with
SNRIs and SSRIs, including CYMBALTA. Advise patients of the signs
and symptoms of hyponatremia <span class="Italics">[see Warnings
and Precautions (<a href="#s42">5.13</a>)]</span>.</li>
<li><span class="Underline">Concomitant Illnesses</span> — Advise
patients to inform their physicians about all of their medical
conditions <span class="Italics">[see Warnings and Precautions
(<a href="#s43">5.14</a>)]</span>.</li>
<li>CYMBALTA is in a class of medicines that may affect urination.
Instruct patients to consult with their healthcare provider if they
develop any problems with urine flow <span class="Italics">[see
Warnings and Precautions (<a href="#s47">5.15</a>)]</span>.</li>
<li><span class="Underline">Pregnancy and Nursing
Mothers<br></span> Advise patients to notify their physician if
they:
<ul class="Disc">
<li>become pregnant during therapy</li>
<li>intend to become pregnant during therapy</li>
<li>are nursing <span class="Italics">[see Use in Specific
Populations (<a href="#s97">8.1</a>, <a href=
"#s104">8.3</a>)]</span>.</li>
</ul>
</li>
<li><span class="Underline">Pediatric Use</span> — Safety and
efficacy of CYMBALTA in patients 7 to 17 years of age have been
established for the treatment of GAD. The types of adverse
reactions observed with CYMBALTA in children and adolescents were
generally similar to those observed in adults. The safety and
effectiveness of CYMBALTA have not been established in pediatric
patients less than 18 years of age with other indications.
<span class="Italics">[See Use in Specific Populations (<a href=
"#s107">8.4</a>)]</span>.</li>
<li><span class="Underline">Interference with Psychomotor
Performance</span> — Any psychoactive drug may impair judgment,
thinking, or motor skills. Although in controlled studies CYMBALTA
has not been shown to impair psychomotor performance, cognitive
function, or memory, it may be associated with sedation and
dizziness. Therefore, caution patients about operating hazardous
machinery including automobiles, until they are reasonably certain
that CYMBALTA therapy does not affect their ability to engage in
such activities.</li>
</ul>
</div>
<div class="Section" data-sectioncode="42229-5"><a name="x999" id=
"x999"></a> <a name="section-16.2" id="section-16.2"></a>
<p class="First">Literature revised June 2015</p>
<p><span class="Bold">Marketed by: Lilly USA, LLC, Indianapolis, IN
46285, USA<br></span> Copyright © 2004, 2015, Eli Lilly and
Company. All rights reserved.</p>
<p>CYM-0006-USPI-20150618</p>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">MEDICATION GUIDE</a>
<div class="Section toggle-content closed" data-sectioncode=
"42231-1"><a name="s148" id="s148"></a> <a name="section-17" id=
"section-17"></a>
<p class="First"><span class="Bold">Medication Guide</span></p>
<p><span class="Bold">Cymbalta<span class="Sup">®</span><br>
[sim-BALL-tah]<br>
(duloxetine delayed-release capsules)</span></p>
<p>Read this Medication Guide before you start taking
Cymbalta<span class="Sup">®</span> and each time you get a refill.
There may be new information. This information does not take the
place of talking to your healthcare provider about your medical
condition or treatment.</p>
<p><span class="Bold">Talk to your healthcare provider
about:</span></p>
<ul class="Disc">
<li>all risks and benefits of treatment with antidepressant
medicines</li>
<li>all treatment choices for depression or other serious mental
illness</li>
</ul>
<p><a name="p01" id="p01"></a><span class="Bold">What is the most
important information I should know about antidepressant medicines,
depression, other serious mental illnesses, and suicidal thoughts
or actions?</span></p>
<p><span class="Bold">1. Cymbalta and other antidepressant
medicines may increase suicidal thoughts or actions in some
children, teenagers, or young adults within the first few months of
treatment or when the dose is changed.</span></p>
<p><span class="Bold">2. Depression and other serious mental
illnesses are the most important causes of suicidal thoughts or
actions. Some people may have a particularly high risk of having
suicidal thoughts or actions.</span> These include people who have
(or have a family history of) bipolar illness (also called
manic-depressive illness).</p>
<p><span class="Bold">3. How can I watch for and try to prevent
suicidal thoughts and actions?</span></p>
<ul class="Disc">
<li>Pay close attention to any changes in mood, behavior, actions,
thoughts, or feelings, especially sudden changes. This is very
important when an antidepressant medicine is started or when the
dose is changed.</li>
<li>Call your healthcare provider right away to report new or
sudden changes in mood, behavior, thoughts, or feelings.
<ul class="Disc">
<li>Keep all follow-up visits with your healthcare provider as
scheduled. Call your healthcare provider between visits as needed,
especially if you have concerns about symptoms.</li>
</ul>
</li>
</ul>
<p><span class="Bold">Call your healthcare provider right away if
you have any of the following symptoms or feelings, especially if
they are new, worse, or worry you. In an emergency, call
911.</span></p>
<ul class="Disc">
<li>attempts to commit suicide</li>
<li>acting on dangerous impulses</li>
<li>acting aggressive, being angry, or violent</li>
<li>thoughts about suicide or dying</li>
<li>new or worse depression</li>
<li>new or worse anxiety</li>
<li>panic attacks</li>
<li>feeling very agitated or restless</li>
<li>new or worse irritability</li>
<li>trouble sleeping</li>
<li>an extreme increase in activity or talking (mania)</li>
<li>other unusual changes in behavior or mood</li>
</ul>
<p><span class="Bold">What else do I need to know about
antidepressant medicines?</span></p>
<ul class="Disc">
<li>Never stop an antidepressant medicine without first talking to
a healthcare provider. Stopping an antidepressant medicine suddenly
can cause other symptoms.</li>
<li>Antidepressants are medicines used to treat depression and
other illnesses. It is important to discuss all the risks of
treating depression and also the risks of not treating it. Patients
should discuss all treatment choices with your healthcare provider,
not just the use of antidepressants.</li>
<li>Antidepressant medicines have other side effects. Talk to your
healthcare provider about the side effects of the medicine
prescribed for you or your family member.</li>
<li>Antidepressant medicines can interact with other medicines.
Know all of the medicines that you or your family member takes.
Keep a list of all medicines to show your healthcare provider. Do
not start new medicines without first checking with your healthcare
provider.</li>
</ul>
<p><span class="Bold">What is Cymbalta?</span></p>
<p>Cymbalta is a prescription medicine used to treat a certain type
of depression called Major Depressive Disorder (MDD). Cymbalta
belongs to a class of medicines known as SNRIs (or
serotonin-norepinephrine reuptake inhibitors).</p>
<p>Cymbalta is also used to treat or manage:</p>
<ul class="Disc">
<li>Generalized Anxiety Disorder (GAD)</li>
<li>Diabetic Peripheral Neuropathic Pain (DPNP)</li>
<li>Fibromyalgia (FM)</li>
<li>Chronic Musculoskeletal Pain</li>
</ul>
<p><span class="Bold">Who should not take Cymbalta?</span></p>
<p><span class="Bold">Do Not take Cymbalta if you:</span></p>
<ul class="Disc">
<li><span class="Bold">take a Monoamine Oxidase Inhibitor
(MAOI).</span> Ask your healthcare provider or pharmacist if you
are not sure if you take an MAOI, including the antibiotic
linezolid or intravenous methylene blue.
<ul class="Disc">
<li>Do not take an MAOI within 5 days of stopping Cymbalta unless
directed to do so by your healthcare provider.</li>
<li>Do not start Cymbalta if you stopped taking an MAOI in the last
14 days unless directed to do so by your healthcare provider.</li>
</ul>
</li>
</ul>
<p><span class="Bold">People who take Cymbalta close in time to an
MAOI may have a serious problem called Serotonin Syndrome (see
“<a href="#p02">What are the possible side effects of
Cymbalta?</a>”).</span></p>
<p><span class="Bold">What should I tell my healthcare provider
before taking Cymbalta?</span></p>
<p>Before starting Cymbalta, tell your healthcare provider if
you:</p>
<ul class="Disc">
<li>have heart problems or high blood pressure</li>
<li>have diabetes (Cymbalta treatment makes it harder for some
people with diabetes to control their blood sugar)</li>
<li>have liver problems</li>
<li>have kidney problems</li>
<li>have glaucoma</li>
<li>have or had seizures or convulsions</li>
<li>have bipolar disorder or mania</li>
<li>have low sodium levels in your blood</li>
<li>have delayed stomach emptying</li>
<li>have or had bleeding problems</li>
<li>are pregnant or plan to become pregnant. It is not known if
Cymbalta will harm your unborn baby. Talk to your healthcare
provider about the benefits and risks of treating depression or
other conditions with Cymbalta during pregnancy.
<ul class="Disc">
<li>If you become pregnant while taking Cymbalta, talk to your
healthcare provider about registering with the Cymbalta Pregnancy
Registry. You can register by calling 1-866-814-6975 or by visiting
www.cymbaltapregnancyregistry.com. The purpose of this registry is
to monitor the pregnancy outcomes in women who have been treated
with Cymbalta at any time during pregnancy.</li>
</ul>
</li>
<li>are breastfeeding or plan to breastfeed. Cymbalta can pass into
your breast milk. Talk to your healthcare provider about the best
way to feed your baby while taking Cymbalta.</li>
</ul>
<p><span class="Bold">Tell your healthcare provider about all the
medicines that you take,</span> including prescription and
over-the-counter medicines, vitamins, and herbal supplements.
Cymbalta and some medicines may interact with each other, may not
work as well, or may cause serious side effects.</p>
<p>Especially tell your healthcare provider if you take:</p>
<ul class="Disc">
<li>triptans used to treat migraine headache</li>
<li>medicines used to treat mood, anxiety, psychotic or thought
disorders, including tricyclics, lithium, buspirone, SSRIs, SNRIs
or MAOIs</li>
<li>tramadol and fentanyl</li>
<li>cimetidine</li>
<li>the antibiotics ciprofloxacin, enoxacin</li>
<li>medicine to treat irregular heart rate (like propafenone,
flecainide, quinidine)</li>
<li>theophylline</li>
<li>the blood thinner warfarin (Coumadin, Jantoven)</li>
<li>non-steroidal anti-inflammatory drug (NSAID) (like ibuprofen,
naproxen or aspirin).</li>
<li>over-the-counter supplements such as tryptophan or St. John’s
Wort</li>
<li>thioridazine (Mellaril). Mellaril together with Cymbalta can
cause serious heart rhythm problems or sudden death.</li>
</ul>
<p>Ask your healthcare provider for a list of these medicines if
you are not sure.</p>
<p>Do not take Cymbalta with any other medicine that contain
duloxetine.</p>
<p><span class="Bold">How should I take Cymbalta?</span></p>
<ul class="Disc">
<li>Take Cymbalta exactly as your healthcare provider tells you to
take it. Your healthcare provider may need to change the dose of
Cymbalta until it is the right dose for you.</li>
<li>Swallow Cymbalta whole. Do not chew or crush Cymbalta.</li>
<li>Do not open the capsule and sprinkle on food or mix with
liquids. Opening the capsule may affect how well Cymbalta
works.</li>
<li>Cymbalta may be taken with or without food.</li>
<li>If you miss a dose of Cymbalta, take the missed dose as soon as
you remember. If it is almost time for the next dose, skip the
missed dose and take your next dose at the regular time. Do not
take two doses of Cymbalta at the same time.</li>
<li>If you take too much Cymbalta, call your healthcare provider or
poison control center at 1-800-222-1222 right away, or get
emergency treatment.</li>
<li>When switching from another antidepressant to Cymbalta your
healthcare provider may want to lower the dose of the initial
antidepressant first to potentially avoid side effects.</li>
</ul>
<p><span class="Bold">What should I avoid while taking
Cymbalta?</span></p>
<ul class="Disc">
<li>Cymbalta can cause sleepiness or may affect your ability to
make decisions, think clearly, or react quickly. You should not
drive, operate heavy machinery, or do other dangerous activities
until you know how Cymbalta affects you.</li>
<li>Use of Cymbalta concomitantly with heavy alcohol intake may be
associated with severe liver injury. Avoid heavy alcohol use while
taking Cymbalta.</li>
</ul>
<p><a name="p02" id="p02"></a><span class="Bold">What are the
possible side effects of Cymbalta?</span></p>
<p>Cymbalta may cause serious side effects, including: See
“<a href="#p01">What is the most important information I should
know about Cymbalta?</a>”</p>
<p>Common possible side effects in people who take Cymbalta
include:</p>
<p><span class="Bold">1. liver damage. Symptoms may
include:</span></p>
<ul class="Disc">
<li>itching</li>
<li>right upper abdominal pain</li>
<li>dark urine</li>
<li>yellow skin or eyes</li>
<li>enlarged liver</li>
<li>increased liver enzymes</li>
</ul>
<p><span class="Bold">2. changes in blood pressure and
falls.</span> Monitor your blood pressure before starting and
throughout treatment. Cymbalta may:</p>
<ul class="Disc">
<li>increase your blood pressure.</li>
<li>decrease your blood pressure when standing and cause dizziness
or fainting, mostly when first starting Cymbalta or when increasing
the dose.</li>
<li>increase risk of falls, especially in elderly.</li>
</ul>
<p><span class="Bold">3. Serotonin Syndrome: This condition can be
life-threatening and symptoms may include:</span></p>
<ul class="Disc">
<li>agitation, hallucinations, coma or other changes in mental
status</li>
<li>coordination problems or muscle twitching (overactive
reflexes)</li>
<li>racing heartbeat, high or low blood pressure</li>
<li>sweating or fever</li>
<li>nausea, vomiting, or diarrhea</li>
<li>muscle rigidity</li>
<li>dizziness</li>
<li>flushing</li>
<li>tremor</li>
<li>seizures</li>
</ul>
<p><span class="Bold">4. abnormal bleeding:</span> Cymbalta and
other antidepressant medicines may increase your risk of bleeding
or bruising, especially if you take the blood thinner warfarin
(Coumadin, Jantoven), a non-steroidal anti-inflammatory drug
(NSAIDs, like ibuprofen or naproxen), or aspirin.</p>
<p><span class="Bold">5. severe skin reactions:</span> Cymbalta may
cause serious skin reactions that may require stopping its use.
This may need to be treated in a hospital and may be
life-threatening. Call your healthcare provider right away or get
emergency help if you have skin blisters, peeling rash, sores in
the mouth, hives or any other allergic reactions.</p>
<p><span class="Bold">6. discontinuation symptoms:</span> Do not
stop Cymbalta without first talking to your healthcare provider.
Stopping Cymbalta too quickly or changing from another
antidepressant too quickly may result in serious symptoms
including:</p>
<ul class="Disc">
<li>anxiety</li>
<li>irritability</li>
<li>feeling tired or problems sleeping</li>
<li>headache</li>
<li>sweating</li>
<li>dizziness</li>
<li>electric shock-like sensations</li>
<li>vomiting or nausea</li>
<li>diarrhea</li>
</ul>
<p><span class="Bold">7. manic episodes:</span></p>
<ul class="Disc">
<li>greatly increased energy</li>
<li>severe trouble sleeping</li>
<li>racing thoughts</li>
<li>reckless behavior</li>
<li>unusually grand ideas</li>
<li>excessive happiness or irritability</li>
<li>talking more or faster than usual</li>
</ul>
<p><span class="Bold">8. visual problems:</span></p>
<ul class="Disc">
<li>eye pain</li>
<li>changes in vision</li>
<li>swelling or redness in or around the eye</li>
</ul>
<p>Only some people are at risk for these problems. You may want to
undergo an eye examination to see if you are at risk and receive
preventative treatment if you are.</p>
<p><span class="Bold">9. seizures or convulsions</span></p>
<p><span class="Bold">10. low salt (sodium) levels in the
blood.</span> Elderly people may be at greater risk for this.
Symptoms may include:</p>
<ul class="Disc">
<li>headache</li>
<li>weakness or feeling unsteady</li>
<li>confusion, problems concentrating or thinking or memory
problems</li>
</ul>
<p><span class="Bold">11. problems with urination. Symptoms may
include:</span></p>
<ul class="Disc">
<li>decreased urine flow</li>
<li>unable to pass any urine</li>
</ul>
<p>The most common side effects of Cymbalta include:</p>
<ul class="Disc">
<li>nausea</li>
<li>dry mouth</li>
<li>sleepiness</li>
<li>fatigue</li>
<li>constipation</li>
<li>loss of appetite</li>
<li>increased sweating</li>
<li>dizziness</li>
</ul>
<p>Common possible side effects in children and adolescents who
take Cymbalta include:</p>
<ul class="Disc">
<li>nausea</li>
<li>decreased weight</li>
<li>dizziness</li>
</ul>
<p>Side effects in adults may also occur in children and
adolescents who take Cymbalta. Children and adolescents should have
height and weight monitored during treatment.</p>
<p>Tell your healthcare provider if you have any side effect that
bothers you or that does not go away. These are not all the
possible side effects of Cymbalta. For more information, ask your
healthcare provider or pharmacist.</p>
<p><span class="Bold">Call your doctor for medical advice about
side effects. You may report side effects to
1-800-FDA-1088.</span></p>
<p><span class="Bold">How should I store Cymbalta?</span></p>
<p>Store Cymbalta at room temperature between 68°F to 77°F (20°C to
25°C).</p>
<p><span class="Bold">Keep Cymbalta and all medicines out of the
reach of children.</span></p>
<p><span class="Bold">General information about the safe and
effective use of Cymbalta.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those
listed in a Medication Guide. Do not use Cymbalta for a condition
for which it was not prescribed. Do not give Cymbalta to other
people, even if they have the same symptoms that you have. It may
harm them.</p>
<p>This Medication Guide summarizes the most important information
about Cymbalta. If you would like more information, talk with your
healthcare provider. You may ask your healthcare provider or
pharmacist for information about Cymbalta that is written for
healthcare professionals.</p>
<p>For more information, call 1-800-545-5979.</p>
<p><span class="Bold">What are the ingredients in
Cymbalta?</span></p>
<p>Active ingredient: duloxetine hydrochloride</p>
<p>Inactive ingredients:</p>
<p>FD&amp;C Blue No. 2, gelatin, hypromellose, hydroxypropyl
methylcellulose acetate succinate, sodium lauryl sulfate, sucrose,
sugar spheres, talc, titanium dioxide, and triethyl citrate. The 20
and 60 mg capsules also contain iron oxide yellow.</p>
<p><span class="Italics">This Medication Guide has been approved by
the U.S. Food and Drug Administration.</span></p>
<p>Coumadin, Jantoven, and Mellaril are trademarks of their
respective owners and not trademarks of Eli Lilly and Company.</p>
<p>Medication Guide revised: November 2014</p>
<p><span class="Bold">Marketed by: Lilly USA, LLC<br>
Indianapolis, IN 46285, USA</span></p>
<p><span class="Bold">Cymbalta is a registered trademark of Eli
Lilly and Company.</span></p>
<p>Copyright © 2009, 2014, Eli Lilly and Company. All rights
reserved.</p>
<p>CYM-0003-MG-20141125</p>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="s149" id="s149"></a> <a name="section-18" id=
"section-18"></a>
<p class="First"><span class="Bold">PACKAGE LABEL- Cymbalta 20 mg,
bottle of 60</span></p>
<p>NDC 0002-3235-60</p>
<p>60 capsules</p>
<p>PU3235</p>
<p>Cymbalta<span class="Sup">®</span></p>
<p>duloxetine</p>
<p>delayed release capsules</p>
<p>20 mg</p>
<p>Each capsule contains 22.4 mg of duloxetine hydrochloride
equivalent to 20 mg duloxetine.</p>
<p>Rx Only</p>
<p>www.Cymbalta.com</p>
<p>Lilly</p>
<div class="Figure"><a name="f11" id="f11"></a> <img src=
"image.cfm?setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba&amp;name=cymbalta-20mg-contain-60-8536.jpg"
alt="PACKAGE LABEL- Cymbalta 20 mg, bottle of 60 "></div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="s150" id="s150"></a> <a name="section-19" id=
"section-19"></a>
<p class="First"><span class="Bold">PACKAGE LABEL- Cymbalta 30 mg,
bottle of 30</span></p>
<p>NDC 0002-3240-30</p>
<p>30 capsules</p>
<p>PU3240</p>
<p>Cymbalta<span class="Sup">®</span></p>
<p>duloxetine</p>
<p>delayed release capsules</p>
<p>30 mg</p>
<p>Each capsule contains 33.7 mg of duloxetine hydrochloride
equivalent to 30 mg duloxetine.</p>
<p>Rx Only</p>
<p>www.Cymbalta.com</p>
<p>Lilly</p>
<div class="Figure"><a name="f12" id="f12"></a> <img src=
"image.cfm?setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba&amp;name=cymbalta-30mg-contain-30-8938.jpg"
alt="PACKAGE LABEL- Cymbalta 30 mg, bottle of 30 "></div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">PRINCIPAL DISPLAY PANEL</a>
<div class="Section toggle-content closed" data-sectioncode=
"51945-4"><a name="s151" id="s151"></a> <a name="section-20" id=
"section-20"></a>
<p class="First"><span class="Bold">PACKAGE LABEL- Cymbalta 60 mg,
bottle of 30</span></p>
<p>NDC 0002-3270-30</p>
<p>30 capsules</p>
<p>PU3270</p>
<p>Cymbalta<span class="Sup">®</span></p>
<p>duloxetine</p>
<p>delayed release capsules</p>
<p>60 mg</p>
<p>Each capsule contains 67.3 mg of duloxetine hydrochloride
equivalent to 60 mg duloxetine.</p>
<p>Rx Only</p>
<p>www.Cymbalta.com</p>
<p>Lilly</p>
<div class="Figure"><a name="f13" id="f13"></a> <img src=
"image.cfm?setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba&amp;name=cymbalta-60mg-contain-30-1932.jpg"
alt="PACKAGE LABEL- Cymbalta 60 mg, bottle of 30 "></div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
<li><a href="#">INGREDIENTS AND APPEARANCE</a>
<div class="DataElementsTables toggle-content">
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>CYMBALTA</strong><br>
<span class="contentTableReg">duloxetine hydrochloride capsule,
delayed release</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0002-3235</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Duloxetine hydrochloride</strong>
(UNII: 9044SC542W) (Duloxetine - UNII:O5TNM5N07U)</td>
<td class="formItem">Duloxetine</td>
<td class="formItem">20 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Gelatin</strong> (UNII:
2G86QN327L)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Hypromelloses</strong> (UNII:
3NXW29V3WO)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE ACETATE SUCCINATE
16070722 (3 MM2/S)</strong> (UNII: 24P2YXD2PW)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium lauryl sulfate</strong> (UNII:
368GB5141J)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sucrose</strong> (UNII:
C151H8M554)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Talc</strong> (UNII: 7SEV7J4R1U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Titanium dioxide</strong> (UNII:
15FIX9V2JP)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Triethyl citrate</strong> (UNII:
8Z96QXD6UM)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong> (UNII:
L06K8R7DQK)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong> (UNII:
EX438O2MRT)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">green (opaque green)</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">15mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">LILLY;3235;20;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:0002-3235-60</td>
<td class="formItem">60 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021427</td>
<td class="formItem">08/24/2004</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>CYMBALTA</strong><br>
<span class="contentTableReg">duloxetine hydrochloride capsule,
delayed release</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0002-3240</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Duloxetine hydrochloride</strong>
(UNII: 9044SC542W) (Duloxetine - UNII:O5TNM5N07U)</td>
<td class="formItem">Duloxetine</td>
<td class="formItem">30 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Gelatin</strong> (UNII:
2G86QN327L)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Hypromelloses</strong> (UNII:
3NXW29V3WO)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE ACETATE SUCCINATE
16070722 (3 MM2/S)</strong> (UNII: 24P2YXD2PW)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium lauryl sulfate</strong> (UNII:
368GB5141J)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sucrose</strong> (UNII:
C151H8M554)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Talc</strong> (UNII: 7SEV7J4R1U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Titanium dioxide</strong> (UNII:
15FIX9V2JP)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Triethyl citrate</strong> (UNII:
8Z96QXD6UM)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong> (UNII:
L06K8R7DQK)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">blue (opaque blue) , white (opaque white)</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">16mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">LILLY;3240;30;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:0002-3240-30</td>
<td class="formItem">30 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem">NDC:0002-3240-33</td>
<td class="formItem">100 in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem">NDC:0002-3240-01</td>
<td class="formItem">1 in 1 BLISTER PACK; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">3</th>
<td class="formItem">NDC:0002-3240-90</td>
<td class="formItem">90 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">4</th>
<td class="formItem">NDC:0002-3240-07</td>
<td class="formItem">7 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021427</td>
<td class="formItem">08/24/2004</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table width="100%" cellpadding="3" cellspacing="0" class=
"contentTablePetite">
<tbody>
<tr>
<td class="contentTableTitle"><strong>CYMBALTA</strong><br>
<span class="contentTableReg">duloxetine hydrochloride capsule,
delayed release</span></td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="5"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product Information</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0002-3270</td>
</tr>
<tr class="formTableRow">
<td class="formLabel" width="30%">Route of Administration</td>
<td class="formItem">ORAL</td>
<td class="formLabel" width="30%">DEA Schedule</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="3">Active Ingredient/Active
Moiety</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Basis of Strength</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Duloxetine hydrochloride</strong>
(UNII: 9044SC542W) (Duloxetine - UNII:O5TNM5N07U)</td>
<td class="formItem">Duloxetine</td>
<td class="formItem">60 mg</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="2">Inactive Ingredients</td>
</tr>
<tr>
<th scope="col" class="formTitle">Ingredient Name</th>
<th scope="col" class="formTitle">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Gelatin</strong> (UNII:
2G86QN327L)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Hypromelloses</strong> (UNII:
3NXW29V3WO)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE ACETATE SUCCINATE
16070722 (3 MM2/S)</strong> (UNII: 24P2YXD2PW)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium lauryl sulfate</strong> (UNII:
368GB5141J)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sucrose</strong> (UNII:
C151H8M554)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Talc</strong> (UNII: 7SEV7J4R1U)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Titanium dioxide</strong> (UNII:
15FIX9V2JP)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Triethyl citrate</strong> (UNII:
8Z96QXD6UM)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong> (UNII:
L06K8R7DQK)</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong> (UNII:
EX438O2MRT)</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="4">Product
Characteristics</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">green (opaque green) , blue (opaque blue)</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">20mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">LILLY;3270;60;mg</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td>
<table class="formTablePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingTitle" colspan="5">Packaging</td>
</tr>
<tr>
<th class="formTitle" width="1" scope="col">#</th>
<th class="formTitle" scope="col">Item Code</th>
<th class="formTitle" scope="col">Package Description</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">1</th>
<td class="formItem">NDC:0002-3270-30</td>
<td class="formItem">30 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem">NDC:0002-3270-33</td>
<td class="formItem">100 in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th class="formItem" scope="row">2</th>
<td class="formItem">NDC:0002-3270-01</td>
<td class="formItem">1 in 1 BLISTER PACK; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th class="formItem" scope="row">3</th>
<td class="formItem">NDC:0002-3270-04</td>
<td class="formItem">1000 in 1 BOTTLE; Type 0: Not a Combination
Product</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td class="normalizer">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Marketing Information</span></td>
</tr>
<tr>
<th class="formTitle" scope="col">Marketing Category</th>
<th class="formTitle" scope="col">Application Number or Monograph
Citation</th>
<th class="formTitle" scope="col">Marketing Start Date</th>
<th class="formTitle" scope="col">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021427</td>
<td class="formItem">01/15/2010</td>
<td class="formItem"></td>
</tr>
</tbody>
</table>
</td>
</tr>
</tbody>
</table>
</div>
<div class="scrollingtable">
<table class="formTableMorePetite" cellspacing="0" cellpadding="3"
width="100%">
<tbody>
<tr>
<td class="formHeadingReg" colspan="4"><span class=
"formHeadingTitle">Labeler -</span> Eli Lilly and Company
(006421325)</td>
</tr>
</tbody>
</table>
</div>
<span class="close-toggle show-js"><a href=
"#">Close</a></span></div>
</li>
</ul>
<div class="control-nav"><a class="open-all" href="#">View All
Sections</a><a class="close-all" href="#">Close All
Sections</a></div>
</div>
</div>
</article>
<div class="articlefooternav">
<h2>Find additional resources</h2>
<strong>(also available in the <a href="#leftmenu">left
menu</a>)</strong>
<h3>Safety</h3>
<p><a href="#boxedwarning" target="_blank">Boxed Warnings</a>,
<a href="//www.accessdata.fda.gov/scripts/medwatch/" target=
"_blank">Report Adverse Events</a>, <a href=
"http://www.fda.gov/Safety/Recalls/" target="_blank">FDA Safety
Recalls</a>, <a href=
"http://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+lactmed:@or+%28@na+%22Duloxetine%22+%29"
target="_blank">Presence in Breast Milk</a></p>
<h3>Related Resources</h3>
<p><a href=
"http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v:project=medlineplus&amp;query=Duloxetine"
target="_blank">Medline Plus</a>, <a href=
"//www.clinicaltrials.gov/ct/search?submit=Search&amp;term=Duloxetine"
target="_blank">Clinical Trials</a>, <a href="#pubmed-menu" id=
"pubmed-bottom">PubMed</a>, <a href=
"http://www.drugbank.ca/search?utf8=%E2%9C%93&amp;query=APRD00060&amp;search_type=drugs&amp;button="
target="_blank">Biochemical Data Summary</a></p>
<h3>More Info on this Drug</h3>
<p><a href="#modal-label-archives" class="modal-open">View Label
Archives</a>, <a href="#modal-rx-norm" class=
"modal-open">RxNorm</a>, <a href="#modal-label-rss" class=
"modal-open">Get Label RSS Feed</a></p>
</div>
</div>
<div class="divider"></div>
</div>
</div>
<!-- Label Archives Modal -->
<div class="mfp-hide modal" id="modal-label-archives">
<div class="modal-wrapper">
<header>
<h2>View Label Archives for this drug</h2>
</header>
<div class="top">
<h3 class="long-title">CYMBALTA- duloxetine hydrochloride capsule,
delayed release<br></h3>
<h4>Number of versions: 29</h4>
</div>
<div class="modal-content">
<table class="modal">
<tbody>
<tr>
<th>Published Date <a class="tip" rel="tooltip" href="#" title=
"&lt;b&gt;Published Date&lt;/b&gt; - The date that a drug label is published on DailyMed for public view. This is distinct from &lt;b&gt;Updated Date&lt;/b&gt;*. &lt;br&gt;&lt;br&gt; *&lt;b&gt;Updated Date&lt;/b&gt; (also known as &lt;b&gt;Effective Time&lt;/b&gt;) - The label revision date included in the SPL.">
(What is this?)</a></th>
<th>Version</th>
<th>Files</th>
</tr>
<tr>
<td>Jun 30, 2015</td>
<td>66 (current)</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=179427">download</a></td>
</tr>
<tr>
<td>Apr 22, 2015</td>
<td>65</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=172672">download</a></td>
</tr>
<tr>
<td>Dec 23, 2014</td>
<td>64</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=160825">download</a></td>
</tr>
<tr>
<td>Dec 5, 2014</td>
<td>63</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=158903">download</a></td>
</tr>
<tr>
<td>Oct 31, 2014</td>
<td>62</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=155956">download</a></td>
</tr>
<tr>
<td>Jul 31, 2014</td>
<td>61</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=146799">download</a></td>
</tr>
<tr>
<td>Apr 23, 2014</td>
<td>59</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=137597">download</a></td>
</tr>
<tr>
<td>Jul 31, 2013</td>
<td>57</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=115565">download</a></td>
</tr>
<tr>
<td>Apr 1, 2013</td>
<td>56</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=104073">download</a></td>
</tr>
<tr>
<td>Feb 8, 2013</td>
<td>55</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=99744">download</a></td>
</tr>
<tr>
<td>Feb 5, 2013</td>
<td>54</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=99336">download</a></td>
</tr>
<tr>
<td>Jan 29, 2013</td>
<td>53</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=98680">download</a></td>
</tr>
<tr>
<td>Dec 5, 2012</td>
<td>52</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=94999">download</a></td>
</tr>
<tr>
<td>Nov 1, 2012</td>
<td>51</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=92351">download</a></td>
</tr>
<tr>
<td>Sep 14, 2012</td>
<td>50</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=88218">download</a></td>
</tr>
<tr>
<td>Apr 16, 2012</td>
<td>48</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=77132">download</a></td>
</tr>
<tr>
<td>Sep 20, 2011</td>
<td>45</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=63489">download</a></td>
</tr>
<tr>
<td>May 18, 2011</td>
<td>43</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=54625">download</a></td>
</tr>
<tr>
<td>Apr 20, 2011</td>
<td>41</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=52575">download</a></td>
</tr>
<tr>
<td>Mar 30, 2011</td>
<td>40</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=51287">download</a></td>
</tr>
<tr>
<td>Jan 13, 2011</td>
<td>39</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=47099">download</a></td>
</tr>
<tr>
<td>Nov 12, 2010</td>
<td>38</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=42608">download</a></td>
</tr>
<tr>
<td>May 18, 2010</td>
<td>37</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=19285">download</a></td>
</tr>
<tr>
<td>Jan 25, 2010</td>
<td>35</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=15669">download</a></td>
</tr>
<tr>
<td>Dec 9, 2009</td>
<td>33</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=14210">download</a></td>
</tr>
<tr>
<td>Oct 27, 2009</td>
<td>31</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=13173">download</a></td>
</tr>
<tr>
<td>Sep 22, 2009</td>
<td>27</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=12273">download</a></td>
</tr>
<tr>
<td>Jun 29, 2009</td>
<td>26</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=10887">download</a></td>
</tr>
<tr>
<td>May 18, 2009</td>
<td>1</td>
<td><a download="" target="_blank" class="download-link" href=
"/dailymed/getArchivalFile.cfm?archive_id=10469">download</a></td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<!-- RxNorm Modal -->
<div class="mfp-hide modal" id="modal-rx-norm">
<div class="modal-wrapper">
<header>
<h2>RxNorm</h2>
</header>
<div class="top">
<h3 class="long-title">CYMBALTA- duloxetine hydrochloride capsule,
delayed release<br></h3>
</div>
<div class="modal-content">
<table class="modal">
<tbody>
<tr>
<th></th>
<th>RxCUI</th>
<th>RxNorm NAME</th>
<th>RxTTY</th>
</tr>
<tr class="psn-rxtty">
<td>1</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=596926">596926</a></td>
<td>DULoxetine 20 MG Delayed Release Oral Capsule</td>
<td>PSN</td>
</tr>
<tr>
<td>2</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=596926">596926</a></td>
<td>duloxetine 20 MG Delayed Release Oral Capsule</td>
<td>SCD</td>
</tr>
<tr>
<td>3</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=596926">596926</a></td>
<td>duloxetine 20 MG (as duloxetine HCl 22.4 MG) Delayed Release
Oral Capsule</td>
<td>SY</td>
</tr>
<tr class="psn-rxtty">
<td>4</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=596928">596928</a></td>
<td>Cymbalta 20 MG Delayed Release Oral Capsule</td>
<td>PSN</td>
</tr>
<tr>
<td>5</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=596928">596928</a></td>
<td>duloxetine 20 MG Delayed Release Oral Capsule [Cymbalta]</td>
<td>SBD</td>
</tr>
<tr>
<td>6</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=596928">596928</a></td>
<td>Cymbalta 20 MG (as duloxetine hydrochloride 22.4 MG) Delayed
Release Oral Capsule</td>
<td>SY</td>
</tr>
<tr>
<td>7</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=596928">596928</a></td>
<td>Cymbalta 20 MG Delayed Release Oral Capsule</td>
<td>SY</td>
</tr>
<tr class="psn-rxtty">
<td>8</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=596930">596930</a></td>
<td>DULoxetine 30 MG Delayed Release Oral Capsule</td>
<td>PSN</td>
</tr>
<tr>
<td>9</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=596930">596930</a></td>
<td>duloxetine 30 MG Delayed Release Oral Capsule</td>
<td>SCD</td>
</tr>
<tr>
<td>10</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=596930">596930</a></td>
<td>duloxetine 30 MG (as duloxetine HCl 33.7 MG) Delayed Release
Oral Capsule</td>
<td>SY</td>
</tr>
<tr class="psn-rxtty">
<td>11</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=596932">596932</a></td>
<td>Cymbalta 30 MG Delayed Release Oral Capsule</td>
<td>PSN</td>
</tr>
<tr>
<td>12</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=596932">596932</a></td>
<td>duloxetine 30 MG Delayed Release Oral Capsule [Cymbalta]</td>
<td>SBD</td>
</tr>
<tr>
<td>13</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=596932">596932</a></td>
<td>Cymbalta 30 MG (as duloxetine hydrochloride 33.7 MG) Delayed
Release Oral Capsule</td>
<td>SY</td>
</tr>
<tr>
<td>14</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=596932">596932</a></td>
<td>Cymbalta 30 MG Delayed Release Oral Capsule</td>
<td>SY</td>
</tr>
<tr class="psn-rxtty">
<td>15</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=596934">596934</a></td>
<td>DULoxetine 60 MG Delayed Release Oral Capsule</td>
<td>PSN</td>
</tr>
<tr>
<td>16</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=596934">596934</a></td>
<td>duloxetine 60 MG Delayed Release Oral Capsule</td>
<td>SCD</td>
</tr>
<tr>
<td>17</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=596934">596934</a></td>
<td>duloxetine 60 MG (as duloxetine hydrochloride 67.3 MG) Delayed
Release Oral Capsule</td>
<td>SY</td>
</tr>
<tr class="psn-rxtty">
<td>18</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=615186">615186</a></td>
<td>Cymbalta 60 MG Delayed Release Oral Capsule</td>
<td>PSN</td>
</tr>
<tr>
<td>19</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=615186">615186</a></td>
<td>duloxetine 60 MG Delayed Release Oral Capsule [Cymbalta]</td>
<td>SBD</td>
</tr>
<tr>
<td>20</td>
<td><a href=
"/dailymed/search.cfm?searchdb=rxcui&amp;query=615186">615186</a></td>
<td>Cymbalta 60 MG (as duloxetine hydrochloride 67.3 MG) Delayed
Release Oral Capsule</td>
<td>SY</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<!-- Label RSS Modal -->
<div class="mfp-hide modal" id="modal-label-rss">
<header>
<h2>Get Label RSS Feed for this Drug</h2>
</header>
<div class="top">
<h3 class="long-title">CYMBALTA- duloxetine hydrochloride capsule,
delayed release<br></h3>
</div>
<div class="modal-content">
<h4>To receive this label RSS feed</h4>
<p>Copy the URL below and paste it into your RSS Reader
application.</p>
<p><a href=
"https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba"
target=
"_blank">https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=2f7d4d67-10c1-4bf4-a7f2-c185fbad64ba</a></p>
<h4>To receive all DailyMed Updates for the last seven days</h4>
<p>Copy the URL below and paste it into your RSS Reader
application.</p>
<p><a href="https://dailymed.nlm.nih.gov/dailymed/rss.cfm" target=
"_blank">https://dailymed.nlm.nih.gov/dailymed/rss.cfm</a></p>
<h4>What will I get with the DailyMed RSS feed?</h4>
<p>DailyMed will deliver notification of updates and additions to
Drug Label information currently shown on this site through its RSS
feed.</p>
<p>DailyMed will deliver this notification to your desktop, Web
browser, or e-mail depending on the RSS Reader you select to use.
To view updated drug label links, paste the RSS feed address (URL)
shown below into a RSS reader, or use a browser which supports RSS
feeds, such as Safari for Mac OS X.</p>
<h4>How to discontinue the RSS feed</h4>
<p>If you no longer wish to have this DailyMed RSS service, simply
delete the copied URL from your RSS Reader.</p>
<a href="/dailymed/rss-updates.cfm" class="rss-icon"></a> <a href=
"/dailymed/rss-updates.cfm">More about getting RSS News &amp;
Updates from DailyMed</a></div>
</div>
<!-- RxImage no more notification modal -->
<div class="mfp-hide modal" id="no-pill-photo-warning-modal">
<div class="modal-content">
<h4>Why is DailyMed no longer displaying pill images on the Search
Results and Drug Info pages?</h4>
<br>
<p>Due to inconsistencies between the drug labels on DailyMed and
the pill images provided by <a href=
"https://rximage.nlm.nih.gov/docs/doku.php?id=rximageapi_support"
target="_blank">RxImage</a>, we no longer display the RxImage pill
images associated with drug labels.</p>
<p>We anticipate reposting the images once we are able identify and
filter out images that do not match the information provided in the
drug labels.</p>
</div>
</div>
<!-- this div is only for jQuery -->
<div class="search-results">
<div class="filter-drop"></div>
</div>
<div class="webview"></div>
<div class="hide-on-mobile"></div>
<div class="mobilenav no-js">
<ul>
<li><a href="/dailymed/index.cfm">Home</a></li>
<li>News
<ul>
<li><a href="/dailymed/dailymed-announcements.cfm">DailyMed
Announcements</a></li>
<li><a href="/dailymed/rss-updates.cfm">Get RSS News &amp;
Updates</a></li>
</ul>
</li>
<li>Search
<ul>
<li><a href="/dailymed/advanced-search.cfm">Advanced
Search</a></li>
<li><a href="/dailymed/browse-drug-classes.cfm">Browse Drug
Classes</a></li>
<li><a href="/dailymed/archives/index.cfm">Labels Archives</a></li>
<li><a href="http://pillbox.nlm.nih.gov">Tablet/Capsule ID
Tool</a></li>
</ul>
</li>
<li><a href="/dailymed/fda-drug-guidance.cfm">FDA Guidances &amp;
Information</a></li>
<li>NLM SPL Resources
<ul>
<li><a href="/dailymed/spl-resources.cfm">Download Data</a>
<ul>
<li><a href="/dailymed/spl-resources-all-drug-labels.cfm">All Drug
Labels</a></li>
<li><a href="/dailymed/spl-resources-all-indexing-files.cfm">All
Index Files</a></li>
<li><a href="/dailymed/spl-resources-all-mapping-files.cfm">All
Mapping Files</a></li>
</ul>
</li>
<li><a href="/dailymed/splimage-guidelines.cfm">SPL Image
Guidelines</a></li>
<li><a href=
"/dailymed/spl-resources-presentations-articles.cfm">Presentations
&amp; Articles</a></li>
</ul>
</li>
<li>Application Development Support
<ul>
<li><a href="/dailymed/app-support.cfm">Resources</a>
<ul>
<li><a href="/dailymed/app-support-web-services.cfm">Web
Services</a></li>
<li><a href="/dailymed/app-support-mapping-files.cfm">Mapping
Files</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="/dailymed/help.cfm">Help</a></li>
</ul>
</div>
<footer class="mainFooter">
<div class="container">
<div class="three columns">
<div class="nihnlmlogoprint"><img src=
"/dailymed/images/nihnlmlogoprint.png" alt="NIH NLM Logo"></div>
<a href="//www.nlm.nih.gov/" class="logo" title=
"National Library of Medicine | National Institutes of Health"><img src="/dailymed/images/footer-logo.png"
width="109" height="37" alt=
"National Library of Medicine | National Institutes of Health"
title=
"National Library of Medicine | National Institutes of Health"></a></div>
<div id="share" class="thirteen columns">
<div class="footer-links">
<ul class="primary">
<li><a href="/dailymed/about-dailymed.cfm" title=
"About DailyMed">About DailyMed</a><span>|</span></li>
<li><a href="/dailymed/contact-us.cfm" title="Contact Us">Contact
Us</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/copyright.html" title="Copyright"
target="_blank" rel="bookmark">Copyright</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/privacy.html" title="Privacy"
target="_blank" rel="bookmark">Privacy</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/accessibility.html" title=
"Web Accessibility" target="_blank" rel="bookmark">Web
Accessibility</a></li>
</ul>
<ul class="secondary">
<li><a href="http://www.nih.gov/" title=
"National Institutes of Health" target="_blank" rel=
"bookmark">National Institutes of Health</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/" title=
"U.S. National Library of Medicine" target="_blank" rel=
"bookmark">U.S. National Library of Medicine</a><span>|</span></li>
<li><a href="http://www.hhs.gov/" title=
"Health &amp; Human Services" target="_blank" rel="bookmark">Health
&amp; Human Services</a></li>
</ul>
<ul class="secondary mobile">
<li><a href="http://www.nih.gov/" title=
"National Institutes of Health" target="_blank" rel=
"bookmark">NIH</a><span>|</span></li>
<li><a href="//www.nlm.nih.gov/" title=
"U.S. National Library of Medicine" target="_blank" rel=
"bookmark">NLM</a><span>|</span></li>
<li><a href="http://www.hhs.gov/" title=
"Health &amp; Human Services" target="_blank" rel="bookmark">Health
&amp; Human Services</a></li>
</ul>
<div class="social">Share <!-- AddThis Button BEGIN -->
 <noscript>: JavaScript needed for Sharing tools</noscript>
<div class=
"addthis_toolbox addthis_default_style addthis_16x16_style">
<a class="email-share" href=
"mailto:?subject=DailyMed%20Web%20site%20information&amp;Body=I%20would%20like%20to%20share%20this%20page%20from%20the%20DailyMed%20website%20with%20you%3A%0A%0ACYMBALTA%2D%20Duloxetine%20Hydrochloride%20Capsule%2C%20Delayed%20Release%0Ahttps%3A%2F%2Fdailymed%2Enlm%2Enih%2Egov%2Fdailymed%2FdrugInfo%2Ecfm%3Fsetid%3D2f7d4d67%2D10c1%2D4bf4%2Da7f2%2Dc185fbad64ba%0A%0ADailyMed%20is%20a%20site%20provided%20by%20The%20National%20Library%20of%20Medicine%20%28NLM%29%20and%20is%20the%20official%20provider%20of%20FDA%20drug%20label%20information%20%28package%20inserts%29%2E"
title="Share by Email"></a> <a class="addthis_button_facebook"></a>
<a class="addthis_button_twitter"></a> <a class=
"at300bs at15nc at15t_compact reveal" title="Bookmark &amp; Share"
href=
"//www.addthis.com/bookmark.php?pub=DailyMed&amp;title=DailyMed"
target="_blank" style="width: 16px; height: 16px"><span style=
"left: -9999px; position: absolute;">Bookmark &amp; Share</span>
<img style="width:17px; margin-top: -2px;" src=
"/dailymed/images/addthis-image.jpg" alt=
"Bookmark &amp; Share"></a></div>
<!-- AddThis Button END --></div>
</div>
</div>
</div>
<div class="divider"></div>
</footer>
<div class="divider"></div>
</div>
<div class="to-top"></div>
<!-- this div is only for jQuery -->
<div class="search-results">
<div class="filter-drop"></div>
</div>
<div class="webview"></div>
<div class="hide-on-mobile"></div>
<script type="text/javascript" src=
"//ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js">
</script> <script type="text/javascript">
        if (typeof jQuery == 'undefined')
        {  
            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-1.10.2.min.js">\x3C/script>');
        }
</script> <script type="text/javascript">
        var basepath = "/dailymed";
;
        var availableClasses =  new Array();
;
        for(var i = 0; i < availableClasses.length; i++){
                availableClasses[i] = availableClasses[i].replace(/"/g, '').trim();
        }
        var labeltitle = "CYMBALTA- duloxetine hydrochloride capsule, delayed release <br>";
;
        var emailLink = "";
;
        var emailrequest = "0";
;
</script> <script src=
"/dailymed/scripts/javascript-html-attribute-encoding.min.js">
</script> <script src="/dailymed/scripts/spin.min.js">
</script> <script src="/dailymed/scripts/scripts.min.js?v=2">
</script> <script type='text/javascript' src=
"//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/jquery-ui.min.js">
</script> <script type="text/javascript">
        if (typeof jQuery.ui == 'undefined')
        {
            document.write('\x3Cscript type="text/javascript" src="/dailymed/scripts/jquery-ui-1.10.4.custom.min.js">\x3C/script>');
            document.write('\x3Clink rel="stylesheet" type="text/css" media="all" href="/dailymed/css/jquery-ui-1.10.4.custom.min.css">');
        }
        else{
            document.write('<link rel="stylesheet" href="//ajax.googleapis.com/ajax/libs/jqueryui/1.11.0/themes/smoothness/jquery-ui.min.css">');
        }
</script> <script type='text/javascript' src=
'/dailymed/scripts/jquery.elevateZoom-3.0.8.min.js'>
</script> <script type="text/javascript" src=
"/dailymed/scripts/jquery.placeholder.min.js">
</script> <script src=
"//www.accessdata.fda.gov/spl/stylesheet/spl.js" type=
"text/javascript" charset="utf-8">
/* */
</script> <!-- Magnific Popup core JS file -->
 <script src="/dailymed/scripts/jquery.magnific-popup.min.js">
</script> <script type="text/javascript">
var addthis_config = {"data_track_addressbar":false};
</script> <script type="text/javascript" src=
"//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-542300cc2097c8b5">
</script> <script>
 var ignore_onbeforeunload = false;

 $("a").on('click',function(){
    if(ignore_onbeforeunload){
        ignore_onbeforeunload = false;
    }
})

$("a[href^='mailto'], a[href$='zip']").on('click',function(){
    ignore_onbeforeunload = true;
});


$(window).on('beforeunload', function(){
    if (!ignore_onbeforeunload){
        // Only run the loading icon if changing the page takes longer than 200ms
        setTimeout(function(){
            // Fade in the grey screen
            $('body').prepend($('<div class="loading-wrapper" style="width: 100%;height: 100%;background-color: rgba(0, 0, 0, 0.50);position: fixed;top:0;z-index: 100000;"><\/div>').fadeIn('fast'));
            var opts = {
                  lines: 12 // The number of lines to draw
                , length: 14 // The length of each line
                , width: 5 // The line thickness
                , radius: 14 // The radius of the inner circle
                , scale: 1 // Scales overall size of the spinner
                , corners: 1 // Corner roundness (0..1)
                , color: '#fff' 
                , opacity: 0.25 // Opacity of the lines
                , rotate: 0 // The rotation offset
                , direction: 1 // 1: clockwise, -1: counterclockwise
                , speed: 1 // Rounds per second
                , trail: 60 // Afterglow percentage
                , fps: 20 // Frames per second when using setTimeout() as a fallback for CSS
                , zIndex: 2e9 // The z-index (defaults to 2000000000)
                , className: 'spinner' // The CSS class to assign to the spinner
                , top: '50%' // Top position relative to parent
                , left: '50%' // Left position relative to parent
                , shadow: false // Whether to render a shadow
                , hwaccel: false // Whether to use hardware acceleration
                , position: 'absolute' // Element positioning
                }
            var spinner = new Spinner(opts).spin();
            $('.loading-wrapper').append(spinner.el);
        }, 200);
    }

    //ignore_onbeforeunload = false;
});
</script> <!-- START OF SmartSource Data Collector TAG -->
<!-- Copyright (c) 1996-2012 Webtrends Inc.  All rights reserved. -->
<!-- Version: 9.4.0 -->
<!-- Tag Builder Version: 3.3  -->
<!-- Created: 1/25/2012 11:57:33 PM -->
<script type="text/javascript" src=
"/dailymed/scripts/webtrends.min.js">
</script> 
<!-- =================================================================================== -->
<!-- Warning: The two script blocks below must remain inline. Moving them to an external -->
<!-- JavaScript include file can cause serious problems with cross-domain tracking.      -->
<!-- =================================================================================== -->
<script type="text/javascript">
//<![CDATA[
var _tag=new WebTrends();
_tag.dcsGetId();
//]]>
</script> <script type="text/javascript">
//<![CDATA[
_tag.dcsCustom=function(){
// Add custom parameters here.
//_tag.DCSext.param_name=param_value;
_tag.DCSext.dcsid=_tag.dcsid
}
_tag.trackAllEvents=true;
_tag.dcsCollect();
//]]>
</script> <noscript>
<div><img alt="DCSIMG" id="DCSIMG" width="1" height="1" src=
"//wtsdc.nlm.nih.gov/dcsm7fmt310000o265ioub7ib_2b7v/njs.gif?dcsuri=/nojavascript&amp;WT.js=No&amp;WT.tv=9.4.0&amp;dcssip=dailymed.nlm.nih.gov&amp;dcsid=dcsm7fmt310000o265ioub7ib_2b7v"></div>
</noscript> <!-- END OF SmartSource Data Collector TAG -->
 <script type="text/javascript">
    setTimeout(function(){var a=document.createElement("script");
    var b=document.getElementsByTagName("script")[0];
    a.src=document.location.protocol+"//dnn506yrbagrg.cloudfront.net/pages/scripts/0027/2050.js?"+Math.floor(new Date().getTime()/3600000);
    a.async=true;a.type="text/javascript";b.parentNode.insertBefore(a,b)}, 1);
</script> <script type="text/javascript">
    function getParameterByName(name) {
        name = name.replace(/[\[]/, "\\[").replace(/[\]]/, "\\]");
        var regex = new RegExp("[\\?&]" + name + "=([^&#]*)"),
            results = regex.exec(location.search);
        return results === null ? "" : decodeURIComponent(results[1].replace(/\+/g, " "));
    }
    /* Tracking label type on search pages */
    function CE_READY() {
        if(!getParameterByName('labeltype')){
           CE2.set(1, "No Label Type");
        }
        else{
            var labeltype = getParameterByName('labeltype');
            if(labeltype == 'all'){
                CE2.set(1, "All");
            }
            else if(labeltype == 'human'){
                CE2.set(1, "Human");
            }
            else if(labeltype == 'animal'){
                CE2.set(1, "Animal");
            }
            else{
                CE2.set(1, "Unknown");
            }
        }
    }
</script> <!-- DAP Universal Analytics -->
 <script language="javascript" id="_fed_an_ua_tag" src=
"/dailymed/scripts/Universal-Federated-Analytics-Min.2.01.js?agency=HHS&amp;subagency=NIH&amp;enhlink=true&amp;dclink=true">
</script> <script src="/dailymed/scripts/preview-text.min.js">
</script>
</body>
</html>
